Título	link	data	tipo	doi	issn	ISSN	Periódico	Qualis	FI (JCR)	H-index	media_citacao_3_anos	Resumo_antigo	Categorias	categories	Resumo	PUBMEDID	Periódico	ISSN	DOI	Tradução do título	Tradução do resumo
A Phase 1: Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine-BBV152.	https://doi.org/10.1101/2020.12.11.20210419	15/12/2020	Preprint	10.1101/2020.12.11.20210419	-	-	-	-	-	-	-	-	['Covaxin']	['Covaxin']	Safe and effective vaccines against SARS-CoV-2 for children are urgently needed. Here we aimed to assess the safety and immunogenicity of an inactivated COVID-19 vaccine candidate, WIBP-CorV, in participants aged 3-17 years. A randomized, double-blind, placebo-controlled, phase 1/2 clinical trial was conducted in Henan Province, China, in healthy children aged 3-17 years. 240 participants in phase 1 trial and 576 participants in phase 2 trial were randomly assigned to vaccine or control with an age de-escalation in three cohorts (3-5, 6-12 and 13-17 years) and dose-escalation in three groups (2.5, 5.0 and 10.0μg/dose), and received 3 intramuscular injections at day 0, 28, and 56. WIBP-CorV showed a promising safety profile with approximately 17% adverse reactions within 30 days after injection and no grade 3 or worse adverse events. The most common adverse reaction was injection site pain, followed by fever, which were mild and self-limiting. The geometric mean titers of neutralizing antibody ranged from 102.2 to 1065.5 in vaccinated participants at 28 days after the third vaccination, and maintained at a range of 14.3 to 218.2 at day 180 after the third vaccination. WIBP-CorV elicited significantly higher titers of neutralizing antibody in the cohort aged 3-5 years than the other two cohorts. There were no detectable antibody responses in all alum-only groups. Taken together, our data demonstrate that WIBP-CorV is safe and well tolerated at all tested doses in participants aged 3-17 years, and elicited robust humoral responses against SARS-CoV-2 lasted for at least 6 months after the third vaccination. This study is ongoing and is registered with www.chictr.org.cn, ChiCTR2000031809.	35812412	Frontiers in immunology	1664-3224	10.3389/fimmu.2022.898151	A Fase 1: Ensaio de segurança e imunogenicidade de uma vacina inativada contra SARS-CoV-2-BBV152. 	Vacinas seguras e eficazes contra SARS-CoV-2 para crianças são urgentemente necessárias. Aqui, nosso objetivo foi avaliar a segurança e a imunogenicidade de uma vacina candidata inativada contra COVID-19, WIBP-CorV, em participantes de 3 a 17 anos. Um ensaio clínico de fase 1/2 randomizado, duplo-cego, controlado por placebo, foi realizado na província de Henan, China, em crianças saudáveis de 3 a 17 anos. 240 participantes no estudo de fase 1 e 576 participantes no estudo de fase 2 foram aleatoriamente designados para vacina ou controle com redução de idade em três coortes (3-5, 6-12 e 13-17 anos) e aumento de dose em três grupos (2,5, 5,0 e 10,0μg/dose) e recebeu 3 injeções intramusculares nos dias 0, 28 e 56. WIBP-CorV mostrou um perfil de segurança promissor com aproximadamente 17% de reações adversas dentro de 30 dias após a injeção e nenhum grau 3 ou pior eventos adversos. A reação adversa mais comum foi dor no local da injeção, seguida de febre, que foi leve e autolimitada. Os títulos médios geométricos de anticorpos neutralizantes variaram de 102,2 a 1065,5 em participantes vacinados aos 28 dias após a terceira vacinação e mantiveram-se em uma faixa de 14,3 a 218,2 no dia 180 após a terceira vacinação. WIBP-CorV provocou títulos significativamente mais elevados de anticorpos neutralizantes na coorte com idades entre 3-5 anos do que as outras duas coortes. Não houve respostas de anticorpos detectáveis em todos os grupos apenas de alúmen. Em conjunto, nossos dados demonstram que o WIBP-CorV é seguro e bem tolerado em todas as doses testadas em participantes de 3 a 17 anos, e provocou respostas humorais robustas contra SARS-CoV-2 que duraram pelo menos 6 meses após a terceira vacinação. Este estudo está em andamento e está registrado em www.chictr.org.cn, ChiCTR2000031809.
Early initiation of prophylactic anticoagulation for prevention of COVID-19 mortality: a nationwide cohort study of hospitalized patients in the United States.	https://doi.org/10.1101/2020.12.09.20246579	11/12/2020	Preprint	10.1101/2020.12.09.20246579	-	-	-	-	-	-	-	-	['Anticoagulantes', 'Anticoagulantes']	['Anticoagulants', 'Anticoagulants']	Early initiation of prophylactic anticoagulation compared with no anticoagulation among patients admitted to hospital with covid-19 was associated with a decreased risk of 30 day mortality and no increased risk of serious bleeding events. These findings provide strong real world evidence to support guidelines recommending the use of prophylactic anticoagulation as initial treatment for patients with covid-19 on hospital admission.	33574135	BMJ (Clinical research ed.)	1756-1833	10.1136/bmj.n311	Início precoce da anticoagulação profilática para prevenção da mortalidade por COVID-19: um estudo de coorte nacional de pacientes hospitalizados nos Estados Unidos. 	O início precoce da anticoagulação profilática em comparação com a ausência de anticoagulação entre os pacientes internados no hospital com covid-19 foi associado a uma diminuição do risco de mortalidade em 30 dias e nenhum aumento do risco de eventos hemorrágicos graves. Esses achados fornecem fortes evidências do mundo real para apoiar as diretrizes que recomendam o uso de anticoagulação profilática como tratamento inicial para pacientes com covid-19 na admissão hospitalar.
The efficacy and safety of hydroxychloroquine in COVID19 patients: a multicenter national retrospective cohort.	https://doi.org/10.1101/2020.11.25.20234914	30/11/2020	Preprint	10.1101/2020.11.25.20234914	-	-	-	-	-	-	-	-	['Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine']	Our results showed no significant beneficial effect of using hydroxychloroquine on the outcome of patients with COVID-19. Moreover, the risk of hypoglycemia due to hydroxychloroquine would possess a significant risk for out-of-hospital use.	33484407	Infectious diseases and therapy	2193-8229	10.1007/s40121-021-00397-8	A eficácia e segurança da hidroxicloroquina em pacientes com COVID19: uma coorte retrospectiva nacional multicêntrica. 	Nossos resultados não mostraram efeito benéfico significativo do uso de hidroxicloroquina no desfecho de pacientes com COVID-19. Além disso, o risco de hipoglicemia devido à hidroxicloroquina possuiria um risco significativo para uso fora do hospital.
Treatment with Zinc is Associated with Reduced In-Hospital Mortality Among COVID-19 Patients: A Multi-Center Cohort Study	https://doi.org/10.21203/rs.3.rs-94509/v1	26/10/2020	Preprint	10.21203/rs.3.rs-94509/v1	-	-	-	-	-	-	-	-	['Zinco']	['Zinc']	-	33140042	Research square	1932-6203	10.21203/rs.3.rs-94509/v1	O tratamento com zinco está associado à redução da mortalidade hospitalar entre pacientes com COVID-19: um estudo de coorte multicêntrico 	-
Clinical Course and Outcomes of coronavirus disease 2019 (COVID-19) in Rheumatic Disease Patients on Immunosuppression: A case Cohort Study at a Single Center with a Significantly Diverse Population	https://doi.org/10.1101/2020.10.26.20219154	27/10/2020	Preprint	10.1101/2020.10.26.20219154	-	-	-	-	-	-	-	-	['Corticosteroides', 'Hidroxicloroquina']	['Corticosteroids', 'Hydroxychloroquine']	-	-	-	-	-	Curso clínico e resultados da doença de coronavírus 2019 (COVID-19) em pacientes com doença reumática em imunossupressão: um estudo de coorte de casos em um único centro com uma população significativamente diversa 	-
Tocilizumab in Treatment of Severe COVID-19 Patients: A Systematic Review and Meta-Analysis of Cohort Studies	https://www.authorea.com/doi/full/10.22541/au.160071232.27950965	21/09/2020	Preprint	10.22541/au.160071232.27950965	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']	Based on cumulative low-to-moderate certainty evidence shows that TCZ could reduce the risk of mortality in hospitalised patients. However, there is no statistically significant difference observed between the TCZ and SOC/control groups in other parameters.	34251307	Clinical and experimental rheumatology	0392-856X	10.55563/clinexprheumatol/4dg0or	Tocilizumabe no tratamento de pacientes graves com COVID-19: uma revisão sistemática e meta-análise de estudos de coorte 	com base em evidências cumulativas de certeza baixa a moderada mostra que o TCZ pode reduzir o risco de mortalidade em pacientes hospitalizados. No entanto, não há diferença estatisticamente significativa observada entre os grupos TCZ e SOC/controle em outros parâmetros.
Anakinra After Corticosteroid and/or Tocilizumab Treatment in Patients with Severe COVID-19 Pneumonia and Moderate Hyperinflammation. A Retrospective Cohort Study	https://doi.org/10.21203/rs.3.rs-88775/v1	09/10/2020	Preprint	10.21203/rs.3.rs-88775/v1	-	-	-	-	-	-	-	-	['Anakinra']	['Anakinra']	-	-	-	-	-	Anakinra após tratamento com corticosteroide e/ou tocilizumabe em pacientes com pneumonia grave por COVID-19 e hiperinflamação moderada. Um estudo de coorte retrospectivo 	-
Early transfusion of a large cohort of COVID-19 patients with high titer anti-SARS-CoV-2 spike protein IgG convalescent plasma confirms a signal of significantly decreased mortality	https://doi.org/10.1101/2020.10.02.20206029	05/10/2020	Preprint	10.1101/2020.10.02.20206029	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']	-	-	-	-	-	A transfusão precoce de uma grande coorte de pacientes com COVID-19 com plasma convalescente IgG anti-SARS-CoV-2 de alto título confirma um sinal de mortalidade significativamente diminuída 	-
Pre exposure Hydroxychloroquine use is associated with reduced COVID19 risk in healthcare workers - a Retrospective cohort	https://doi.org/10.1101/2020.06.09.20116806	01/10/2020	Preprint	10.1101/2020.06.09.20116806	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']	-	-	-	-	-	Pré-exposição O uso de hidroxicloroquina está associado à redução do risco de COVID19 em profissionais de saúde - uma coorte retrospectiva 	-
Combination of Tocilizumab and steroids to improve mortality in patients with severe COVID-19 infection: A spanish, multicenter, cohorty study	https://doi.org/10.1101/2020.09.07.20189357	10/09/2020	Preprint	10.1101/2020.09.07.20189357	-	-	-	-	-	-	-	-	['Corticosteroides', 'Tocilizumabe']	['Corticosteroids', 'Tocilizumab']	There is no benefit of the addition of lopinavir-ritonavir to the standard care in COVID-19 patients.	33928532	Infectious diseases and therapy	2193-8229	10.1007/s40121-021-00444-4	Combinação de tocilizumabe e esteróides para melhorar a mortalidade em pacientes com infecção grave por COVID-19: um estudo de coorte espanhol, multicêntrico 	Não há benefício da adição de lopinavir-ritonavir ao tratamento padrão em pacientes com COVID-19.
The Effect of Early Hydroxychloroquine-based Therapy in COVID-19 Patients in Ambulatory Care Settings: A Nationwide Prospective Cohort Study	https://doi.org/10.1101/2020.09.09.20184143	13/09/2020	Preprint	10.1101/2020.09.09.20184143	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']	-	-	-	-	-	O efeito da terapia precoce à base de hidroxicloroquina em pacientes com COVID-19 em ambientes de atendimento ambulatorial: um estudo de coorte prospectivo nacional 	-
Hydroxychloroquine for prevention of COVID-19 mortality: a population-based cohort study	https://doi.org/10.1101/2020.09.04.20187781	09/09/2020	Preprint	10.1101/2020.09.04.20187781	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']	Medical Research Council.	33349815	The Lancet. Rheumatology	2665-9913	10.1016/S2665-9913(20)30378-7	Hidroxicloroquina para prevenção da mortalidade por COVID-19: um estudo de coorte de base populacional 	Medical Research Council.
Role of Drugs used for chronic disease management on Susceptibility and Severity of COVID-19: A Large Case-Control Study	https://www.medrxiv.org/content/10.1101/2020.04.24.20077875v2	07/09/2020	Preprint	10.1101/2020.04.24.20077875v2	-	-	-	-	-	-	-	-	['Anti-hipertensivos', 'Antidiabéticos', 'Corticosteroides']	['Anti-hypertensives', 'Antidiabetics', 'Corticosteroids']	This study aimed to investigate whether specific medications used in the treatment chronic diseases affected either the development and/ or severity of coronavirus disease 2019 (COVID-19) in a cohort of 610 COVID-19 cases and 48,667 population-based controls from Zhejiang, China. Using a cohort of 578 COVID-19 cases and 48,667 population-based controls from Zhejiang, China, we tested the role of usage of cardiovascular, antidiabetic, and other medications on risk and severity of COVID-19. Analyses were adjusted for age, sex, and body mass index and for presence of relevant comorbidities. Individuals with hypertension taking calcium channel blockers had significantly increased risk (odds ratio (OR) = 1.73, 95% confidence interval (CI) 1.2-2.3) of manifesting symptoms of COVID-19, whereas those taking angiotensin receptor blockers and diuretics had significantly lower disease risk (OR = 0.22, 95% CI 0.15-0.30 and OR = 0.30, 95% CI 0.19-0.58, respectively). Among those with type 2 diabetes, dipeptidyl peptidase-4 inhibitors (OR = 6.02, 95% CI 2.3-15.5) and insulin (OR = 2.71, 95% CI 1.6-5.5) were more and glucosidase inhibitors were less prevalent (OR = 0.11, 95% CI 0.1-0.3) among with patients with COVID-19. Drugs used in the treatment of hypertension and diabetes influence the risk of development of COVID-19, but, not its severity.	32910830	Clinical pharmacology and therapeutics	1532-6535	10.1002/cpt.2047	Papel dos medicamentos usados para o tratamento de doenças crônicas na suscetibilidade e gravidade do COVID-19: um grande estudo de caso- 	controle COVID-19) em uma coorte de 610 casos de COVID-19 e 48.667 controles populacionais de Zhejiang, China. Usando uma coorte de 578 casos de COVID-19 e 48.667 controles populacionais de Zhejiang, China, testamos o papel do uso de medicamentos cardiovasculares, antidiabéticos e outros no risco e gravidade do COVID-19. As análises foram ajustadas para idade, sexo, índice de massa corporal e presença de comorbidades relevantes. Indivíduos com hipertensão tomando bloqueadores dos canais de cálcio tiveram risco significativamente aumentado (odds ratio (OR) = 1,73, intervalo de confiança de 95% (IC) 1,2-2,3) de manifestar sintomas de COVID-19, enquanto aqueles que tomaram bloqueadores dos receptores de angiotensina e diuréticos tiveram significativamente menor risco de doença (OR = 0,22, IC 95% 0,15-0,30 e OR = 0,30, IC 95% 0,19-0,58, respectivamente). Entre aqueles com diabetes tipo 2, os inibidores da dipeptidil peptidase-4 (OR = 6,02, IC 95% 2,3-15,5) e insulina (OR = 2,71, IC 95% 1,6-5,5) foram mais e os inibidores da glicosidase foram menos prevalentes (OR = 0,11 , IC 95% 0,1-0,3) entre pacientes com COVID-19. Os medicamentos usados no tratamento da hipertensão e do diabetes influenciam o risco de desenvolvimento da COVID-19, mas não sua gravidade.
Corticosteroid Use in Severely Hypoxemic COVID-19 Patients: An Observational Cohort Analysis of Dosing Patterns and Outcomes in the Early Phase of the Pandemic	https://doi.org/10.1101/2020.07.29.20164277	30/07/2020	Preprint	10.1101/2020.07.29.20164277	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']	-	-	-	-	-	Uso de corticosteróides em pacientes gravemente hipoxêmicos com COVID-19: uma análise de coorte observacional de padrões de dosagem e resultados na fase inicial da pandemia 	-
Renin-Angiotensin-Aldosterone-System inhibitor use in patients with COVID-19 infection and prevention of serious events: a cohort study in commercially insured patients in the US	https://doi.org/10.1101/2020.07.22.20159855	24/07/2020	Preprint	10.1101/2020.07.22.20159855	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Bloqueadores do Canal de Cálcio', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Calcium Channel Blockers', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	-	-	-	-	-	Uso de inibidores do sistema renina-angiotensina-aldosterona em pacientes com infecção por COVID-19 e prevenção de eventos graves: um estudo de coorte em pacientes com seguro comercial nos EUA 	-
Adjunctive Corticosteroids for COVID-19: A Retrospective Cohort Study	https://doi.org/10.1101/2020.07.18.20157008	21/07/2020	Preprint	10.1101/2020.07.18.20157008	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']	-	-	-	-	-	Corticosteroides adjuvantes para COVID-19: um estudo de coorte retrospectivo 	-
Treatment response to hydroxychloroquine and antibiotics for mild to moderate COVID-19: a retrospective cohort study from South Korea	https://doi.org/10.1101/2020.07.04.20146548	07/07/2020	Preprint	10.1101/2020.07.04.20146548	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']	-	-	-	-	-	Resposta ao tratamento com hidroxicloroquina e antibióticos para COVID-19 leve a moderado: um estudo de coorte retrospectivo da Coréia do Sul 	-
Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France	https://doi.org/10.1101/2020.06.16.20132597	19/06/2020	Preprint	10.1101/2020.06.16.20132597	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']	-	-	-	-	-	Hidroxicloroquina com ou sem azitromicina e mortalidade ou alta hospitalar em pacientes hospitalizados por infecção por COVID-19: um estudo de coorte de 4.642 pacientes internados na França 	-
Renin-angiotensin system blockers and susceptibility to COVID-19: a multinational open science cohort study	http://medrxiv.org/content/early/2020/06/12/2020.06.11.20125849.abstract	12/06/2020	Preprint	http://medrxiv.org/content/early/2020/06/12/2020.06.11.20125849.abstract	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Antagonistas do Receptor da Angiotensina II']	['Angiotensin II Receptor Antagonists', 'Angiotensin II Receptor Antagonists']	There is no clinically significant increased risk of COVID-19 diagnosis or hospitalization with ACE or ARB use. Users should not discontinue or change their treatment to avoid COVID-19.	32587982	medRxiv : the preprint server for health sciences	1432-1416	10.1101/2020.06.11.20125849	Bloqueadores do sistema renina-angiotensina e suscetibilidade ao COVID-19: um estudo multinacional de coorte de ciência aberta 	Não há risco aumentado clinicamente significativo de diagnóstico de COVID-19 ou hospitalização com uso de ECA ou BRA. Os usuários não devem interromper ou alterar seu tratamento para evitar o COVID-19.
Pre exposure Hydroxychloroquine Prophylaxis for COVID-19 in healthcare workers: a retrospective cohort	https://doi.org/10.1101/2020.06.09.20116806	12/06/2020	Preprint	10.1101/2020.06.09.20116806	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']	-	-	-	-	-	Profilaxia com hidroxicloroquina pré-exposição para COVID-19 em profissionais de saúde: uma coorte retrospectiva 	-
Effect of tocilizumab in hospitalized patients with severe pneumonia COVID-19: a cohort study.	http://medrxiv.org/content/early/2020/06/09/2020.06.06.20122341.abstract	09/06/2020	Preprint	http://medrxiv.org/content/early/2020/06/09/2020.06.06.20122341.abstract	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Efeito do tocilizumab em pacientes hospitalizados com pneumonia grave COVID-19: um estudo de coorte. 	-
Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19: A Multicenter Cohort Study.	https://doi.org/10.1101/2020.06.08.20125245	09/06/2020	Preprint	10.1101/2020.06.08.20125245	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Efeitos do tocilizumab na mortalidade em pacientes hospitalizados com COVID-19: um estudo de coorte multicêntrico. 	-
Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs tested positive for SARS-CoV-2: a danish nationwide cohort study.	https://doi.org/10.1101/2020.06.08.20115683	09/06/2020	Preprint	10.1101/2020.06.08.20115683	-	-	-	-	-	-	-	-	['Anti-inflamatórios não esteroidais']	['Non-steroidal anti-inflammatory drugs']	The European Union electronic Register of Post-Authorisation Studies EUPAS34734.	32898149	PLoS medicine	1549-1676	10.1371/journal.pmed.1003308	Resultados adversos e mortalidade em usuários de anti-inflamatórios não esteroides com resultado positivo para SARS-CoV-2: um estudo de coorte nacional dinamarquês. 	O Registo Electrónico de Estudos Pós-Autorização da União Europeia EUPAS34734.
A shred of evidence that BCG vaccine may protect against COVID-19: Comparing cohorts in Spain and Italy.	http://medrxiv.org/content/early/2020/06/07/2020.06.05.20123539.abstract	07/06/2020	Preprint	http://medrxiv.org/content/early/2020/06/07/2020.06.05.20123539.abstract	-	-	-	-	-	-	-	-	['Vacina BCG']	['BCG vaccine']	-	-	-	-	-	Um fragmento de evidência de que a vacina BCG pode proteger contra o COVID-19: Comparando coortes na Espanha e na Itália. 	-
Ozone therapy for patients with SARS-COV-2 pneumonia: a single-center prospective cohort study.	https://www.medrxiv.org/content/10.1101/2020.06.03.20117994v2	01/06/2020	Preprint	10.1101/2020.06.03.20117994v2	-	-	-	-	-	-	-	-	['Ozonioterapia']	['Ozone Therapy']	-	-	-	-	-	Terapia de ozônio para pacientes com pneumonia por SARS-COV-2: um estudo de coorte prospectivo de centro único. 	-
Plasma concentration and safety of lopinavir/ritonavir in patients with Covid-19: a 2 retrospective cohort study	https://doi.org/10.1101/2020.05.18.20105650	22/05/2020	Preprint	10.1101/2020.05.18.20105650	-	-	-	-	-	-	-	-	[]	[]	-	-	-	-	-	Concentração plasmática e segurança de lopinavir/ritonavir em pacientes com Covid-19: um estudo de coorte retrospectivo de 2 	-
Impact of glucocorticoid treatment in Sars-CoV-2 infection mortality: a retrospective controlled Cohort Study	https://doi.org/10.1101/2020.05.22.20110544	26/05/2020	Preprint	10.1101/2020.05.22.20110544	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']	-	-	-	-	-	Impacto do tratamento com glicocorticóides na mortalidade por infecção por Sars-CoV-2: um estudo de coorte retrospectivo controlado 	-
Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs	https://www.medrxiv.org/content/10.1101/2020.04.30.20086090v1	05/05/2020	Preprint	10.1101/2020.04.30.20086090v1	-	-	-	-	-	-	-	-	['Abatacept', 'Adalimumabe', 'Anakinra', 'Baricitinibe', 'Certolizumabe Pegol', 'Etanercepte', 'Golimumabe', 'Infliximabe', 'Inibidores da fosfodiesterase-4', 'Ixequizumab', 'Ruxolitinibe', 'Sarilumabe', 'Secuquinumabe', 'Tocilizumabe', 'Tofacitinibe', 'Ustekinumabe']	['Abatacept', 'Adalimumab', 'Anakinra', 'Baricitinib', 'Certolizumab Pegol', 'Etanercept', 'Golimumab', 'Infliximab', 'Phosphodiesterase-4 inhibitors', 'Ixequizumab', 'Ruxolitinib', 'Sarilumab', 'Secukinumab', 'Tocilizumab', 'Tofacitinib', 'Ustekinumab']	-	-	-	-	-	Incidência de COVID-19 em uma coorte de pacientes adultos e pediátricos com doenças reumáticas tratados com medicamentos antirreumáticos modificadores da doença biológicos e sintéticos direcionados 	-
Clinical Efficacy of Intravenous Immunoglobulin Therapy in Critical Patients with COVID-19: A multicenter retrospective cohort study	http://medrxiv.org/content/early/2020/04/15/2020.04.11.20061739	11/04/2020	Preprint	http://medrxiv.org/content/early/2020/04/15/2020.04.11.20061739	-	-	-	-	-	-	-	-	['Imunoglobulina']	['Immunoglobulin']	-	-	-	-	-	Eficácia clínica da terapia com imunoglobulina intravenosa em pacientes críticos com COVID-19: um estudo de coorte retrospectivo multicêntrico 	-
Hydroxychloroquine (HCQ): an observational cohort study in primary and secondary prevention of pneumonia in an at-risk population	https://www.medrxiv.org/content/10.1101/2020.04.08.20057893v1	10/04/2020	Preprint	10.1101/2020.04.08.20057893v1	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']	-	-	-	-	-	Hidroxicloroquina (HCQ): um estudo de coorte observacional na prevenção primária e secundária de pneumonia em uma população de risco 	-
Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study	https://www.medrxiv.org/content/10.1101/2020.04.08.20054551v2	10/04/2020	Preprint	10.1101/2020.04.08.20054551v2	-	-	-	-	-	-	-	-	['Azitromicina', 'Azitromicina', 'Azitromicina', 'Azitromicina', 'Azitromicina', 'Azitromicina', 'Azitromicina', 'Azitromicina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Azithromycin', 'Azithromycin', 'Azithromycin', 'Azithromycin', 'Azithromycin', 'Azithromycin', 'Azithromycin', 'Azithromycin', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', ' Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine']	-	-	-	-	-	Segurança da hidroxicloroquina, sozinha e em combinação com azitromicina, à luz do uso rápido e generalizado para COVID-19: um estudo multinacional, de coorte de rede e série de casos autocontrolado 	-
A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort	https://doi.org/10.1007/s10096-020-04016-1	27/08/2020	Comunicação breve	10.1007/s10096-020-04016-1	0934-9723	9349723	EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (PRINT)	A3	1.205	111	4.42	-	['Ceftriaxona', 'Doxiciclina', 'Hidroxicloroquina', 'Lopinavir']	['Ceftriaxone', 'Doxycycline', 'Hydroxychloroquine', 'Lopinavir']	-	-	-	-	-	Uma nova abordagem para o gerenciamento de pacientes com COVID-19; resultados da coorte de lopinavir mais doxiciclina 	-
A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia	https://doi.org/10.1038/s41392-020-0158-2	28/04/2020	Carta do editor	10.1038/s41392-020-0158-2	2059-3635	20593635	Signal Transduction and Targeted Therapy	-	5.157	53	17.87	-	['Prednisona']	['Prednisone']	-	-	-	-	-	Um estudo de coorte retrospectivo da terapia com metilprednisolona em pacientes graves com pneumonia por COVID-19 	-
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact	https://doi.org/10.1016/j.jinf.2020.04.017	23/04/2020	Carta do editor	10.1016/j.jinf.2020.04.017	0163-4453	1634453	THE JOURNAL OF INFECTION	A2	5.027	119	15.14	-	['Baricitinibe']	['Baricitinib']	Personalizing the dose and duration of methylprednisolone according to the patient's disease severity assessed with demographic, clinical, and laboratory results may benefit mortality in severe COVID-19 patients receiving ventilatory support in the ICU. Hematologic disorders and malignancies, arterial blood pH and HCO3, neutrophil count, and NLR at admission were associated with mortality in our patient cohort.	32333918	The Journal of infection	1532-2742	10.1016/j.jinf.2020.04.017	Terapia com baricitinibe na COVID-19: um estudo piloto sobre segurança e impacto clínico 	Personalizar a dose e a duração da metilprednisolona de acordo com a gravidade da doença do paciente avaliada com resultados demográficos, clínicos e laboratoriais pode beneficiar a mortalidade em pacientes graves com COVID-19 que recebem suporte ventilatório em a UTI. Distúrbios hematológicos e malignidades, pH do sangue arterial e HCO3, contagem de neutrófilos e NLR na admissão foram associados à mortalidade em nossa coorte de pacientes.
Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study.	https://doi.org/10.1186/s12879-021-05773-w	14/01/2021	Artigo completo publicado em periódico científico	10.1186/s12879-021-05773-w	1471-2334	14712334	BMC INFECTIOUS DISEASES (ONLINE)	A3	1.042	112	3.75	 Abstract                  Background                 Hydroxychloroquine has not been associated with improved survival among hospitalized COVID-19 patients in the majority of observational studies and similarly was not identified as an effective prophylaxis following exposure in a prospective randomized trial. We aimed to explore the role of hydroxychloroquine therapy in mildly symptomatic patients diagnosed in the outpatient setting.                                Methods                 We examined the association between outpatient hydroxychloroquine exposure and the subsequent progression of disease among mildly symptomatic non-hospitalized patients with documented SARS-CoV-2 infection. The primary outcome assessed was requirement of hospitalization. Data was obtained from a retrospective review of electronic health records within a New Jersey USA multi-hospital network. We compared outcomes in patients who received hydroxychloroquine with those who did not applying a multivariable logistic model with propensity matching.                                Results                 Among 1274 outpatients with documented SARS-CoV-2 infection 7.6% were prescribed hydroxychloroquine. In a 1067 patient propensity matched cohort, 21.6% with outpatient exposure to hydroxychloroquine were hospitalized, and 31.4% without exposure were hospitalized. In the primary multivariable logistic regression analysis with propensity matching there was an association between exposure to hydroxychloroquine and a decreased rate of hospitalization from COVID-19 (OR 0.53; 95% CI, 0.29, 0.95). Sensitivity analyses revealed similar associations. QTc prolongation events occurred in 2% of patients prescribed hydroxychloroquine with no reported arrhythmia events among those with data available.                                Conclusions                 In this retrospective observational study of SARS-CoV-2 infected non-hospitalized patients hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization. Additional exploration of hydroxychloroquine in this mildly symptomatic outpatient population is warranted.              	['Hidroxicloroquina']	['Hydroxychloroquine']	In this retrospective observational study of SARS-CoV-2 infected non-hospitalized patients hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization. Additional exploration of hydroxychloroquine in this mildly symptomatic outpatient population is warranted.	33446136	BMC infectious diseases	1471-2334	10.1186/s12879-021-05773-w	Hidroxicloroquina no tratamento de pacientes ambulatoriais com COVID-19 levemente sintomático: um estudo observacional multicêntrico. 	Neste estudo observacional retrospectivo de pacientes não hospitalizados infectados com SARS-CoV-2, a exposição à hidroxicloroquina foi associada a uma diminuição da taxa de hospitalização subsequente. A exploração adicional de hidroxicloroquina nesta população ambulatorial levemente sintomática é justificada.
Corticosteroid treatment has no efect on hospital mortality in COVID‐19 patients.	https://doi.org/10.1038/s41598-020-80654-x	13/01/2021	Artigo completo publicado em periódico científico	10.1038/s41598-020-80654-x	2045-2322	20452322	SCIENTIFIC REPORTS	A2	1.005	242	4.81	 Abstract Since the start of the novel coronavirus 2019 (COVID-19) pandemic, corticosteroid use has been the subject of debate. The available evidence is uncertain, and knowledge on the subject is evolving. The aim of our cohort study was to evaluate the association between corticosteroid therapy and hospital mortality, in patients hospitalized with COVID-19 after balancing for possible confounders. One thousand four hundred forty four patients were admitted to our hospital with a positive RT-PCR test for SARS-CoV-2, 559 patients (39%) were exposed to corticosteroids during hospital stay, 844 (61%) were not exposed to corticosteroids. In the cohort of patients exposed to corticosteroids, 171 (30.6%) died. In the cohort of patients not exposed to corticosteroids, 183 (21.7%) died (unadjusted  p &lt; 0.001). Nonetheless, exposure to corticosteroids was not associated with in-hospital mortality after balancing with overlap weight propensity score (adjusted  p = 0.25). Patients in the corticosteroids cohort had a reduced risk of ICU admission (adjusted  p &lt; 0.001). Treatment with corticosteroids did not affect hospital mortality in patients with COVID-19 after balancing for confounders. A possible advantage of corticosteroid therapy was to reduce Intensive Care Unit admission, which could be useful in reducing pressure on Intensive Care Units in times of limited resources, as during the COVID-19 pandemic.	['Corticosteroides']	['Corticosteroids']	-	-	-	-	-	O tratamento com corticosteroides não tem efeito na mortalidade hospitalar em pacientes com COVID-19. 	-
The use of methylprednisolone in COVID-19 patients: A propensity score matched retrospective cohort study.	https://doi.org/10.1371/journal.pone.0244128	31/12/2020	Artigo completo publicado em periódico científico	10.1371/journal.pone.0244128	1932-6203	19326203	PLOS ONE	A1	0.852	367	3.8	<jats:sec id="sec001"> Purpose To evaluate the efficacy and safety of methylprednisolone in treating the coronavirus disease 2019 (COVID-19) patients.<jats:sec id="sec002"> Methods A retrospective cohort study was conducted, and all COVID-19 patients were recruited who were admitted to the Yichang Third People’s Hospital from February 1 st to March 31 st, 2020. One-to-one propensity score matching (PSM) was used for minimizing confounding effects. The primary outcome was hospital mortality, with the secondary outcomes being the time needed for a positive SARS-CoV-2 nucleic acid test to turn negative and the length of hospital stay.<jats:sec id="sec003"> Results Totaling 367 patients with COVID-19 hospitalized at the Yichang Third People’s Hospital were identified, of whom 276 were mild or stable COVID-19, and 67 were serious or critically ill. Among them, 255 patients were treated using methylprednisolone, and 188 did not receive any corticosteroid-related treatment. After PSM, no statistically significant difference was found in the baseline characteristics between the two groups. Regarding the outcomes, there also were no statistically significant difference between the two groups. Patients without the use of methylprednisolone were more quickly to obtain negative results of their nasopharyngeal swab tests of SARS-CoV-2 nucleic acid after treatment, compared to those receiving methylprednisolone.<jats:sec id="sec004"> Conclusion Methylprednisolone could not improve the prognosis of patients with COVID-19, and the efficacy and safety of the use of methylprednisolone in patients with COVID-19 still remain uncertain, thus the use of corticosteroids clinically in patients with COVID-19 should be with cautions.	['Prednisona']	['Prednisone']	-	-	-	-	-	O uso de metilprednisolona em pacientes com COVID-19: um estudo de coorte retrospectivo combinado com escore de propensão. 	-
Efficacy Evaluation of Intravenous Immunoglobulin in Non-severe Patients with COVID-19: A Retrospective Cohort Study Based on Propensity Score Matching.	https://doi.org/10.1016/j.ijid.2021.01.009	09/01/2021	Artigo completo publicado em periódico científico	10.1016/j.ijid.2021.01.009	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Imunoglobulina']	['Immunoglobulin']	In non-severe patients with COVID-19, no benefit was observed with IVIG therapy beyond standard therapy.	33434674	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases	1878-3511	10.1016/j.ijid.2021.01.009	Avaliação da eficácia da imunoglobulina intravenosa em pacientes não graves com COVID-19: um estudo de coorte retrospectivo baseado na correspondência de pontuação de propensão. 	Em pacientes não graves com COVID-19, nenhum benefício foi observado com a terapia IVIG além da terapia padrão.
Impact of oral anticoagulation on clinical outcomes of COVID‐19: a nationwide cohort study of hospitalized patients in Germany.	https://doi.org/10.1007/s00392-020-01783-x	08/01/2021	Artigo completo publicado em periódico científico	10.1007/s00392-020-01783-x	1861-0684	18610684	CLINICAL RESEARCH IN CARDIOLOGY (PRINT)	A2	1.772	75	4.86	-	['Antagonistas da vitamina K (AVK)', 'Anticoagulantes']	['Vitamin K antagonists (VKA)', 'Anticoagulants']	In a multivariable analysis, a therapy with both direct oral anticoagulants or vitamin-K antagonists-but not with antiplatelet therapy-was associated with improved clinical outcomes. ACE inhibitors did not impact outcomes. Prospective randomized trials are needed to verify this hypothesis.	33416918	Clinical research in cardiology : official journal of the German Cardiac Society	1861-0692	10.1007/s00392-020-01783-x	Impacto da anticoagulação oral nos resultados clínicos do COVID-19: um estudo de coorte nacional de pacientes hospitalizados na Alemanha. 	Em uma análise multivariada, uma terapia com anticoagulantes orais diretos ou antagonistas da vitamina K, mas não com terapia antiplaquetária, foi associada a melhores resultados clínicos. Os inibidores da ECA não afetaram os resultados. Ensaios prospectivos randomizados são necessários para verificar essa hipótese.
Matched cohort study on the efficacy of tocilizumab in patients with COVID-19.	https://doi.org/10.1016/j.onehlt.2021.100214	05/01/2021	Artigo completo publicado em periódico científico	10.1016/j.onehlt.2021.100214	2352-7714	23527714	ONE HEALTH	A4	1.149	29	7.65	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Estudo de coorte pareado sobre a eficácia do tocilizumabe em pacientes com COVID-19. 	-
Therapeutic plasma exchange for coronavirus disease-2019 triggered cytokine release syndrome; a retrospective propensity matched control study.	https://doi.org/10.1371/journal.pone.0244853	07/01/2021	Artigo completo publicado em periódico científico	10.1371/journal.pone.0244853	1932-6203	19326203	PLOS ONE	A1	0.852	367	3.8	<jats:sec id="sec001"> Background Cytokine release syndrome (CRS) plays a pivotal role in the pathophysiology and progression of Coronavirus disease-2019 (COVID-19). Therapeutic plasma exchange (TPE) by removing the pathogenic cytokines is hypothesized to dampen CRS.<jats:sec id="sec002"> Objective To evaluate the outcomes of the patients with COVID-19 having CRS being treated with TPE compared to controls on the standard of care.<jats:sec id="sec003"> Methodology Retrospective propensity score-matched analysis in a single centre from 1st April to 31st July 2020. We retrospectively analyzed data of 280 hospitalized patients developing CRS initially. PSM was used to minimize bias from non-randomized treatment assignment. Using PSM 1:1, 90 patients were selected and assigned to 2 equal groups. Forced matching was done for disease severity, routine standard care and advanced supportive care. Many other Co-variates were matched. Primary outcome was 28 days overall survival. Secondary outcomes were duration of hospitalization, CRS resolution time and timing of viral clearance on Polymerase chain reaction testing.<jats:sec id="sec004"> Results After PS-matching, the selected cohort had a median age of 60 years (range 32–73 in TPE, 37–75 in controls), p = 0.325 and all were males. Median symptoms duration was 7 days (range 3–22 days’ TPE and 3–20 days controls), p = 0.266. Disease severity in both groups was 6 (6.6%) moderate, 40 (44.4%) severe and 44 (49%) critical. Overall, 28-day survival was significantly superior in the TPE group (91.1%), 95% CI 78.33–97.76; as compared to PS-matched controls (61.5%), 95% CI 51.29–78.76 (log rank 0.002), p&lt;0.001. Median duration of hospitalization was significantly reduced in the TPE treated group (10 days vs 15 days) (p&lt; 0.01). CRS resolution time was also significantly reduced in the TPE group (6 days vs. 12 days) (p&lt; 0.001). In 71 patients who underwent TPE, the mortality was 0 (n = 43) if TPE was done within the first 12 days of illness while it was 17.9% (deaths 5, n = 28 who received it after 12 th day (p = 0.0045).<jats:sec id="sec005"> Conclusion An earlier use of TPE was associated with improved overall survival, early CRS resolution and time to discharge compared to SOC for COVID-19 triggered CRS in this selected cohort of PS-matched male patients from one major hospital in Pakistan.	['Plasma convalescente']	['Convalescent Plasma']	-	-	-	-	-	A troca de plasma terapêutica para a doença de coronavírus-2019 desencadeou a síndrome de liberação de citocinas; um estudo de controle retrospectivo com correspondência de propensão. 	-
A single center cohort of 40 severe COVID-19 patients who were treated with convalescent plasma.	https://pubmed.ncbi.nlm.nih.gov/33078604/	17/12/2020	Artigo completo publicado em periódico científico	PUBMED_ID:33078604/	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']	According  to  the  results  of  this  study,  CP  is  an  efficient  conjunct  to  conventional  therapy  against  COVID-19  with  a  favorable safety profile.	33078604	Turkish journal of medical sciences	1303-6165	10.3906/sag-2009-77	Uma coorte de centro único de 40 pacientes graves com COVID-19 que foram tratados com plasma convalescente. 	De acordo com os resultados deste estudo, a CP é um conjunto eficiente à terapia convencional contra a COVID-19 com perfil de segurança favorável.
Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study.	https://doi.org/10.1186/s13054-020-03422-3	04/01/2021	Artigo completo publicado em periódico científico	10.1186/s13054-020-03422-3	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	 Abstract                  Background                 Critically ill patients with coronavirus disease 19 (COVID-19) have a high fatality rate likely due to a dysregulated immune response. Corticosteroids could attenuate this inappropriate response, although there are still some concerns regarding its use, timing, and dose.                                Methods                 This is a nationwide, prospective, multicenter, observational, cohort study in critically ill adult patients with COVID-19 admitted into Intensive Care Units (ICU) in Spain from 12th March to 29th June 2020. Using a multivariable Cox model with inverse probability weighting, we compared relevant outcomes between patients treated with early corticosteroids (before or within the first 48 h of ICU admission) with those who did not receive early corticosteroids (delayed group) or any corticosteroids at all (never group). Primary endpoint was ICU mortality. Secondary endpoints included 7-day mortality, ventilator-free days, and complications.                                Results                 A total of 691 patients out of 882 (78.3%) received corticosteroid during their hospital stay. Patients treated with early-corticosteroids (n = 485) had lower ICU mortality (30.3% vs. never 36.6% and delayed 44.2%) and lower 7-day mortality (7.2% vs. never 15.2%) compared to non-early treated patients. They also had higher number of ventilator-free days, less length of ICU stay, and less secondary infections than delayed treated patients. There were no differences in medical complications between groups. Of note, early use of moderate-to-high doses was associated with better outcomes than low dose regimens.                                Conclusion                 Early use of corticosteroids in critically ill patients with COVID-19 is associated with lower mortality than no or delayed use, and fewer complications than delayed use.              	['Corticosteroides']	['Corticosteroids']	-	-	-	-	-	Corticosteroides precoces estão associados a menor mortalidade em pacientes críticos com COVID-19: um estudo de coorte. 	-
Long-term ACE Inhibitor/ARB Use Is Associated With Severe Renal Dysfunction and Acute Kidney Injury in Patients With Severe COVID-19: Results From a Referral Center Cohort in the Northeast of France.	https://doi.org/10.1093/cid/ciaa677	05/07/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa677	1058-4838	10584838	CLINICAL INFECTIOUS DISEASES	A1	4.394	353	8.72	 Abstract                                   Background                   In patients with severe coronavirus disease 2019 (COVID-19), data are scarce and conflicting regarding whether chronic use of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) influences disease outcomes. In patients with severe COVID-19, we assessed the association between chronic ACEI/ARB use and the occurrence of kidney, lung, heart, and liver dysfunctions and the severity of the inflammatory reaction as evaluated by biomarkers kinetics, and their association with disease outcomes.                                                  Methods                   We performed a retrospective longitudinal cohort study on consecutive patients with newly diagnosed severe COVID-19. Independent predictors were assessed through receiver operating characteristic analysis, time-series analysis, logistic regression analysis, and multilevel modeling for repeated measures.                                                  Results                   On the 149 patients included in the study 30% (44/149) were treated with ACEI/ARB. ACEI/ARB use was independently associated with the following biochemical variations: phosphorus &amp;gt;40 mg/L (odds ratio [OR], 3.35, 95% confidence interval [CI], 1.83–6.14), creatinine &amp;gt;10.1 mg/L (OR, 3.22, 2.28–4.54), and urea nitrogen (UN) &amp;gt;0.52 g/L (OR, 2.65, 95% CI, 1.89–3.73). ACEI/ARB use was independently associated with acute kidney injury stage ≥1 (OR, 3.28, 95% CI, 2.17–4.94). The daily dose of ACEI/ARB was independently associated with altered kidney markers with an increased risk of +25 to +31% per each 10 mg increment of lisinopril-dose equivalent. In multivariable multilevel modeling, UN &amp;gt;0.52 g/L was independently associated with the risk of acute respiratory failure (OR, 3.54, 95% CI, 1.05–11.96).                                                  Conclusions                   Patients chronically treated with ACEI/ARB who have severe COVID-19 are at increased risk of acute kidney injury. In these patients, the increase in UN associated with ACEI/ARB use could predict the development of acute respiratory failure.               	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	Patients chronically treated with ACEI/ARB who have severe COVID-19 are at increased risk of acute kidney injury. In these patients, the increase in UN associated with ACEI/ARB use could predict the development of acute respiratory failure.	32623470	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America	1537-6591	10.1093/cid/ciaa677	O uso prolongado de inibidor da ECA/BRA está associado a disfunção renal grave e lesão renal aguda em pacientes com COVID-19 grave: resultados de uma coorte de centro de referência no nordeste da França. 	Pacientes tratados cronicamente com IECA/BRA que têm COVID-19 grave têm risco aumentado de lesão renal aguda. Nesses pacientes, o aumento do UN associado ao uso de IECA/BRA poderia predizer o desenvolvimento de insuficiência respiratória aguda.
Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: a retrospective cohort study.	https://doi.org/10.1016/j.diabres.2020.108619	10/12/2020	Artigo completo publicado em periódico científico	10.1016/j.diabres.2020.108619	0168-8227	1688227	DIABETES RESEARCH AND CLINICAL PRACTICE (PRINT)	A3	1.677	122	6.69	-	['Metformina']	['Metformin']	-	-	-	-	-	Associação de metformina com mortalidade ou SDRA em pacientes com COVID-19 e diabetes tipo 2: um estudo de coorte retrospectivo. 	-
Effects of Tocilizumab in COVID-19 patients: a cohort study.	https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05701-4	22/12/2020	Artigo completo publicado em periódico científico	https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05701-4	1471-2334	14712334	BMC INFECTIOUS DISEASES (ONLINE)	A3	1.042	112	3.75	 Abstract                  Background                 Due to the lack of proven therapies, we evaluated the effects of early administration of tocilizumab for COVID-19. By inhibition of the IL-6 receptor, tocilizumab may help to mitigate the hyperinflammatory response associated with progressive respiratory failure from SARS-CoV-2.                                Methods                 A retrospective, observational study was conducted on hospitalized adults who received intravenous tocilizumab for COVID-19 between March 23, 2020 and April 10, 2020.                                Results                 Most patients were male (66.7%), Hispanic (63.3%) or Black (23.3%), with a median age of 54 years. Tocilizumab was administered at a median of 8 days (range 1–21) after initial symptoms and 2 days (range 0–12) after hospital admission. Within 30 days from receiving tocilizumab, 36 patients (60.0%) demonstrated clinical improvement, 9 (15.0%) died, 33 (55.0%) were discharged alive, and 18 (30.0%) remained hospitalized. Successful extubation occurred in 13 out of 29 patients (44.8%). Infectious complications occurred in 16 patients (26.7%) at a median of 10.5 days. After tocilizumab was administered, there was a slight increase in PaO 2/FiO 2 and an initial reduction in CRP, but this effect was not sustained beyond day 10.                                Conclusions                 Majority of patients demonstrated clinical improvement and were successfully discharged alive from the hospital after receiving tocilizumab. We observed a rebound effect with CRP, which may suggest the need for higher or subsequent doses to adequately manage cytokine storm. Based on our findings, we believe that tocilizumab may have a role in the early treatment of COVID-19, however larger randomized controlled studies are needed to confirm this.              	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Efeitos do Tocilizumab em pacientes com COVID-19: um estudo de coorte. 	-
Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation, the experience from Shanghai	https://pubmed.ncbi.nlm.nih.gov/33342929/	18/12/2020	Artigo completo publicado em periódico científico	PUBMED_ID:33342929/	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']	The aim of this study is to assess the efficacy of multiple treatments, especially hydroxychloroquine, used in different disease stages of coronavirus disease 2019 (COVID-19). All consecutive patients with COVID-19 admitted to Shanghai Public Health Clinical Center (Shanghai, China) between January 20, 2020, and April 30, 2020, were enrolled, and their clinical data were retrospectively collected. Binary logistic regression was used to screen the factors associated with disease aggravation, and multivariable analyses with the Cox proportional hazards model were used to estimate the effects of prognostic factors on the improvement time and PCR conversion days in throat swabs and stool swabs. A total of 616 patients, including 50 (8.11%) severe and 18 (2.92%) critical patients, were enrolled in our retrospective cohort study. The early use of hydroxychloroquine was a protective factor associated with disease aggravation (95% CI: 0.040-0.575, p = 0.006). Clinical improvement by 20 days was significantly different between patients with hydroxychloroquine used early and those with hydroxychloroquine not used (p = 0.016, 95% CI: 1.052-1.647). The median time to clinical improvement was 6 days in the hydroxychloroquine used early group, compared with 9 days in the without hydroxychloroquine used group and 8 days in the with hydroxychloroquine not used early group (p < 0.001). Hydroxychloroquine used early was associated with earlier PCR conversion in both throat swabs (HR = 1.558, p = 0.001) and stool swabs (HR = 1.400, p = 0.028). The use of hydroxychloroquine at an early stage is a potential therapeutic strategy for treating patients before irreversible severe respiratory complications occur. The early use of hydroxychloroquine decreased the improvement time and the duration of COVID-19 detection in throat and stool swabs.	33342929	Bioscience trends	1881-7823	10.5582/bst.2020.03340	Eficácia do tratamento precoce com hidroxicloroquina na prevenção do agravamento da pneumonia por COVID-19, a experiência de 	Xangai Todos os pacientes consecutivos com COVID-19 admitidos no Centro Clínico de Saúde Pública de Xangai (Xangai, China) entre 20 de janeiro de 2020 e 30 de abril de 2020 foram inscritos e seus dados clínicos foram coletados retrospectivamente. A regressão logística binária foi usada para rastrear os fatores associados ao agravamento da doença, e análises multivariáveis com o modelo de risco proporcional de Cox foram usadas para estimar os efeitos dos fatores prognósticos no tempo de melhora e dias de conversão de PCR em swabs de garganta e fezes. Um total de 616 pacientes, incluindo 50 (8,11%) pacientes graves e 18 (2,92%) críticos, foram incluídos em nosso estudo de coorte retrospectivo. O uso precoce de hidroxicloroquina foi fator protetor associado ao agravamento da doença (IC 95%: 0,040-0,575, p = 0,006). A melhora clínica em 20 dias foi significativamente diferente entre os pacientes com hidroxicloroquina usada precocemente e aqueles com hidroxicloroquina não usada (p = 0,016, IC 95%: 1,052-1,647). A mediana de tempo para melhora clínica foi de 6 dias no grupo precoce com hidroxicloroquina, comparado com 9 dias no grupo sem uso de hidroxicloroquina e 8 dias no grupo sem uso de hidroxicloroquina precoce (p < 0,001). A hidroxicloroquina usada precocemente foi associada à conversão precoce de PCR em swabs de garganta (HR = 1,558, p = 0,001) e swabs de fezes (HR = 1,400, p = 0,028). O uso de hidroxicloroquina em estágio inicial é uma estratégia terapêutica potencial para tratar pacientes antes que ocorram complicações respiratórias graves irreversíveis. O uso precoce de hidroxicloroquina diminuiu o tempo de melhora e a duração da detecção de COVID-19 em swabs de garganta e fezes.
Corticosteroid therapy in critically ill patients with COVID‑19: a multicenter, retrospective study.	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03429-w	18/12/2020	Artigo completo publicado em periódico científico	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03429-w	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	 Abstract                  Background                 Corticoid therapy has been recommended in the treatment of critically ill patients with COVID-19, yet its efficacy is currently still under evaluation. We investigated the effect of corticosteroid treatment on 90-day mortality and SARS-CoV-2 RNA clearance in severe patients with COVID-19.                                Methods                 294 critically ill patients with COVID-19 were recruited between December 30, 2019 and February 19, 2020. Logistic regression, Cox proportional-hazards model and marginal structural modeling (MSM) were applied to evaluate the associations between corticosteroid use and corresponding outcome variables.                                Results                 Out of the 294 critically ill patients affected by COVID-19, 183 (62.2%) received corticosteroids, with methylprednisolone as the most frequently administered corticosteroid (175 accounting for 96%). Of those treated with corticosteroids, 69.4% received corticosteroid prior to ICU admission. When adjustments and subgroup analysis were not performed, no significant associations between corticosteroids use and 90-day mortality or SARS-CoV-2 RNA clearance were found. However, when stratified analysis based on corticosteroid initiation time was performed, there was a significant correlation between corticosteroid use (≤ 3 day after ICU admission) and 90-day mortality (logistic regression adjusted for baseline: OR 4.49, 95% CI 1.17–17.25,  p = 0.025; Cox adjusted for baseline and time varying variables: HR 3.89, 95% CI 1.94–7.82,  p &lt; 0.001; MSM adjusted for baseline and time-dependent variants: OR 2.32, 95% CI 1.16–4.65,  p = 0.017). No association was found between corticosteroid use and SARS-CoV-2 RNA clearance even after stratification by initiation time of corticosteroids and adjustments for confounding factors (corticosteroids use ≤ 3 days initiation vs no corticosteroids use) using MSM were performed.                                Conclusions                 Early initiation of corticosteroid use (≤ 3 days after ICU admission) was associated with an increased 90-day mortality. Early use of methylprednisolone in the ICU is therefore not recommended in patients with severe COVID-19.              	['Corticosteroides', 'Corticosteroides']	['Corticosteroids', 'Corticosteroids']	in our multicenter retrospective cohort of COVID-19 patients undergoing MV, early corticosteroid therapy was independently associated with VA-LRTI.	35630429	Microorganisms	2076-2607	10.3390/microorganisms10050984	Corticoterapia em pacientes críticos com COVID-19: um estudo multicêntrico, retrospectivo. 	em nossa coorte retrospectiva multicêntrica de pacientes com COVID-19 submetidos a VM, a terapia precoce com corticosteróides foi independentemente associada a AV-LRTI.
Tocilizumab in the Treatment of Critical COVID-19 Pneumonia: A Retrospective Cohort Study of Mechanically Ventilated Patients.	https://doi.org/10.1016/j.ijid.2020.12.021	10/12/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.12.021	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Tocilizumabe']	['Tocilizumab']	When controlling for age, severity of illness, and co-morbidities, tocilizumab was not associated with reduction in mortality in this retrospective cohort study of mechanically ventilated patients with COVID-19 pneumonia. Further studies are needed to determine the role of tocilizumab in the treatment of COVID-19.	33333252	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases	1878-3511	10.1016/j.ijid.2020.12.021	Tocilizumab no tratamento da pneumonia crítica por COVID-19: um estudo de coorte retrospectivo de pacientes ventilados mecanicamente. 	Ao controlar a idade, gravidade da doença e comorbidades, o tocilizumabe não foi associado à redução da mortalidade neste estudo de coorte retrospectivo de pacientes ventilados mecanicamente com pneumonia por COVID-19. Mais estudos são necessários para determinar o papel do tocilizumab no tratamento da COVID-19.
Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study.	https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0243961	16/12/2020	Artigo completo publicado em periódico científico	https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0243961	-	-	-	-	-	-	-	-	['Anakinra', 'Corticosteroides']	['Anakinra', 'Corticosteroids']	In COVID-19 non-ICU inpatients at the cytokine release phase, corticosteroids with or without anakinra were associated with a 30% decrease of death risk on Day 15.	33326457	PloS one	1932-6203	10.1371/journal.pone.0243961	Glicocorticóides com resgate de anakinra anti-IL1 em baixa dose em infecção grave por COVID-19 não UTI: Um estudo de coorte. 	Em pacientes com COVID-19 não internados em UTI na fase de liberação de citocinas, corticosteroides com ou sem anakinra foram associados a uma redução de 30% no risco de morte no dia 15.
Low 25-Hydroxyvitamin D Levels on Admission to the Intensive Care Unit May Predispose COVID-19 Pneumonia Patients to a Higher 28-Day Mortality Risk: A Pilot Study on a Greek ICU Cohort.	https://www.mdpi.com/2072-6643/12/12/3773	09/12/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2072-6643/12/12/3773	-	-	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']	-	-	-	-	-	Níveis baixos de 25-hidroxivitamina D na admissão à unidade de terapia intensiva podem predispor pacientes com pneumonia por COVID-19 a um risco maior de mortalidade em 28 dias: um estudo piloto em uma coorte de UTI grega. 	-
High-Dose Cholecalciferol Booster Therapy is Associated with a Reduced Risk of Mortality in Patients with COVID-19: A Cross-Sectional Multi-Centre Observational Study.	https://www.mdpi.com/2072-6643/12/12/3799	11/12/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2072-6643/12/12/3799	-	-	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']	The worldwide pandemic of 2019 novel coronavirus disease (COVID-19) has posed the most substantial and severe public health issue for several generations, and therapeutic options have not yet been optimised. Vitamin D (in its "parent" form, cholecalciferol) has been proposed in the pharmacological management of COVID-19 by various sources. We aimed to determine whether COVID-19 mortality was affected by serum 25-hydroxyvitamin D (25(OH)D) levels, vitamin D status, or cholecalciferol therapy, and to elucidate any other predictors of COVID-19 mortality. Patients hospitalised with COVID-19 were opportunistically recruited from three UK hospitals, and their data were collected retrospectively. Logistic regression was used to determine any relationships between COVID-19 mortality and potential predictors, including 25(OH)D levels and cholecalciferol booster therapy. A total of 986 participants with COVID-19 were studied, of whom 151 (16.0%) received cholecalciferol booster therapy. In the primary cohort of 444 patients, cholecalciferol booster therapy was associated with a reduced risk of COVID-19 mortality, following adjustment for potential confounders (OR	33322317	Nutrients	2072-6643	10.3390/nu12123799	A terapia de reforço com colecalciferol em altas doses está associada a um risco reduzido de mortalidade em pacientes com COVID-19: um estudo observacional multicêntrico transversal. 	A pandemia mundial de 2019 da doença do novo coronavírus (COVID-19) representou o problema de saúde pública mais substancial e grave por várias gerações, e as opções terapêuticas ainda não foram otimizadas. A vitamina D (em sua forma "pai", colecalciferol) foi proposta no manejo farmacológico do COVID-19 por várias fontes. Nosso objetivo foi determinar se a mortalidade por COVID-19 foi afetada pelos níveis séricos de 25-hidroxivitamina D (25(OH)D), status de vitamina D ou terapia com colecalciferol e elucidar quaisquer outros preditores de mortalidade por COVID-19. Pacientes hospitalizados com COVID-19 foram recrutados de forma oportunista em três hospitais do Reino Unido e seus dados foram coletados retrospectivamente. A regressão logística foi usada para determinar quaisquer relações entre a mortalidade por COVID-19 e potenciais preditores, incluindo níveis de 25(OH)D e terapia de reforço com colecalciferol. Um total de 986 participantes com COVID-19 foram estudados, dos quais 151 (16,0%) receberam terapia de reforço com colecalciferol. Na coorte primária de 444 pacientes, a terapia de reforço com colecalciferol foi associada a um risco reduzido de mortalidade por COVID-19, após ajuste para possíveis fatores de confusão (OR
Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: A population-based cohort study	https://doi.org/10.1016/j.cmi.2020.12.003	10/12/2020	Artigo completo publicado em periódico científico	10.1016/j.cmi.2020.12.003	1198-743X	1198743X	CLINICAL MICROBIOLOGY AND INFECTION (PRINT)	A1	3.111	167	7.73	-	['Hidroxicloroquina']	['Hydroxychloroquine']	HCQ prophylactic use at a usual dose did not prevent COVID-19 in patients with rheumatic disease.	33316402	Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases	1469-0691	10.1016/j.cmi.2020.12.003	Efeito da pré-exposição à hidroxicloroquina na infecção por SARS-CoV-2 em pacientes com doença reumática: Um estudo de coorte 	populacional O uso profilático de HCQ em uma dose usual não preveniu o COVID-19 em pacientes com doença reumática.
First Report of Tocilizumab Use in a Cohort of Latin American Patients Hospitalized for Severe COVID-19 Pneumonia.	https://www.frontiersin.org/articles/10.3389/fmed.2020.596916/full	16/11/2020	Artigo completo publicado em periódico científico	10.3389/fmed.2020.596916/full	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Primeiro relato de uso de tocilizumabe em uma coorte de pacientes latino-americanos hospitalizados por pneumonia grave por COVID-19. 	-
Anakinra treatment in critically ill COVID‑19 patients: a prospective cohort study.	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03364-w	10/12/2020	Artigo completo publicado em periódico científico	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03364-w	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	 Abstract                  Background                 A subset of critically ill COVID-19 patients develop a hyperinflammatory state. Anakinra, a recombinant interleukin-1 receptor antagonist, is known to be effective in several hyperinflammatory diseases. We investigated the effects of anakinra on inflammatory parameters and clinical outcomes in critically ill, mechanically ventilated COVID-19 patients with clinical features of hyperinflammation.                                Methods                 In this prospective cohort study, 21 critically ill COVID-19 patients treated with anakinra were compared to a group of standard care. Serial data of clinical inflammatory parameters and concentrations of multiple circulating cytokines were determined and aligned on start day of anakinra in the treatment group, and median start day of anakinra in the control group. Analysis was performed for day − 10 to + 10 relative to alignment day. Clinical outcomes were analyzed during 28 days. Additionally, three sensitivity analyses were performed: (1) using propensity score-matched groups, (2) selecting patients who did not receive corticosteroids, and (3) using a subset of the control group aimed to match the criteria (fever, elevated ferritin) for starting anakinra treatment.                                Results                 Baseline patient characteristics and clinical parameters on ICU admission were similar between groups. As a consequence of bias by indication, plasma levels of aspartate aminotransferase (ASAT) ( p = 0.0002), ferritin ( p = 0.009), and temperature ( p = 0.001) were significantly higher in the anakinra group on alignment day. Following treatment, no relevant differences in kinetics of circulating cytokines were observed between both groups. Decreases of clinical parameters, including temperature ( p = 0.03), white blood cell counts ( p = 0.02), and plasma levels of ferritin ( p = 0.003), procalcitonin ( p = 0.001), creatinine ( p = 0.01), and bilirubin ( p = 0.007), were more pronounced in the anakinra group. No differences in duration of mechanical ventilation or ICU length of stay were observed between groups. Sensitivity analyses confirmed these results.                                Conclusions                 Anakinra is effective in reducing clinical signs of hyperinflammation in critically ill COVID-19 patients. A randomized controlled trial is warranted to draw conclusion about the effects of anakinra on clinical outcomes.              	['Anakinra', 'Anakinra']	['Anakinra', 'Anakinra']	-	-	-	-	-	Tratamento com Anakinra em pacientes criticamente doentes com COVID-19: um estudo de coorte prospectivo. 	-
Severe COVID-19 pneumonia in Piacenza, Italy – a cohort study of the first pandemic wave.	https://www.sciencedirect.com/science/article/pii/S1876034120307516?via%3Dihub	09/12/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S1876034120307516?via%3Dihub	-	-	-	-	-	-	-	-	['Antivirais', 'Antivirais', 'Antivirais', 'Antivirais', 'Corticosteroides', 'Corticosteroides', 'Corticosteroides', 'Corticosteroides']	['Antivirals', 'Antivirals', 'Antivirals', 'Antivirals', 'Corticosteroids', 'Corticosteroids', 'Corticosteroids', 'Corticosteroids']	Overall case fatality rates were high and associated with comorbidities, extensive lung involvement, ARDS at admission, and advanced age. The use of antivirals was not associated with increased survival.	33497876	Journal of infection and public health	1876-035X	10.1016/j.jiph.2020.11.012	Pneumonia grave por COVID-19 em Piacenza, Itália – um estudo de coorte da primeira onda pandêmica. 	As taxas gerais de letalidade foram altas e associadas a comorbidades, envolvimento pulmonar extenso, SDRA na admissão e idade avançada. O uso de antivirais não foi associado ao aumento da sobrevida.
Association between statin use and outcomes in patients with coronavirus disease 2019 (COVID-19): a nationwide cohort study.	https://bmjopen.bmj.com/content/10/12/e044421.citation-tools	04/12/2020	Artigo completo publicado em periódico científico	https://bmjopen.bmj.com/content/10/12/e044421.citation-tools	-	-	-	-	-	-	-	-	['Estatina']	['Statin']	-	-	-	-	-	Associação entre uso de estatinas e resultados em pacientes com doença por coronavírus 2019 (COVID-19): um estudo de coorte nacional. 	-
Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis.	https://doi.org/10.1016/S2666-7568(20)30033-7	03/12/2020	Artigo completo publicado em periódico científico	10.1016/S2666-7568(20)30033-7	2666-7568	26667568	Lancet Healthy Longevity, The	-	4.366	10	7.42	-	['Metformina']	['Metformin']	-	-	-	-	-	Metformina e risco de mortalidade em pacientes hospitalizados com COVID-19: uma análise de coorte retrospectiva. 	-
Mortality reduction in 46 patients with severe COVID-19 treated with hyperimmune plasma. A proof-of-concept, single-arm, multicenter trial.	https://pubmed.ncbi.nlm.nih.gov/32703797/	23/07/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32703797/	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']	Hyperimmune plasma from Covid-19 convalescent is a potential treatment for severe Covid-19. We conducted a multicenter one arm proof of concept interventional study. Patients with Covid-19 disease with moderate-to-severe Acute Respiratory Distress Syndrome, elevated C-reactive Protein and need for mechanical ventilation and/or CPAP were enrolled. One to three 250-300 ml unit of hyperimmune plasma (neutralizing antibodies titer ≥1:160) were administered. Primary outcome was 7-days hospital mortality. Secondary outcomes were PaO2/FiO2, laboratory and radiologic changes, as well as weaning from mechanical ventilation and safety. The study observed 46 patients from March, 25 to April, 21 2020. Patients were aged 63, 61% male, of them, 30 were on CPAP and 7 intubated. PaO2/FiO2 was 128 (SD 47). Bilateral infiltrates on chest X-ray was present in 36 patients (84%). Symptoms and ARDS duration were 14 (SD 7) and 6 days (SD 3). Three patients (6.5%) died within 7 days as compared to an expected 15% from the National Statistics and 30% from a small concurrent cohort of 23 patients. The upper one-sided 90%CI was 13.9%, allowing to reject the null hypothesis of a 15% mortality. PaO2/FiO2 increased by 112 units (95%CI 82 to142) in survivors, the chest radiogram severity decreased in 23% (95%CI 5% to 42%); CRP, Ferritin and LDH decreased by 60, 36 and 20% respectively. Weaning from CPAP was obtained in 26/30 patients and 3/7 were extubated. Five serious adverse events occurred in 4 patients (2 likely, 2 possible treatment related). In conclusion, Hyperimmune plasma in Covid-19 shows promising benefits, to be confirmed in a randomized controlled trial. This proof of concept study could open to future developments including hyperimmune plasma banking, development of standardized pharmaceutical products and monoclonal antibodies.	33256382	Haematologica	1592-8721	10.3324/haematol.2020.261784	Redução da mortalidade em 46 pacientes com COVID-19 grave tratados com plasma hiperimune. Um estudo multicêntrico de prova de conceito, de braço único. 	O plasma hiperimune da convalescença do Covid-19 é um tratamento potencial para o Covid-19 grave. Realizamos um estudo intervencionista multicêntrico de prova de conceito de um braço. Pacientes com doença Covid-19 com síndrome do desconforto respiratório agudo moderado a grave, proteína C reativa elevada e necessidade de ventilação mecânica e/ou CPAP foram incluídos. Foram administradas uma a três unidades de 250-300 ml de plasma hiperimune (título de anticorpos neutralizantes ≥1:160). O desfecho primário foi mortalidade hospitalar em 7 dias. Os desfechos secundários foram PaO2/FiO2, alterações laboratoriais e radiológicas, bem como desmame da ventilação mecânica e segurança. O estudo observou 46 pacientes de 25 de março a 21 de abril de 2020. Os pacientes tinham 63 anos, 61% do sexo masculino, sendo 30 em CPAP e 7 intubados. PaO2/FiO2 foi de 128 (DP 47). Infiltrados bilaterais na radiografia de tórax estavam presentes em 36 pacientes (84%). Os sintomas e a duração da SDRA foram 14 (DP 7) e 6 dias (DP 3). Três pacientes (6,5%) morreram em 7 dias, em comparação com os 15% esperados das Estatísticas Nacionais e 30% de uma pequena coorte simultânea de 23 pacientes. O IC 90% unilateral superior foi de 13,9%, permitindo rejeitar a hipótese nula de mortalidade de 15%. PaO2/FiO2 aumentou em 112 unidades (IC 95% 82 a 142) nos sobreviventes, a gravidade da radiografia de tórax diminuiu em 23% (IC 95% 5% a 42%); CRP, ferritina e LDH diminuíram 60, 36 e 20%, respectivamente. O desmame do CPAP foi obtido em 26/30 pacientes e 3/7 foram extubados. Cinco eventos adversos graves ocorreram em 4 pacientes (2 prováveis, 2 possíveis relacionados ao tratamento). Em conclusão, o plasma hiperimune na Covid-19 mostra benefícios promissores, a serem confirmados em um estudo controlado randomizado. Este estudo de prova de conceito pode abrir para desenvolvimentos futuros, incluindo bancos de plasma hiperimunes, desenvolvimento de produtos farmacêuticos padronizados e anticorpos monoclonais.
Predictors of Mortality and Effect of Drug Therapies in Mechanically Ventilated Patients With Coronavirus Disease 2019: A Multicenter Cohort Study.	https://pubmed.ncbi.nlm.nih.gov/33251522/	25/11/2020	Artigo completo publicado em periódico científico	PUBMED_ID:33251522/	-	-	-	-	-	-	-	-	['Prednisona']	['Prednisone']	We conducted a multicenter cohort study to determine the effect of drug therapies on survival in mechanically ventilated patients with coronavirus disease 2019. All consecutive adult patients admitted to ICU for coronavirus disease 2019 from March 1, 2020, to April 25, 2020, and under invasive mechanical ventilation for more than 24 hours were included. Out of 2,003 patients hospitalized for coronavirus disease 2019, 361 were admitted to ICU, 257 were ventilated for more than 24 hours, and 247 were included in the study. Simple and multiple time-dependent Cox regression models were used to assess the effects of factors on survival. Methylprednisolone administration during the first week of mechanical ventilation was associated with a decrease in mortality rate from 48% to 34% (	33251522	Critical care explorations	2639-8028	10.1097/CCE.0000000000000305	Preditores de mortalidade e efeito de terapias medicamentosas em pacientes ventilados mecanicamente com doença de coronavírus 2019: um estudo de coorte multicêntrico. 	Conduzimos um estudo de coorte multicêntrico para determinar o efeito das terapias medicamentosas na sobrevida em pacientes ventilados mecanicamente com doença por coronavírus 2019. Todos os pacientes adultos consecutivos admitidos na UTI por doença por coronavírus 2019 de 1º de março de 2020 a 25 de abril de 2020 e sob tratamento invasivo ventilação mecânica por mais de 24 horas foram incluídos. Dos 2.003 pacientes hospitalizados por doença de coronavírus em 2019, 361 foram admitidos na UTI, 257 foram ventilados por mais de 24 horas e 247 foram incluídos no estudo. Modelos simples e múltiplos de regressão de Cox dependentes do tempo foram usados para avaliar os efeitos dos fatores na sobrevida. A administração de metilprednisolona durante a primeira semana de ventilação mecânica foi associada a uma diminuição na taxa de mortalidade de 48% para 34%.
The effectiveness of early anticoagulant treatment in Covid-19 patients.	https://journals.sagepub.com/doi/abs/10.1177/0268355520975595	27/11/2020	Artigo completo publicado em periódico científico	10.1177/0268355520975595	0268-3555	2683555	PHLEBOLOGY (LONDON)	A4	0.504	52	1.79	  Objectives  Coronavirus disease 2019 (Covid-19) is an emerging, fast-spreading and worldwide infectious disease that would be deteriorated with the precipitation of systemic or local thrombosis. The aim of current study was evaluating the effects of early anticoagulant treatment in hospitalized Covid-19 patients.   Method  The present retrospective and comparative cohort study investigated 413 hospitalized Covid-19 patients treated with or without Low Molecular Weight Heparin (LMWH) (n = 187 and 226, respectively) in the Covid Clinics of Gulhane Education and Research Hospital in Ankara, Turkey, between March 18 and May 03, 2020. The treatment groups were consisted of the patients evaluated before and after The Covid-19 Treatment Guide update on April 12, 2020 that included the anticoagulant treatment thereafter.   Results  The mean age of all 413 patients (204 male and 209 female) at disease onset was 50.6 ± 16.7 years. The LMWH-treated patients had significantly higher coagulation markers such as d-dimer and platelet count than LMWH-untreated patients (p values &lt; 0.05). The inflammatory markers, ferritin, interleukin-6 and procalcitonin were significantly increased in LMWH-untreated patients (p values &lt; 0.05). The presence of any comorbidity was significantly more common in LMWH-treated patients compared to LMWH-untreated group (39.6% vs 19.9%, respectively; p &lt; 0.001). Hypertension and diabetes mellitus were the most frequent comorbidities in both groups. The number of intensive care unit (ICU) transfer and longer length of hospital stay were more commonly observed in LMWH-untreated patients (p values &lt;0.05).   Conclusions  Early anticoagulant treatment with relatively higher doses of LMWH may improve the clinical outcome of Covid-19 patients and shorten the length of hospital stay. 	['Heparina']	['Heparin']	-	-	-	-	-	A eficácia do tratamento anticoagulante precoce em pacientes com Covid-19. 	-
Safety and Efficacy of Apixaban For Therapeutic Anticoagulation in Critically Ill ICU Patients with Severe COVID-19 Respiratory Disease.	https://doi.org/10.1055/s-0040-1720962	23/11/2020	Artigo completo publicado em periódico científico	10.1055/s-0040-1720962	2512-9465	25129465	-	-	-	-	-	 Abstract           Introduction Despite the use of unfractionated heparin (UFH) or low molecular weight heparin (LMWH), rates of thromboembolic disease, and subsequent morbidity and mortality remain unacceptably high in patients with severe novel coronavirus disease 2019 (COVID-19) disease. Direct oral anticoagulants (DOACs), such as apixaban, have numerous purported benefits although the safety and efficacy of their use in intensive care unit (ICU) patients with severe COVID-19 has yet to be evaluated.           Materials and Methods Single-center, retrospective cohort study of 21 ICU patients with severe COVID-19 respiratory disease treated with apixaban for atrial fibrillation (AFib), venous thromboembolism (VTE), catheter-induced thrombosis, and/or COVID-19-induced coagulopathy. The primary objective was to evaluate the incidence of bleeding events and secondary objectives included thromboembolic events, coagulation parameters, and mortality.           Results Ninety percent of patients were non-White, 43% were obese, 90% had acute respiratory distress syndrome, and 76% required mechanical ventilation. Nearly half of (47.6%) also experienced renal dysfunction and required renal replacement therapy. Eighty-six percent of patients received prophylaxis or treatment with UFH or LMWH within the 24-hour period prior to apixaban initiation. Patients were initiated on apixaban for the treatment of suspected or confirmed VTE (67%) or AFib (33%). All coagulation parameters remained abnormal but stable throughout the 10-day monitoring period. No patients experienced any major bleeding events or thrombosis throughout the study period. There were four deaths during the follow-up period, all deemed unrelated to coagulopathy or bleeding.           Conclusion Apixaban appeared safe and efficacious in ICU patients with severe COVID-19 disease. These data encourage future trials seeking to optimize anticoagulation strategies in patients with severe COVID-19.	['Apixabana']	['Apixaban']	-	33244512	TH open : companion journal to thrombosis and haemostasis	2512-9465	10.1055/s-0040-1720962	Segurança e Eficácia do Apixabano para Anticoagulação Terapêutica em Pacientes Críticos de UTI com Doença Respiratória Grave de COVID-19. 	-
Effects of Recent Use of Renin-Angiotensin System Inhibitors on Mortality of Patients With Coronavirus Disease 2019.	https://doi.org/10.1093/ofid/ofaa519	27/10/2020	Artigo completo publicado em periódico científico	10.1093/ofid/ofaa519	2328-8957	23288957	OPEN FORUM INFECTIOUS DISEASES	A3	1.317	45	3.66	 Abstract                                   Background                   There is growing concern about the potential harmful effects of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) in patients with coronavirus disease 2019 (COVID-19) and cardiovascular diseases (CVDs). The aim of this study was to evaluate the association between recent exposure to ACEIs/ARBs and in-hospital mortality in patients with COVID-19.                                                  Methods                   We used data from a nationwide cohort of patients with COVID-19 from the health insurance claims data of South Korea, which were released for research purposes for public health by the Ministry of Health and Welfare of South Korea. Patients with COVID-19 were identified using the relevant diagnostic code. Propensity score matching (1:1) was carried out among patients with CVD according to the type of medication (ACEIs/ARBs vs other), and the risk of death was assessed.                                                  Results                   A total of 4936 patients with COVID-19 were analyzed, of whom 1048 (21.2%) had CVD. Of the 1048 patients with CVD, 864 (82.4%) received at least 1 antihypertensive medication before the diagnosis of COVID-19, including 359 (41.6%) who received ACEIs/ARBs and 505 (58.4%) who received drugs other than ACEIs/ARBs. Using the propensity scores for ACEI/ARB use, we matched 305 pairs of patients receiving ACEIs/ARBs and patients receiving other drugs. Recent use of ACEIs/ARBs was not significantly associated with in-hospital mortality in unadjusted analysis (odds ratio [OR], 0.62; 95% CI, 0.33–1.14) or propensity score matching analysis (OR, 1.00; 95% CI, 0.46–2.16).                                                  Conclusions                   In patients with COVID-19 and underlying CVDs, the recent use of ACEIs/ARBs was not significantly associated with in-hospital mortality. These findings do not support stopping or modifying ACEIs/ARBs in patients during the current COVID-19 pandemic.               	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	-	-	-	-	-	Efeitos do uso recente de inibidores do sistema renina-angiotensina na mortalidade de pacientes com doença de coronavírus 2019. 	-
Antivirals With Adjunctive Corticosteroids Prevent Clinical Progression of Early Coronavirus 2019 Pneumonia: A Retrospective Cohort Study.	https://doi.org/10.1093/ofid/ofaa486	14/10/2020	Artigo completo publicado em periódico científico	10.1093/ofid/ofaa486	2328-8957	23288957	OPEN FORUM INFECTIOUS DISEASES	A3	1.317	45	3.66	 Abstract                This is a retrospective cohort study of hospitalized adults with coronavirus disease 2019 (COVID-19). Fifty-seven patients received treatment alone, and 35 patients received treatment with adjunctive prednisolone. A combination of corticosteroids and antivirals was associated with lower risk of clinical progression and invasive mechanical ventilation or death in early COVID-19 pneumonia.	['Antivirais', 'Corticosteroides']	['Antivirals', 'Corticosteroids']	This is a retrospective cohort study of hospitalized adults with coronavirus disease 2019 (COVID-19). Fifty-seven patients received treatment alone, and 35 patients received treatment with adjunctive prednisolone. A combination of corticosteroids and antivirals was associated with lower risk of clinical progression and invasive mechanical ventilation or death in early COVID-19 pneumonia.	33235888	Open forum infectious diseases	2328-8957	10.1093/ofid/ofaa486	Antivirais com corticosteróides adjuvantes impedem a progressão clínica da pneumonia precoce por coronavírus 2019: um estudo de coorte retrospectivo. 	Este é um estudo de coorte retrospectivo de adultos hospitalizados com doença de coronavírus 2019 (COVID-19). Cinquenta e sete pacientes receberam tratamento isolado e 35 pacientes receberam tratamento com prednisolona adjuvante. Uma combinação de corticosteróides e antivirais foi associada a menor risco de progressão clínica e ventilação mecânica invasiva ou morte na pneumonia precoce por COVID-19.
Treatment of SARS-cov-2 pneumonia with favipiravir: Early results from the Ege University cohort, Turkey.	https://pubmed.ncbi.nlm.nih.gov/33237663/	25/11/2020	Artigo completo publicado em periódico científico	PUBMED_ID:33237663/	-	-	-	-	-	-	-	-	['Favipiravir']	['Favipiravir']	-	-	-	-	-	Tratamento da pneumonia por SARS-cov-2 com favipiravir: resultados iniciais da coorte da Universidade de Ege, Turquia. 	-
Evidence for treatment with estradiol for women with SARS-CoV-2 infection.	https://doi.org/10.1186/s12916-020-01851-z	25/11/2020	Artigo completo publicado em periódico científico	10.1186/s12916-020-01851-z	1741-7015	17417015	BMC MEDICINE	A1	3.405	155	10.07	 Abstract                  Background                 Given that an individual’s age and gender are strongly predictive of coronavirus disease 2019 (COVID-19) outcomes, do such factors imply anything about preferable therapeutic options?                                Methods                 An analysis of electronic health records for a large (68,466-case), international COVID-19 cohort, in 5-year age strata, revealed age-dependent sex differences. In particular, we surveyed the effects of systemic hormone administration in women. The primary outcome for estradiol therapy was death. Odds ratios (ORs) and Kaplan-Meier survival curves were analyzed for 37,086 COVID-19 women in two age groups: pre- (15–49 years) and peri-/post-menopausal (&gt; 50 years).                                Results                 The incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is higher in women than men (by about + 15%) and, in contrast, the fatality rate is higher in men (about + 50%). Interestingly, the relationships between these quantities are linked to age: pre-adolescent girls and boys had the same risk of infection and fatality rate, while adult premenopausal women had a significantly higher risk of infection than men in the same 5-year age stratum (about 16,000 vs. 12,000 cases). This ratio changed again in peri- and postmenopausal women, with infection susceptibility converging with men. While fatality rates increased continuously with age for both sexes, at 50 years, there was a steeper increase for men. Thus far, these types of intricacies have been largely neglected. Because the hormone 17ß-estradiol influences expression of the human angiotensin-converting enzyme 2 (ACE2) protein, which plays a role in SARS-CoV-2 cellular entry, propensity score matching was performed for the women’s sub-cohort, comparing users vs. non-users of estradiol. This retrospective study of hormone therapy in female COVID-19 patients shows that the fatality risk for women &gt; 50 years receiving estradiol therapy (user group) is reduced by more than 50%; the OR was 0.33, 95% CI [0.18, 0.62] and the hazard ratio (HR) was 0.29, 95% CI [0.11,0.76]. For younger, pre-menopausal women (15–49 years), the risk of COVID-19 fatality is the same irrespective of estradiol treatment, probably because of higher endogenous estradiol levels.                                Conclusions                 As of this writing, still no effective drug treatment is available for COVID-19; since estradiol shows such a strong improvement regarding fatality in COVID-19, we suggest prospective studies on the potentially more broadly protective roles of this naturally occurring hormone.              	['Estradiol', 'Estradiol', 'Estradiol']	['Estradiol', 'Estradiol', 'Estradiol']	-	-	-	-	-	Evidência para tratamento com estradiol para mulheres com infecção por SARS-CoV-2. 	-
The effect of anticoagulation on clinical outcomes in novel Coronavirus (COVID-19) pneumonia in a U.S. cohort.	https://doi.org/10.1016/j.thromres.2020.10.031	05/11/2020	Artigo completo publicado em periódico científico	10.1016/j.thromres.2020.10.031	0049-3848	493848	THROMBOSIS RESEARCH	A3	1.678	118	5.91	-	['Anticoagulantes']	['Anticoagulants']	-	-	-	-	-	O efeito da anticoagulação nos resultados clínicos da nova pneumonia por coronavírus (COVID-19) em uma coorte dos EUA. 	-
A Propensity-Matched Cohort Study of Tocilizumab in Patients With Coronavirus Disease 2019.	https://journals.lww.com/ccejournal/Fulltext/2020/11000/A_Propensity_Matched_Cohort_Study_of_Tocilizumab.15.aspx	16/11/2020	Artigo completo publicado em periódico científico	https://journals.lww.com/ccejournal/Fulltext/2020/11000/A_Propensity_Matched_Cohort_Study_of_Tocilizumab.15.aspx	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Um estudo de coorte com correspondência de propensão de tocilizumabe em pacientes com doença de coronavírus 2019. 	-
Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality	https://doi.org/10.1055/s-0040-1720978	13/11/2020	Artigo completo publicado em periódico científico	10.1055/s-0040-1720978	0340-6245	3406245	THROMBOSIS AND HAEMOSTASIS	A1	1.745	195	5.58	 Abstract           Background Mortality in coronavirus disease of 2019 (COVID-19) is associated with increases in prothrombotic parameters, particularly D-dimer levels. Anticoagulation has been proposed as therapy to decrease mortality, often adjusted for illness severity.           Objective We wanted to investigate whether anticoagulation improves survival in COVID-19 and if this improvement in survival is associated with disease severity.           Methods This is a cohort study simulating an intention-to-treat clinical trial, by analyzing the effect on mortality of anticoagulation therapy chosen in the first 48 hours of hospitalization. We analyzed 3,625 COVID-19+ inpatients, controlling for age, gender, glomerular filtration rate, oxygen saturation, ventilation requirement, intensive care unit admission, and time period, all determined during the first 48 hours.           Results Adjusted logistic regression analyses demonstrated a significant decrease in mortality with prophylactic use of apixaban (odds ratio [OR] 0.46, p = 0.001) and enoxaparin (OR = 0.49, p = 0.001). Therapeutic apixaban was also associated with decreased mortality (OR 0.57, p = 0.006) but was not more beneficial than prophylactic use when analyzed over the entire cohort or within D-dimer stratified categories. Higher D-dimer levels were associated with increased mortality (p &lt; 0.0001). When adjusted for these same comorbidities within D-dimer strata, patients with D-dimer levels &lt; 1 µg/mL did not appear to benefit from anticoagulation while patients with D-dimer levels &gt; 10 µg/mL derived the most benefit. There was no increase in transfusion requirement with any of the anticoagulants used.           Conclusion We conclude that COVID-19+ patients with moderate or severe illness benefit from anticoagulation and that apixaban has similar efficacy to enoxaparin in decreasing mortality in this disease.	['Apixabana', 'Enoxaparina']	['Apixaban', 'Enoxaparin']	 We conclude that COVID-19+ patients with moderate or severe illness benefit from anticoagulation and that apixaban has similar efficacy to enoxaparin in decreasing mortality in this disease.	33186991	Thrombosis and haemostasis	2567-689X	10.1055/s-0040-1720978	Anticoagulação na COVID-19: Efeito da enoxaparina, heparina e apixabana na 	mortalidade
Adverse impact of renin–angiotensin system blockade on the clinical course in hospitalized patients with severe COVID‐19: a retrospective cohort study.	https://doi.org/10.1038/s41598-020-76915-4	20/11/2020	Artigo completo publicado em periódico científico	10.1038/s41598-020-76915-4	2045-2322	20452322	SCIENTIFIC REPORTS	A2	1.005	242	4.81	 Abstract The association between angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB) and the risk of mortality in hospitalized patients with severe coronavirus disease 2019 (COVID-19) was investigated. This retrospective cohort study was performed in all hospitalized patients with COVID-19 in tertiary hospitals in Daegu, Korea. Patients were classified based on whether they received ACE-I or ARB before COVID-19 diagnosis. The analysis of the primary outcome, in-hospital mortality, was performed using the Cox proportional hazards regression model. Of 130 patients with COVID-19, 30 (23.1%) who received ACE-I or ARB exhibited an increased risk of in-hospital mortality (adjusted hazard ratio, 2.20; 95% confidence interval [CI], 1.10–4.38;  P = 0.025). ACE-I or ARB was also associated with severe complications, such as acute respiratory distress syndrome (ARDS) (adjusted odds ratio [aOR], 2.58; 95% CI, 1.02–6.51;  P = 0.045) and acute kidney injury (AKI) (aOR, 3.06; 95% CI, 1.15–8.15;  P = 0.026). Among the patients with ACE-I or ARB therapy, 8 patients (26.7%) used high equivalent doses of ACE-I or ARB and they had higher in-hospital mortality and an increased risk of ARDS and AKI (all,  P &lt; 0.05). ACE-I or ARB therapy in patients with severe COVID-19 was associated with the occurrence of severe complications and increased in-hospital mortality. The potentially harmful effect of ACE-I or ARB therapy may be higher in patients who received high doses.	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	The association between angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB) and the risk of mortality in hospitalized patients with severe coronavirus disease 2019 (COVID-19) was investigated. This retrospective cohort study was performed in all hospitalized patients with COVID-19 in tertiary hospitals in Daegu, Korea. Patients were classified based on whether they received ACE-I or ARB before COVID-19 diagnosis. The analysis of the primary outcome, in-hospital mortality, was performed using the Cox proportional hazards regression model. Of 130 patients with COVID-19, 30 (23.1%) who received ACE-I or ARB exhibited an increased risk of in-hospital mortality (adjusted hazard ratio, 2.20; 95% confidence interval [CI], 1.10-4.38; P = 0.025). ACE-I or ARB was also associated with severe complications, such as acute respiratory distress syndrome (ARDS) (adjusted odds ratio [aOR], 2.58; 95% CI, 1.02-6.51; P = 0.045) and acute kidney injury (AKI) (aOR, 3.06; 95% CI, 1.15-8.15; P = 0.026). Among the patients with ACE-I or ARB therapy, 8 patients (26.7%) used high equivalent doses of ACE-I or ARB and they had higher in-hospital mortality and an increased risk of ARDS and AKI (all, P < 0.05). ACE-I or ARB therapy in patients with severe COVID-19 was associated with the occurrence of severe complications and increased in-hospital mortality. The potentially harmful effect of ACE-I or ARB therapy may be higher in patients who received high doses.	33219294	Scientific reports	2045-2322	10.1038/s41598-020-76915-4	Impacto adverso do bloqueio do sistema renina-angiotensina no curso clínico em pacientes hospitalizados com COVID-19 grave: um estudo de coorte retrospectivo. 	A associação entre inibidor da enzima conversora de angiotensina (IECA) ou bloqueador do receptor de angiotensina II (BRA) e o risco de mortalidade em pacientes hospitalizados com doença grave por coronavírus 2019 (COVID-19) foi investigada. Este estudo de coorte retrospectivo foi realizado em todos os pacientes hospitalizados com COVID-19 em hospitais terciários em Daegu, Coréia. Os pacientes foram classificados com base se receberam ACE-I ou BRA antes do diagnóstico de COVID-19. A análise do desfecho primário, mortalidade intra-hospitalar, foi realizada por meio do modelo de regressão de riscos proporcionais de Cox. Dos 130 pacientes com COVID-19, 30 (23,1%) que receberam IECA ou BRA apresentaram um risco aumentado de mortalidade hospitalar (razão de risco ajustada, 2,20; intervalo de confiança de 95% [CI], 1,10-4,38; P = 0,025). O IECA ou BRA também foi associado a complicações graves, como síndrome do desconforto respiratório agudo (SDRA) (razão de chances ajustada [aOR], 2,58; IC 95%, 1,02-6,51; P = 0,045) e lesão renal aguda (LRA) (aOR, 3,06; IC 95%, 1,15-8,15; P = 0,026). Entre os pacientes em terapia com IECA ou BRA, 8 pacientes (26,7%) usaram altas doses equivalentes de IECA ou BRA e tiveram maior mortalidade hospitalar e risco aumentado de SDRA e LRA (todos, P < 0,05) . A terapia com IECA ou BRA em pacientes com COVID-19 grave foi associada à ocorrência de complicações graves e aumento da mortalidade hospitalar. O efeito potencialmente prejudicial da terapia com IECA ou BRA pode ser maior em pacientes que receberam altas doses.
Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study.	https://doi.org/10.1016/j.jaci.2020.11.006	06/11/2020	Artigo completo publicado em periódico científico	10.1016/j.jaci.2020.11.006	0091-6749	916749	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY	A1	3.810	307	8.93	-	['Anakinra', 'Prednisona']	['Anakinra', 'Prednisone']	In patients with moderate hyperinflammatory state associated with severe COVID-19 pneumonia, treatment with anakinra after non-response to corticosteroids or corticosteroids plus tocilizumab therapy may be an option for the management of these patients and may improve their prognosis.	33400157	Internal and emergency medicine	1970-9366	10.1007/s11739-020-02600-z	Anakinra combinado com metilprednisolona em pacientes com pneumonia grave por COVID-19 e hiperinflamação: um estudo de coorte observacional. 	Em pacientes com estado hiperinflamatório moderado associado à pneumonia grave por COVID-19, o tratamento com anakinra após a não resposta a corticosteroides ou corticosteroides mais terapia com tocilizumabe pode ser uma opção para o manejo desses pacientes e pode melhorar seu prognóstico.
BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of healthcare workers.	https://doi.org/10.1172/JCI145157	19/11/2020	Artigo completo publicado em periódico científico	10.1172/JCI145157	0021-9738	219738	THE JOURNAL OF CLINICAL INVESTIGATION	A1	5.527	505	14.12	-	['Vacina BCG']	['BCG vaccine']	BACKGROUNDSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused more than 1 million deaths worldwide; thus, there is an urgent need to develop preventive and therapeutic strategies. The antituberculosis vaccine bacillus Calmette-Guérin (BCG) demonstrates nonspecific, protective innate immune-boosting effects. Here, we determined whether a history of BCG vaccination was associated with decreased SARS-CoV-2 infection and seroconversion in a longitudinal, retrospective observational study of a diverse cohort of health care workers (HCWs).METHODSWe assessed SARS-CoV-2 seroprevalence and collected medical questionnaires, which included information on BCG vaccination status and preexisting demographic and clinical characteristics, from an observational cohort of HCWs in a multisite Los Angeles health care organization. We used multivariate analysis to determine whether a history of BCG vaccination was associated with decreased rates of SARS-CoV-2 infection and seroconversion.RESULTSOf the 6201 HCWs, 29.6% reported a history of BCG vaccination, whereas 68.9% had not received BCG vaccination. Seroprevalence of anti-SARS-CoV-2 IgG as well as the incidence of self-reported clinical symptoms associated with coronavirus disease 2019 (COVID-19) were markedly decreased among HCWs with a history of BCG vaccination compared with those without BCG vaccination. After adjusting for age and sex, we found that a history of BCG vaccination, but not meningococcal, pneumococcal, or influenza vaccination, was associated with decreased SARS-CoV-2 IgG seroconversion.CONCLUSIONSA history of BCG vaccination was associated with a decrease in the seroprevalence of anti-SARS-CoV-2 IgG and a lower number of participants who self-reported experiencing COVID-19-related clinical symptoms in this cohort of HCWs. Therefore, large randomized, prospective clinical trials of BCG vaccination are urgently needed to confirm whether BCG vaccination can confer a protective effect against SARS-CoV-2 infection.	33211672	The Journal of clinical investigation	1558-8238	145157	O histórico de vacinação com BCG está associado à diminuição da soroprevalência de SARS-CoV-2 em uma coorte diversificada de profissionais de saúde. 	ANTECEDENTES O coronavírus 2 da síndrome respiratória aguda grave (SARS-CoV-2) causou mais de 1 milhão de mortes em todo o mundo; assim, há uma necessidade urgente de desenvolver estratégias preventivas e terapêuticas. A vacina antituberculose bacilo Calmette-Guérin (BCG) demonstra efeitos protetores inespecíficos de reforço da imunidade inata. Aqui, determinamos se um histórico de vacinação com BCG estava associado à diminuição da infecção por SARS-CoV-2 e soroconversão em um estudo observacional longitudinal e retrospectivo de uma coorte diversificada de profissionais de saúde (HCWs). MÉTODOSAvaliamos a soroprevalência e a soroprevalência de SARS-CoV-2 coletaram questionários médicos, que incluíam informações sobre o status de vacinação BCG e características demográficas e clínicas preexistentes, de uma coorte observacional de profissionais de saúde em uma organização de saúde de vários locais de Los Angeles. Usamos análise multivariada para determinar se um histórico de vacinação BCG estava associado a taxas reduzidas de infecção por SARS-CoV-2 e soroconversão. RESULTADOSDos 6.201 profissionais de saúde, 29,6% relataram histórico de vacinação BCG, enquanto 68,9% não receberam a vacinação BCG. A soroprevalência de IgG anti-SARS-CoV-2, bem como a incidência de sintomas clínicos autorrelatados associados à doença por coronavírus 2019 (COVID-19) foram marcadamente diminuídas entre os profissionais de saúde com histórico de vacinação BCG em comparação com aqueles sem vacinação BCG. Após o ajuste para idade e sexo, descobrimos que uma história de vacinação BCG, mas não meningocócica, pneumocócica ou vacina contra influenza, estava associada à diminuição da soroconversão de IgG para SARS-CoV-2. soroprevalência de IgG anti-SARS-CoV-2 e um número menor de participantes que relataram sintomas clínicos relacionados ao COVID-19 nesta coorte de profissionais de saúde. Portanto, grandes ensaios clínicos prospectivos e randomizados da vacinação com BCG são urgentemente necessários para confirmar se a vacinação com BCG pode conferir um efeito protetor contra a infecção por SARS-CoV-2.
Role of low-molecular weight heparin in hospitalized patients with SARS-CoV-2 pneumonia: a prospective observational study.	https://doi.org/10.1093/ofid/ofaa563	19/11/2020	Artigo completo publicado em periódico científico	10.1093/ofid/ofaa563	2328-8957	23288957	OPEN FORUM INFECTIOUS DISEASES	A3	1.317	45	3.66	 Abstract  Background This study was conducted to evaluate the impact of low-molecular-weight heparin (LMWH) on the outcome of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia.  Methods This is a prospective observational study including consecutive patients with laboratory-confirmed SARS-CoV-2 pneumonia admitted to the University Hospital of Pisa (March 4–April 30, 2020). Demographic, clinical, and outcome data were collected. The primary endpoint was 30-day mortality. The secondary endpoint was a composite of death or severe acute respiratory distress syndrome (ARDS). Low-molecular-weight heparin, hydroxychloroquine, doxycycline, macrolides, antiretrovirals, remdesivir, baricitinib, tocilizumab, and steroids were evaluated as treatment exposures of interest. First, a Cox regression analysis, in which treatments were introduced as time-dependent variables, was performed to evaluate the association of exposures and outcomes. Then, a time-dependent propensity score (PS) was calculated and a PS matching was performed for each treatment variable.  Results Among 315 patients with SARS-CoV-2 pneumonia, 70 (22.2%) died during hospital stay. The composite endpoint was achieved by 114 (36.2%) patients. Overall, 244 (77.5%) patients received LMWH, 238 (75.5%) received hydroxychloroquine, 201 (63.8%) received proteases inhibitors, 150 (47.6%) received doxycycline, 141 (44.8%) received steroids, 42 (13.3%) received macrolides, 40 (12.7%) received baricitinib, 13 (4.1%) received tocilizumab, and 13 (4.1%) received remdesivir. At multivariate analysis, LMWH was associated with a reduced risk of 30-day mortality (hazard ratio [HR], 0.36; 95% confidence interval [CI], 0.21–0.6; P &amp;lt; .001) and composite endpoint (HR, 0.61; 95% CI, 0.39–0.95; P = .029). The PS-matched cohort of 55 couples confirmed the same results for both primary and secondary endpoint.  Conclusions This study suggests that LMWH might reduce the risk of in-hospital mortality and severe ARDS in coronavirus disease 2019. Randomized controlled trials are warranted to confirm these preliminary findings.	['Heparina']	['Heparin']	-	-	-	-	-	Papel da heparina de baixo peso molecular em pacientes hospitalizados com pneumonia por SARS-CoV-2: um estudo observacional prospectivo. 	-
Remdesivir Use in Patients Requiring Mechanical Ventilation due to COVID-19.	https://doi.org/10.1093/ofid/ofaa481	13/10/2020	Artigo completo publicado em periódico científico	10.1093/ofid/ofaa481	2328-8957	23288957	OPEN FORUM INFECTIOUS DISEASES	A3	1.317	45	3.66	 Abstract                                   Background                   Remdesivir has been associated with accelerated recovery of severe coronavirus disease 2019 (COVID-19). However, whether it is also beneficial in patients requiring mechanical ventilation is uncertain.                                                  Methods                   All consecutive intensive care unit (ICU) patients requiring mechanical ventilation due to COVID-19 were enrolled. Univariate and multivariable Cox models were used to explore the possible association between in-hospital death or hospital discharge, considered competing-risk events, and baseline or treatment-related factors, including the use of remdesivir. The rate of extubation and the number of ventilator-free days were also calculated and compared between treatment groups.                                                  Results                   One hundred thirteen patients requiring mechanical ventilation were observed for a median of 31 days of follow-up; 32% died, 69% were extubated, and 66% were discharged alive from the hospital. Among 33 treated with remdesivir (RDV), lower mortality (15.2% vs 38.8%) and higher rates of extubation (88% vs 60%), ventilator-free days (median [interquartile range], 11 [0–16] vs 5 [0–14.5]), and hospital discharge (85% vs 59%) were observed. Using multivariable analysis, RDV was significantly associated with hospital discharge (hazard ratio [HR], 2.25; 95% CI, 1.27–3.97; P = .005) and with a nonsignificantly lower mortality (HR, 0.73; 95% CI, 0.26–2.1; P = .560). RDV was also independently associated with extubation (HR, 2.10; 95% CI, 1.19–3.73; P = .011), which was considered a competing risk to death in the ICU in an additional survival model.                                                  Conclusions                   In our cohort of mechanically ventilated patients, RDV was not associated with a significant reduction of mortality, but it was consistently associated with shorter duration of mechanical ventilation and higher probability of hospital discharge, independent of other risk factors.               	['Remdesivir']	['Remdesivir']	-	-	-	-	-	Uso de remdesivir em pacientes que necessitam de ventilação mecânica devido ao COVID-19. 	-
Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study.	https://doi.org/10.1186/s12916-020-01832-2	16/11/2020	Artigo completo publicado em periódico científico	10.1186/s12916-020-01832-2	1741-7015	17417015	BMC MEDICINE	A1	3.405	155	10.07	 Abstract  Background Limited evidence exists on the role of glucose-lowering drugs in patients with COVID-19. Our main objective was to examine the association between in-hospital death and each routine at-home glucose-lowering drug both individually and in combination with metformin in patients with type 2 diabetes mellitus admitted for COVID-19. We also evaluated their association with the composite outcome of the need for ICU admission, invasive and non-invasive mechanical ventilation, or in-hospital death as well as on the development of in-hospital complications and a long-time hospital stay.  Methods We selected all patients with type 2 diabetes mellitus in the Spanish Society of Internal Medicine’s registry of COVID-19 patients (SEMI-COVID-19 Registry). It is an ongoing, observational, multicenter, nationwide cohort of patients admitted for COVID-19 in Spain from March 1, 2020. Each glucose-lowering drug user was matched with a user of other glucose-lowering drugs in a 1:1 manner by propensity scores. In order to assess the adequacy of propensity score matching, we used the standardized mean difference found in patient characteristics after matching. There was considered to be a significant imbalance in the group if a standardized mean difference &gt; 10% was found. To evaluate the association between treatment and study outcomes, both conditional logit and mixed effect logistic regressions were used when the sample size was ≥ 100.  Results A total of 2666 patients were found in the SEMI-COVID-19 Registry, 1297 on glucose-lowering drugs in monotherapy and 465 in combination with metformin. After propensity matching, 249 patients on metformin, 105 on dipeptidyl peptidase-4 inhibitors, 129 on insulin, 127 on metformin/dipeptidyl peptidase-4 inhibitors, 34 on metformin/sodium-glucose cotransporter 2 inhibitor, and 67 on metformin/insulin were selected. No at-home glucose-lowering drugs showed a significant association with in-hospital death; the composite outcome of the need of intensive care unit admission, mechanical ventilation, or in-hospital death; in-hospital complications; or long-time hospital stays.  Conclusions In patients with type 2 diabetes mellitus admitted for COVID-19, at-home glucose-lowering drugs showed no significant association with mortality and adverse outcomes. Given the close relationship between diabetes and COVID-19 and the limited evidence on the role of glucose-lowering drugs, prospective studies are needed.	['Metformina']	['Metformin']	In patients with type 2 diabetes mellitus admitted for COVID-19, at-home glucose-lowering drugs showed no significant association with mortality and adverse outcomes. Given the close relationship between diabetes and COVID-19 and the limited evidence on the role of glucose-lowering drugs, prospective studies are needed.	33190637	BMC medicine	1741-7015	10.1186/s12916-020-01832-2	Mortalidade e outros resultados adversos em pacientes com diabetes mellitus tipo 2 admitidos por COVID-19 em associação com medicamentos hipoglicemiantes: um estudo de coorte nacional. 	Em pacientes com diabetes mellitus tipo 2 admitidos por COVID-19, os medicamentos para baixar a glicose em casa não mostraram associação significativa com mortalidade e resultados adversos. Dada a estreita relação entre diabetes e COVID-19 e as evidências limitadas sobre o papel dos medicamentos para baixar a glicose, são necessários estudos prospectivos.
Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort.	https://doi.org/10.1016/j.clim.2020.108631	12/11/2020	Artigo completo publicado em periódico científico	10.1016/j.clim.2020.108631	1521-6616	15216616	CLINICAL IMMUNOLOGY (ORLANDO, FLA. PRINT)	A3	1.609	130	6.8	-	['Tocilizumabe']	['Tocilizumab']	Although the starting event in COVID-19 is a viral infection some patients present with an over-exuberant inflammatory response, leading to acute lung injury (ALI) and adult respiratory distress syndrome (ARDS). Since IL-6 plays a critical role in the inflammatory response, we assessed the efficacy and safety of tocilizumab (TCZ) in this single-centre, observational study in all Covid-19 in-patient with a proven SARS-CoV-2 rapidly progressing infection to prevent ALI and ARDS. 104 patients with COVID-19 treated with TCZ had a lower mortality rate (5·8%) compared with the regional mortality rate (11%), hospitalized patient's mortality (10%), and slightly lower than hospitalized patients treated with our standard of care alone (6%). We found that TCZ rapidly decreased acute phase reactants, ferritin and liver release of proteins. D-Dimer decreased slowly. We did not observe specific safety concerns. Early administration of IL6-R antagonists in COVID-19 patients with impending hyperinflammatory response, may be safe and effective treatment to prevent, ICU admission and further complications.	33189888	Clinical immunology (Orlando, Fla.)	1521-7035	10.1016/j.clim.2020.108631	Eficácia e segurança do tocilizumab intravenoso no tratamento da síndrome hiperinflamatória associada ao COVID-19: coorte observacional do Covizumab-6. 	Embora o evento inicial no COVID-19 seja uma infecção viral, alguns pacientes apresentam uma resposta inflamatória excessivamente exuberante, levando à lesão pulmonar aguda (LPA) e à síndrome do desconforto respiratório do adulto (SDRA). Como a IL-6 desempenha um papel crítico na resposta inflamatória, avaliamos a eficácia e a segurança do tocilizumabe (TCZ) neste estudo observacional de centro único em todos os pacientes internados com Covid-19 com SARS-CoV-2 comprovado em rápida progressão infecção para prevenir ALI e SDRA. 104 pacientes com COVID-19 tratados com TCZ tiveram uma taxa de mortalidade menor (5,8%) em comparação com a taxa de mortalidade regional (11%), mortalidade de pacientes hospitalizados (10%) e um pouco menor do que pacientes hospitalizados tratados com nosso padrão de cuidar sozinho (6%). Descobrimos que o TCZ diminuiu rapidamente os reagentes de fase aguda, a ferritina e a liberação hepática de proteínas. D-dímero diminuiu lentamente. Não observamos preocupações específicas de segurança. A administração precoce de antagonistas de IL6-R em pacientes com COVID-19 com resposta hiperinflamatória iminente pode ser um tratamento seguro e eficaz para prevenir, admissão na UTI e outras complicações.
Letter: severe COVID‐19 infection and biologic therapies—a cohort study of 7808 patients in France.	https://onlinelibrary.wiley.com/doi/10.1111/apt.16040	09/09/2020	Artigo completo publicado em periódico científico	10.1111/apt.16040	-	-	-	-	-	-	-	-	['Adalimumabe', 'Etanercepte', 'Infliximabe', 'Ustekinumabe', 'Vedolizumab']	['Adalimumab', 'Etanercept', 'Infliximab', 'Ustekinumab', 'Vedolizumab']	Recently the coronavirus disease (COVID-19) outbreak has been declared a pandemic. Despite its aggressive extension and significant morbidity and mortality, risk factors are poorly characterized outside China. We designed a registry, HOPE COVID-19 (NCT04334291), assessing data of 1021 patients discharged (dead or alive) after COVID-19, from 23 hospitals in 4 countries, between 8 February and 1 April. The primary end-point was all-cause mortality aiming to produce a mortality risk score calculator. The median age was 68 years (IQR 52-79), and 59.5% were male. Most frequent comorbidities were hypertension (46.8%) and dyslipidemia (35.8%). A relevant heart or lung disease were depicted in 20%. And renal, neurological, or oncological disease, respectively, were detected in nearly 10%. Most common symptoms were fever, cough, and dyspnea at admission. 311 patients died and 710 were discharged alive. In the death-multivariate analysis, raised as most relevant: age, hypertension, obesity, renal insufficiency, any immunosuppressive disease, 02 saturation < 92% and an elevated C reactive protein (AUC = 0.87; Hosmer-Lemeshow test, p > 0.999; bootstrap-optimist: 0.0018). We provide a simple clinical score to estimate probability of death, dividing patients in four grades (I-IV) of increasing probability. Hydroxychloroquine (79.2%) and antivirals (67.6%) were the specific drugs most commonly used. After a propensity score adjustment, the results suggested a slight improvement in mortality rates (adjusted-OR	33016549	Alimentary pharmacology & therapeutics	1365-2036	10.1111/apt.16055	Carta: infecção grave por COVID-19 e terapias biológicas - um estudo de coorte de 7.808 pacientes na França. 	Recentemente, o surto de doença por coronavírus (COVID-19) foi declarado uma pandemia. Apesar de sua extensão agressiva e morbidade e mortalidade significativas, os fatores de risco são pouco caracterizados fora da China. Projetamos um registro, HOPE COVID-19 (NCT04334291), avaliando dados de 1.021 pacientes que receberam alta (vivos ou mortos) após COVID-19, de 23 hospitais em 4 países, entre 8 de fevereiro e 1 de abril. O desfecho primário foi a mortalidade por todas as causas com o objetivo de produzir uma calculadora de pontuação de risco de mortalidade. A idade mediana foi de 68 anos (IQR 52-79), e 59,5% eram do sexo masculino. As comorbidades mais frequentes foram hipertensão (46,8%) e dislipidemia (35,8%). Uma doença cardíaca ou pulmonar relevante foi descrita em 20%. E doença renal, neurológica ou oncológica, respectivamente, foram detectadas em quase 10%. Os sintomas mais comuns foram febre, tosse e dispneia na admissão. 311 pacientes morreram e 710 receberam alta vivos. Na análise multivariada de óbito, levantaram como mais relevantes: idade, hipertensão, obesidade, insuficiência renal, qualquer doença imunossupressora, saturação 02 < 92% e proteína C reativa elevada (AUC = 0,87; teste de Hosmer-Lemeshow, p > 0,999; bootstrap-otimista: 0,0018). Fornecemos um escore clínico simples para estimar a probabilidade de morte, dividindo os pacientes em quatro graus (I-IV) de probabilidade crescente. Hidroxicloroquina (79,2%) e antivirais (67,6%) foram os medicamentos específicos mais utilizados. Após um ajuste do escore de propensão, os resultados sugeriram uma ligeira melhora nas taxas de mortalidade (OR ajustado
Clinical characteristics in 545 patients with severe asthma on biological treatment during the COVID-19 outbreak.	https://covid19.elsevierpure.com/en/publications/clinical-characteristics-in-545-patients-with-severe-asthma-on-bi	01/01/2021	Artigo completo publicado em periódico científico	https://covid19.elsevierpure.com/en/publications/clinical-characteristics-in-545-patients-with-severe-asthma-on-bi	-	-	-	-	-	-	-	-	['Benralizumabe', 'Dupilumabe', 'Mepolizumabe', 'Omalizumabe', 'Reslizumabe']	['Benralizumab', 'Dupilumab', 'Mepolizumab', 'Omalizumab', 'Reslizumab']	In high-risk COVID-19 patients with severe pneumonia, granulocyte-macrophage colony-stimulating factor neutralization with lenzilumab was safe and associated with faster improvement in clinical outcomes, including oxygenation, and greater reductions in inflammatory markers compared with a matched control cohort of patients hospitalized with severe COVID-19 pneumonia. A randomized, placebo-controlled clinical trial to validate these findings is ongoing (NCT04351152).	33045398	The journal of allergy and clinical immunology. In practice	2213-2201	10.1016/j.jaip.2020.09.050	Características clínicas em 545 pacientes com asma grave em tratamento biológico durante o surto de COVID-19. 	Em pacientes de alto risco com COVID-19 com pneumonia grave, a neutralização do fator estimulador de colônias de granulócitos-macrófagos com lenzilumab foi segura e associada a melhora mais rápida nos resultados clínicos, incluindo oxigenação e maiores reduções nos marcadores inflamatórios em comparação com uma coorte de pacientes de controle pareado hospitalizado com pneumonia grave por COVID-19. Um ensaio clínico randomizado controlado por placebo para validar esses achados está em andamento (NCT04351152).
Corticosteroid therapy for coronavirus disease 2019‑related acute respiratory distress syndrome: a cohort study with propensity score analysis.	https://doi.org/10.1186/s13054-020-03340-4	10/11/2020	Artigo completo publicado em periódico científico	10.1186/s13054-020-03340-4	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	 Abstract  Background The impact of corticosteroid therapy on outcomes of patients with coronavirus disease 2019 (COVID-19) is highly controversial. We aimed to compare the risk of death between COVID-19-related ARDS patients with corticosteroid treatment and those without.  Methods In this single-center retrospective observational study, patients with ARDS caused by COVID-19 between January 20, 2020, and February 24, 2020, were enrolled. The primary outcome was 60-day in-hospital death. The exposure was prescribed systemic corticosteroids or not. Time-dependent Cox regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for 60-day in-hospital mortality.  Results A total of 382 patients [60.7 ± 14.1 years old (mean ± SD), 61.3% males] were analyzed. The median of sequential organ failure assessment (SOFA) score was 2.0 (IQR 2.0–3.0). Of these cases, 94 (24.6%) patients had invasive mechanical ventilation. The number of patients received systemic corticosteroids was 226 (59.2%), and 156 (40.8%) received standard treatment. The maximum dose of corticosteroids was 80.0 (IQR 40.0–80.0) mg equivalent methylprednisolone per day, and duration of corticosteroid treatment was 7.0 (4.0–12.0) days in total. In Cox regression analysis using corticosteroid treatment as a time-varying variable, corticosteroid treatment was associated with a significant reduction in risk of in-hospital death within 60 days after adjusting for age, sex, SOFA score at hospital admission, propensity score of corticosteroid treatment, comorbidities, antiviral treatment, and respiratory supports (HR 0.42; 95% CI 0.21, 0.85;  p = 0.0160). Corticosteroids were not associated with delayed viral RNA clearance in our cohort.  Conclusion In this clinical practice setting, low-dose corticosteroid treatment was associated with reduced risk of in-hospital death within 60 days in COVID-19 patients who developed ARDS.	['Dexametasona', 'Prednisolona', 'Prednisona']	['Dexamethasone', 'Prednisolone', 'Prednisone']	In this clinical practice setting, low-dose corticosteroid treatment was associated with reduced risk of in-hospital death within 60 days in COVID-19 patients who developed ARDS.	33172477	Critical care (London, England)	1466-609X	10.1186/s13054-020-03340-4	Terapia com corticosteroides para síndrome do desconforto respiratório agudo relacionado à doença de coronavírus 2019: um estudo de coorte com análise de escore de propensão. 	Neste cenário de prática clínica, o tratamento com baixas doses de corticosteroides foi associado à redução do risco de morte hospitalar em 60 dias em pacientes com COVID-19 que desenvolveram SDRA.
Significantly decreased mortality in a large cohort of COVID-19 patients transfused early with convalescent plasma containing high titer anti-SARS-CoV-2 spike protein IgG.	https://www.sciencedirect.com/science/article/pii/S0002944020304892	04/11/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S0002944020304892	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']	-	-	-	-	-	Diminuição significativa da mortalidade em uma grande coorte de pacientes com COVID-19 transfundidos precocemente com plasma convalescente contendo IgG de proteína de pico anti-SARS-CoV-2 de alto título. 	-
Asociación entre el tratamiento esteroideo a dosis alta, la función respiratoria y el tiempo hasta el alta en pacientes con COVID-19: Estudio de cohortes.	https://www.x-mol.com/paper/1309585002089123840	25/09/2020	Artigo completo publicado em periódico científico	https://www.x-mol.com/paper/1309585002089123840	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']	-	-	-	-	-	Associação entre o tratamento de esteróides em dose alta, a função respiratória e o tempo de duração da alta em pacientes com COVID-19: Estúdio de coortes. 	-
Outcome of patients hospitalized for COVID-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: results of the ACE-CoV study.	https://onlinelibrary.wiley.com/doi/10.1111/fcp.12613	28/10/2020	Artigo completo publicado em periódico científico	10.1111/fcp.12613	0767-3981	7673981	FUNDAMENTAL & CLINICAL PHARMACOLOGY	A4	0.534	77	2.61	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	Data are lacking on the impact of ACEI/ARB exposure on unfavorable outcome in the population of patients hospitalized for COVID-19 with hypertension/cardiovascular disease, particularly in Europe. The ACE-CoV study was designed to assess this question. The study was conducted in the Covid-Clinic-Toul cohort, which contains data about all patients hospitalized at Toulouse University hospital, France with a SARS-CoV-2 infection since March, 2020. We selected the patients with a history of cardiovascular disease (heart failure or coronary disease) and/or arterial hypertension. We conducted a subgroup analysis in patients with arterial hypertension. ACEI/ARB exposures at admission were assessed. The outcome was composite: admission to intensive care unit, need of mechanical ventilation or death during the 14 days after admission to hospital. We used logistic regression models with propensity scores (PS) weighted by overlap weighting (OW) and inverse probability of treatment weighting (IPTW). Between March 2020 and April 20, 2020, the Covid-Clinic-Toul included 263 patients. Among them, 111 were included in the ACE-CoV study population. In OW-PS-adjusted analyses, the association of exposure to ACEIs or ARBs with outcome occurrence was OR: 1.56 (95% CI: 0.73-3.33). It was 0.99 (95% CI: 0.68-1.45) for ACEIs and 1.64 (95% CI: 0.77-3.50) for ARBs. Analyses with weighting by the IPTW-PS method gave similar results. Results were similar when considering the subgroup of patients with arterial hypertension. The ACE-CoV study found no association between exposure to ACEIs or ARBs and unfavorable outcome in hospitalized patients for COVID-19 with a history of cardiovascular disease/arterial hypertension.	33111329	Fundamental & clinical pharmacology	1472-8206	10.1111/fcp.12613	Resultado de pacientes hospitalizados por COVID-19 e exposição a inibidores da enzima conversora de angiotensina e bloqueadores dos receptores de angiotensina na França: resultados do estudo ACE-CoV. 	Faltam dados sobre o impacto da exposição a IECA/BRA no desfecho desfavorável na população de pacientes hospitalizados por COVID-19 com hipertensão/doença cardiovascular, particularmente na Europa. O estudo ACE-CoV foi projetado para avaliar essa questão. O estudo foi realizado na coorte Covid-Clinic-Toul, que contém dados sobre todos os pacientes internados no hospital da Universidade de Toulouse, França, com infecção por SARS-CoV-2 desde março de 2020. Selecionamos os pacientes com histórico de doença cardiovascular ( insuficiência cardíaca ou doença coronária) e/ou hipertensão arterial. Realizamos uma análise de subgrupo em pacientes com hipertensão arterial. As exposições de IECA/BRA na admissão foram avaliadas. O desfecho foi composto: admissão em unidade de terapia intensiva, necessidade de ventilação mecânica ou óbito durante os 14 dias após a admissão no hospital. Usamos modelos de regressão logística com escores de propensão (PS) ponderados por ponderação de sobreposição (OW) e probabilidade inversa de ponderação de tratamento (IPTW). Entre março de 2020 e 20 de abril de 2020, a Covid-Clinic-Toul incluiu 263 pacientes. Entre eles, 111 foram incluídos na população do estudo ACE-CoV. Nas análises ajustadas por OW-PS, a associação da exposição a IECAs ou BRAs com a ocorrência do desfecho foi OR: 1,56 (IC 95%: 0,73-3,33). Foi 0,99 (IC 95%: 0,68-1,45) para IECA e 1,64 (IC 95%: 0,77-3,50) para BRA. As análises com ponderação pelo método IPTW-PS apresentaram resultados semelhantes. Os resultados foram semelhantes ao considerar o subgrupo de pacientes com hipertensão arterial. O estudo ACE-CoV não encontrou associação entre exposição a IECAs ou BRAs e desfecho desfavorável em pacientes hospitalizados por COVID-19 com histórico de doença cardiovascular/hipertensão arterial.
Ibuprofen and NSAID Use in COVID-19 Infected Patients Is Not Associated with Worse Outcomes:  Prospective Cohort Study.	https://link.springer.com/article/10.1007/s40121-020-00363-w	02/11/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s40121-020-00363-w	2193-8229	21938229	INFECTIOUS DISEASES AND THERAPY	A4	1.141	33	4.82	-	['Anti-inflamatórios não esteroidais', 'Anti-inflamatórios não esteroidais', 'Ibuprofeno', 'Ibuprofeno']	['Non-steroidal anti-inflammatory drugs', 'Non-steroidal anti-inflammatory drugs', 'Ibuprofen', 'Ibuprofen']	-	-	-	-	-	O uso de ibuprofeno e AINE em pacientes infectados com COVID-19 não está associado a piores resultados: estudo de coorte prospectivo. 	-
Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study	https://onlinelibrary.wiley.com/doi/10.1111/jcpt.13303	24/10/2020	Artigo completo publicado em periódico científico	10.1111/jcpt.13303	0269-4727	2694727	JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (PRINT)	B1	0.517	76	2.22	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Uso de tocilizumabe em pacientes com COVID-19 moderado a grave: um estudo de coorte retrospectivo 	-
Inhaled Corticosteroids and COVID-19 Risk and Mortality: A Nationwide Cohort Study	https://www.mdpi.com/2077-0383/9/11/3406	23/10/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2077-0383/9/11/3406	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']	Inhaled corticosteroids (ICS) could increase both the risk of coronavirus disease 2019 (COVID-19) and experiencing poor outcomes. To compare the clinical outcomes between ICS users and nonusers, COVID-19-related claims in the Korean Health Insurance Review and Assessment database were evaluated. To evaluate susceptibility to COVID-19 among patients with COPD or asthma, a nested case-control study was performed using the same database. In total, 7341 patients were confirmed to have COVID-19, including 114 ICS users and 7227 nonusers. Among 5910 patients who were hospitalized, death was observed for 9% of ICS users and 4% of nonusers. However, this association was not significant when adjusted for age, sex, region, comorbidities, and hospital type (aOR, 0.94; 95% CI, 0.43-2.07). The case-control analysis of COPD compared 640 cases with COVID-19 to 2560 matched controls without COVID-19, and the analysis of asthma compared 90 cases with COVID-19 to 360 matched controls without COVID-19. Use of ICS was not significantly associated with COVID-19 among patients with COPD (aOR, 1.02; 95% CI, 0.46-2.25) or asthma (aOR, 0.38; 95% CI, 0.13-1.17). Prior ICS use was not significantly associated with COVID-19 in patients with COPD or asthma, nor with clinical outcomes among patients with COVID-19.	33114246	Journal of clinical medicine	2077-0383	10.3390/jcm9113406	Corticosteroides inalados e risco e mortalidade por COVID-19: um estudo de coorte nacional 	Os corticosteroides inalados (ICS) podem aumentar o risco de doença por coronavírus 2019 (COVID-19) e apresentar resultados ruins. Para comparar os resultados clínicos entre usuários e não usuários de ICS, foram avaliadas as reivindicações relacionadas ao COVID-19 no banco de dados Korean Health Insurance Review and Assessment. Para avaliar a suscetibilidade à COVID-19 entre pacientes com DPOC ou asma, foi realizado um estudo de caso-controle aninhado usando o mesmo banco de dados. No total, 7.341 pacientes foram confirmados como portadores de COVID-19, incluindo 114 usuários de ICS e 7.227 não usuários. Entre 5.910 pacientes que foram internados, o óbito foi observado para 9% dos usuários de ICS e 4% dos não usuários. No entanto, essa associação não foi significativa quando ajustada para idade, sexo, região, comorbidades e tipo de hospital (aOR, 0,94; IC 95%, 0,43-2,07). A análise caso-controle da DPOC comparou 640 casos com COVID-19 a 2.560 controles pareados sem COVID-19, e a análise de asma comparou 90 casos com COVID-19 a 360 controles pareados sem COVID-19. O uso de CI não foi significativamente associado à COVID-19 entre pacientes com DPOC (aOR, 1,02; 95% CI, 0,46-2,25) ou asma (aOR, 0,38; 95% CI, 0,13-1,17). O uso prévio de ICS não foi significativamente associado com COVID-19 em pacientes com DPOC ou asma, nem com desfechos clínicos entre pacientes com COVID-19.
Influenza Vaccination and Risk of SARS-CoV-2 Infection in a Cohort of HealthWorkers	https://www.mdpi.com/2076-393X/8/4/611	15/10/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2076-393X/8/4/611	-	-	-	-	-	-	-	-	['Vacina influenza']	['Influenza vaccine']	-	-	-	-	-	Vacinação contra a gripe e risco de infecção por SARS-CoV-2 em uma coorte de trabalhadores da saúde 	-
VITAMIN D TREATMENT IS ASSOCIATED WITH REDUCED RISK OF MORTALITY IN PATIENTS WITH COVID-19: A CROSS-SECTIONAL MULTI-CENTRE OBSERVATIONAL STUDY	https://ssrn.com/abstract=3690902	20/10/2020	Artigo completo publicado em periódico científico	https://ssrn.com/abstract=3690902	-	-	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']	The worldwide pandemic of 2019 novel coronavirus disease (COVID-19) has posed the most substantial and severe public health issue for several generations, and therapeutic options have not yet been optimised. Vitamin D (in its "parent" form, cholecalciferol) has been proposed in the pharmacological management of COVID-19 by various sources. We aimed to determine whether COVID-19 mortality was affected by serum 25-hydroxyvitamin D (25(OH)D) levels, vitamin D status, or cholecalciferol therapy, and to elucidate any other predictors of COVID-19 mortality. Patients hospitalised with COVID-19 were opportunistically recruited from three UK hospitals, and their data were collected retrospectively. Logistic regression was used to determine any relationships between COVID-19 mortality and potential predictors, including 25(OH)D levels and cholecalciferol booster therapy. A total of 986 participants with COVID-19 were studied, of whom 151 (16.0%) received cholecalciferol booster therapy. In the primary cohort of 444 patients, cholecalciferol booster therapy was associated with a reduced risk of COVID-19 mortality, following adjustment for potential confounders (OR	33322317	Nutrients	2072-6643	10.3390/nu12123799	OBSERVACIONAL MULTI-CENTRO TRANSVERSAL 	várias gerações, e as opções terapêuticas ainda não foram otimizadas. A vitamina D (em sua forma "pai", colecalciferol) foi proposta no manejo farmacológico do COVID-19 por várias fontes. Nosso objetivo foi determinar se a mortalidade por COVID-19 foi afetada pelos níveis séricos de 25-hidroxivitamina D (25(OH)D), status de vitamina D ou terapia com colecalciferol e elucidar quaisquer outros preditores de mortalidade por COVID-19. Pacientes hospitalizados com COVID-19 foram recrutados de forma oportunista em três hospitais do Reino Unido e seus dados foram coletados retrospectivamente. A regressão logística foi usada para determinar quaisquer relações entre a mortalidade por COVID-19 e potenciais preditores, incluindo níveis de 25(OH)D e terapia de reforço com colecalciferol. Um total de 986 participantes com COVID-19 foram estudados, dos quais 151 (16,0%) receberam terapia de reforço com colecalciferol. Na coorte primária de 444 pacientes, a terapia de reforço com colecalciferol foi associada a um risco reduzido de mortalidade por COVID-19, após ajuste para possíveis fatores de confusão (OR
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial	https://doi.org/10.1186/s12967-020-02573-9	21/10/2020	Artigo completo publicado em periódico científico	10.1186/s12967-020-02573-9	1479-5876	14795876	JOURNAL OF TRANSLATIONAL MEDICINE (ONLINE)	A2	1.570	121	7.38	 Abstract                  Background                 Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients.                                Methods                 A multicenter, single-arm, hypothesis-driven trial was planned, according to a phase 2 design, to study the effect of tocilizumab on lethality rates at 14 and 30 days (co-primary endpoints, a priori expected rates being 20 and 35%, respectively). A further prospective cohort of patients, consecutively enrolled after the first cohort was accomplished, was used as a secondary validation dataset. The two cohorts were evaluated jointly in an exploratory multivariable logistic regression model to assess prognostic variables on survival.                                Results                 In the primary intention-to-treat (ITT) phase 2 population, 180/301 (59.8%) subjects received tocilizumab, and 67 deaths were observed overall. Lethality rates were equal to 18.4% (97.5% CI: 13.6–24.0,  P = 0.52) and 22.4% (97.5% CI: 17.2–28.3,  P &lt; 0.001) at 14 and 30 days, respectively. Lethality rates were lower in the validation dataset, that included 920 patients. No signal of specific drug toxicity was reported. In the exploratory multivariable logistic regression analysis, older age and lower PaO2/FiO2 ratio negatively affected survival, while the concurrent use of steroids was associated with greater survival. A statistically significant interaction was found between tocilizumab and respiratory support, suggesting that tocilizumab might be more effective in patients not requiring mechanical respiratory support at baseline.                                Conclusions                 Tocilizumab reduced lethality rate at 30 days compared with null hypothesis, without significant toxicity. Possibly, this effect could be limited to patients not requiring mechanical respiratory support at baseline.                  Registration EudraCT (2020-001110-38); clinicaltrials.gov (NCT04317092).              	['Tocilizumabe']	['Tocilizumab']	The worldwide pandemic of 2019 novel coronavirus disease (COVID-19) has posed the most substantial and severe public health issue for several generations, and therapeutic options have not yet been optimised. Vitamin D (in its "parent" form, cholecalciferol) has been proposed in the pharmacological management of COVID-19 by various sources. We aimed to determine whether COVID-19 mortality was affected by serum 25-hydroxyvitamin D (25(OH)D) levels, vitamin D status, or cholecalciferol therapy, and to elucidate any other predictors of COVID-19 mortality. Patients hospitalised with COVID-19 were opportunistically recruited from three UK hospitals, and their data were collected retrospectively. Logistic regression was used to determine any relationships between COVID-19 mortality and potential predictors, including 25(OH)D levels and cholecalciferol booster therapy. A total of 986 participants with COVID-19 were studied, of whom 151 (16.0%) received cholecalciferol booster therapy. In the primary cohort of 444 patients, cholecalciferol booster therapy was associated with a reduced risk of COVID-19 mortality, following adjustment for potential confounders (OR	34674735	Journal of translational medicine	1479-5876	10.1186/s12967-021-03094-9	Tocilizumabe para pacientes com pneumonia por COVID-19. O estudo prospectivo de braço único TOCIVID-19 	A pandemia mundial de 2019 da doença do novo coronavírus (COVID-19) representou o problema de saúde pública mais substancial e grave por várias gerações, e as opções terapêuticas ainda não foram otimizadas. A vitamina D (em sua forma "pai", colecalciferol) foi proposta no manejo farmacológico do COVID-19 por várias fontes. Nosso objetivo foi determinar se a mortalidade por COVID-19 foi afetada pelos níveis séricos de 25-hidroxivitamina D (25(OH)D), status de vitamina D ou terapia com colecalciferol e elucidar quaisquer outros preditores de mortalidade por COVID-19. Pacientes hospitalizados com COVID-19 foram recrutados de forma oportunista em três hospitais do Reino Unido e seus dados foram coletados retrospectivamente. A regressão logística foi usada para determinar quaisquer relações entre a mortalidade por COVID-19 e potenciais preditores, incluindo níveis de 25(OH)D e terapia de reforço com colecalciferol. Um total de 986 participantes com COVID-19 foram estudados, dos quais 151 (16,0%) receberam terapia de reforço com colecalciferol. Na coorte primária de 444 pacientes, a terapia de reforço com colecalciferol foi associada a um risco reduzido de mortalidade por COVID-19, após ajuste para possíveis fatores de confusão (OR
The Use of Therapeutic-Dose Anticoagulation and Its Effect on Mortality in Patients With COVID-19: A Systematic Review	https://journals.sagepub.com/doi/full/10.1177/1076029620960797	20/10/2020	Artigo completo publicado em periódico científico	10.1177/1076029620960797	1076-0296	10760296	CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS	B1	0.758	55	2.76	  The incidence of venous thromboembolism (VTE) events in patients with COVID-19 treated with a standard thromboprophylaxis dose of anticoagulants remains high. We conducted a systematic review in order to explore the association between therapeutic-dose anticoagulation and its effect on mortality in patients with COVID-19. A systematic search was carried out using the electronic databases of PubMed, EuropePMC, and the Cochrane Central Database, using specific keywords. All articles that fulfilled the inclusion criteria were included in the qualitative analysis. There were 8 observational studies included in the final qualitative analysis. Quality assessment using the Newcastle-Ottawa Scale (NOS) showed a mean score of 7.5 ± 1.06, indicating moderate to high quality of the studies. Three retrospective cohort studies reported a reduction in the mortality rate, while 6 other studies showed no mortality benefits among patients with COVID-19 treated with therapeutic-dose anticoagulation. There was a slight tendency toward a reduction in the mortality rate among mechanically-ventilated patients with COVID-19 receiving therapeutic-dose anticoagulation. Bleeding events and thrombotic complications among patients receiving therapeutic-dose anticoagulation were reported in 3 studies. Although it is too soon to draw any conclusions, this systematic review draws attention to current evidence regarding the association between therapeutic-dose anticoagulation and its effect on mortality in patients with COVID-19. 	['Antagonistas da vitamina K (AVK)', 'Anticoagulantes', 'Heparina']	['Vitamin K (VKA) antagonists', 'Anticoagulants', 'Heparin']	-	-	-	-	-	O uso da anticoagulação de dose terapêutica e seu efeito na mortalidade em pacientes com COVID-19: uma revisão sistemática 	-
Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study	https://doi.org/10.1016/j.ijid.2020.10.062	27/10/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.10.062	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Hydroxychloroquine', 'Lopinavir', 'Ritonavir']	The viral shedding duration was similar between HCQ and LPV/r treatment groups. There was no benefit in improving viral clearance compared to the control group.	33127507	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases	1878-3511	10.1016/j.ijid.2020.10.062	Comparação do efeito antiviral para casos leves a moderados de COVID-19 entre lopinavir/ritonavir versus hidroxicloroquina: um estudo de coorte nacional pareado com escore de propensão 	A duração da disseminação viral foi semelhante entre os grupos de tratamento com HCQ e LPV/r. Não houve benefício em melhorar a depuração viral em comparação com o grupo controle.
Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort)	https://doi.org/10.1016/j.eclinm.2020.100591	15/10/2020	Artigo completo publicado em periódico científico	10.1016/j.eclinm.2020.100591	2589-5370	25895370	EClinicalMedicine	-	4.657	44	9.79	-	['Ciclosporina', 'Corticosteroides', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir', 'Tocilizumabe']	['Cyclosporin', 'Corticosteroids', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir', 'Tocilizumab']	Hospital Universitario Quironsalud Madrid. Own fundings for COVID-19 research.	33078138	EClinicalMedicine	2589-5370	10.1016/j.eclinm.2020.100591	Características clínicas e resultados entre adultos hospitalizados com COVID-19 grave admitidos em um centro médico terciário e recebendo antivirais, antimaláricos, glicocorticóides ou imunomodulação com tocilizumabe ou ciclosporina: um estudo observacional retrospectivo (coorte COQUIMA) 	Hospital Universitario Quironsalud Madrid. Financiamentos próprios para pesquisa COVID-19.
Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study	https://www.mdpi.com/1424-8247/13/10/317	17/10/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/1424-8247/13/10/317	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Efeito do Tocilizumabe em Pacientes Hospitalizados com Pneumonia Grave por COVID-19: Um Estudo de Coorte Caso-Controle 	-
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19	https://pubmed.ncbi.nlm.nih.gov/33080002/	20/10/2020	Artigo completo publicado em periódico científico	PUBMED_ID:33080002/	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']	Among critically ill patients with COVID-19 in this cohort study, the risk of in-hospital mortality in this study was lower in patients treated with tocilizumab in the first 2 days of ICU admission compared with patients whose treatment did not include early use of tocilizumab. However, the findings may be susceptible to unmeasured confounding, and further research from randomized clinical trials is needed.	33080002	JAMA internal medicine	2168-6114	10.1001/jamainternmed.2020.6252	Associação entre tratamento precoce com tocilizumabe e mortalidade entre pacientes 	criticamente doentes com COVID-19 dias de internação na UTI em comparação com pacientes cujo tratamento não incluiu uso precoce de tocilizumabe. No entanto, os resultados podem ser suscetíveis a confusão não mensurada, e mais pesquisas de ensaios clínicos randomizados são necessárias.
Statin use is associated with lower disease severity in COVID‑19 infection	https://doi.org/10.1038/s41598-020-74492-0	15/10/2020	Artigo completo publicado em periódico científico	10.1038/s41598-020-74492-0	2045-2322	20452322	SCIENTIFIC REPORTS	A2	1.005	242	4.81	 Abstract We aim to study the association of hyperlipidemia and statin use with COVID-19 severity. We analysed a retrospective cohort of 717 patients admitted to a tertiary centre in Singapore for COVID-19 infection. Clinical outcomes of interest were oxygen saturation ≤ 94% requiring supplemental oxygen, intensive-care unit (ICU) admission, invasive mechanical-ventilation and death. Patients on long term dyslipidaemia medications (statins, fibrates or ezetimibe) were considered to have dyslipidaemia. Logistic regression models were used to study the association between dyslipidaemia and clinical outcomes adjusted for age, gender and ethnicity. Statin treatment effect was determined, in a nested case–control design, through logistic treatment models with 1:3 propensity matching for age, gender and ethnicity. All statistical tests were two-sided, and statistical significance was taken as  p &lt; 0.05. One hundred fifty-six (21.8%) patients had dyslipidaemia and 97% of these were on statins. Logistic treatment models showed a lower chance of ICU admission for statin users when compared to non-statin users (ATET: Coeff (risk difference): − 0.12 (− 0.23, − 0.01);  p = 0.028). There were no other significant differences in other outcomes. Statin use was independently associated with lower ICU admission. This supports current practice to continue prescription of statins in COVID-19 patients.	['Estatina', 'Ezetimiba', 'Fibratos']	['Statin', 'Ezetimibe', 'Fibrates']	-	-	-	-	-	O uso de estatinas está associado a menor gravidade da doença na infecção por COVID-19 	-
High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study	https://doi.org/10.1007/s10096-020-04078-1	20/10/2020	Artigo completo publicado em periódico científico	10.1007/s10096-020-04078-1	0934-9723	9349723	EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (PRINT)	A3	1.205	111	4.42	-	['Hidrocortisona', 'Prednisolona']	['Hydrocortisone', 'Prednisolone']	-	-	-	-	-	Doses altas versus padrão de corticosteroides em COVID-19 grave: um estudo de coorte retrospectivo 	-
No harm from angiotensin-converting enzyme inhibitors or angiotensin receptor inhibitors in patients with COVID-19. Results of a prospective study on a hospital-based cohort	https://www.italjmed.org/index.php/ijm/article/view/itjm.2020.1313	18/09/2020	Artigo completo publicado em periódico científico	https://www.italjmed.org/index.php/ijm/article/view/itjm.2020.1313	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	-	-	-	-	-	Nenhum dano de inibidores da enzima conversora de angiotensina ou inibidores do receptor de angiotensina em pacientes com COVID-19. Resultados de um estudo prospectivo em uma coorte hospitalar 	-
Cohort study to evaluate effect of vitamin D, magnesium, and vitamin B12 in combination on severe outcome progression in older patients with coronavirus (COVID-19)	https://doi.org/10.1016/j.nut.2020.111017	08/09/2020	Artigo completo publicado em periódico científico	10.1016/j.nut.2020.111017	0899-9007	8999007	NUTRITION	A1	0.892	150	4.65	-	['Magnésio', 'Vitamina B12', 'Vitamina D (25-hidroxivitamina D)']	['Magnesium', 'Vitamin B12', 'Vitamin D (25-hydroxyvitamin D)']	-	-	-	-	-	Estudo de coorte para avaliar o efeito da vitamina D, magnésio e vitamina B12 em combinação na progressão grave do resultado em pacientes idosos com coronavírus (COVID-19) 	-
Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study.	https://www.sciencedirect.com/science/article/pii/S2589537020303060	05/10/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S2589537020303060	-	-	-	-	-	-	-	-	['Enoxaparina']	['Enoxaparin']	-	-	-	-	-	A tromboprofilaxia com enoxaparina está associada a uma menor taxa de mortalidade em pacientes hospitalizados com infecção por SARS-CoV-2. Um estudo de coorte. 	-
Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men	https://doi.org/10.1111/jdv.16953	25/09/2020	Artigo completo publicado em periódico científico	10.1111/jdv.16953	0926-9959	9269959	JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY	A1	1.613	116	3.95	-	['Bicalutamida', 'Bicalutamida', 'Bicalutamida', 'Bicalutamida', 'Dutasterida', 'Dutasterida', 'Dutasterida', 'Dutasterida', 'Espironolactona', 'Espironolactona', 'Espironolactona', 'Espironolactona', 'Finasterida', 'Finasterida', 'Finasterida', 'Finasterida']	['Bicalutamide', 'Bicalutamide', 'Bicalutamide', 'Bicalutamide', 'Dutasteride', 'Dutasteride', 'Dutasteride', 'Dutasteride', 'Spironolactone', 'Spironolactone', 'Spironolactone', 'Spironolactone', ' Finasteride', 'Finasteride', 'Finasteride', 'Finasteride']	Comparison of hospitalization and mortality were not statistically significant. It seems that a respect to similar effect on mortality and hospitalization. ATV regimen is superior to Kaletra especially for better GI tolerance and less daily pills.	32977363	Journal of the European Academy of Dermatology and Venereology : JEADV	1468-3083	10.1111/jdv.16953	Antiandrógenos podem proteger contra desfechos graves de COVID-19: resultados de um estudo de coorte prospectivo de 77 homens hospitalizados 	Comparação de hospitalização e mortalidade não foram estatisticamente significativas. Parece que um efeito semelhante sobre a mortalidade e hospitalização. O regime ATV é superior ao Kaletra, especialmente para melhor tolerância GI e menos pílulas diárias.
Anticoagulation outcomes in hospitalized Covid‐19 patients: A systematic review and meta‐analysis of case‐control and cohort studies	https://doi.org/10.1002/rmv.2180	06/10/2020	Artigo completo publicado em periódico científico	10.1002/rmv.2180	1052-9276	10529276	REVIEWS IN MEDICAL VIROLOGY (PRINT)	A1	2.371	96	9.42	-	['Anticoagulantes']	['Anticoagulants']	Findings support the association of AC with mortality in Covid-19 patients. The results, synthesized from mostly low-quality studies, show that prophylactic and therapeutic AC might reduce mortality in Covid-19 patients. Findings suggest that therapeutic doses might be associated with better survival compared to prophylactic doses.	33022834	Reviews in medical virology	1099-1654	10.1002/rmv.2180	Resultados da anticoagulação em pacientes hospitalizados com Covid-19: uma revisão sistemática e meta-análise de estudos de caso-controle e coorte 	. Os resultados, sintetizados principalmente a partir de estudos de baixa qualidade, mostram que o AC profilático e terapêutico pode reduzir a mortalidade em pacientes com Covid-19. Os resultados sugerem que as doses terapêuticas podem estar associadas a uma melhor sobrevida em comparação com as doses profiláticas.
Comparing the impact of Hydroxychloroquine based regimens and standard treatment on COVID-19 patient outcomes: A retrospective cohort study	https://doi.org/10.1016/j.jsps.2020.09.019	01/10/2020	Artigo completo publicado em periódico científico	10.1016/j.jsps.2020.09.019	1319-0164	13190164	SAUDI PHARMACEUTICAL JOURNAL	A2	0.613	57	4.71	-	['Hidroxicloroquina']	['Hydroxychloroquine']	HCQ had a modest effect on hospital length stay and days in ICU compared with SC. However, these results need to be interpreted with caution. Larger observational studies and RCTs that evaluate the efficacy of HCQ in COVID-19 patients in the Saudi population are urgently needed.	33020690	Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society	1319-0164	10.1016/j.jsps.2020.09.019	Comparando o impacto dos regimes à base de hidroxicloroquina e do tratamento padrão nos resultados dos pacientes com COVID-19: um estudo de coorte retrospectivo 	HCQ teve um efeito modesto na permanência hospitalar e nos dias na UTI em comparação com SC. No entanto, esses resultados precisam ser interpretados com cautela. Estudos observacionais maiores e ECRs que avaliam a eficácia do HCQ em pacientes com COVID-19 na população saudita são urgentemente necessários.
Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo	https://www.ajtmh.org/content/journals/10.4269/ajtmh.20-1240	02/10/2020	Artigo completo publicado em periódico científico	https://www.ajtmh.org/content/journals/10.4269/ajtmh.20-1240	0002-9637	29637	American Journal of Tropical Medicine and Hygiene	-	1.013	157	2.87	-	['Azitromicina', 'Cloroquina']	['Azithromycin', 'Chloroquine']	Little is known about the clinical features and outcomes of SARS-CoV-2 infection in Africa. We conducted a retrospective cohort study of patients hospitalized for COVID-19 between March 10, 2020 and July 31, 2020 at seven hospitals in Kinshasa, Democratic Republic of the Congo (DRC). Outcomes included clinical improvement within 30 days (primary) and in-hospital mortality (secondary). Of 766 confirmed COVID-19 cases, 500 (65.6%) were male, with a median (interquartile range [IQR]) age of 46 (34-58) years. One hundred ninety-one (25%) patients had severe/critical disease requiring admission in the intensive care unit (ICU). Six hundred twenty patients (80.9%) improved and were discharged within 30 days of admission. Overall in-hospital mortality was 13.2% (95% CI: 10.9-15.8), and almost 50% among those in the ICU. Independent risk factors for death were age < 20 years (adjusted hazard ratio [aHR] = 6.62, 95% CI: 1.85-23.64), 40-59 years (aHR = 4.45, 95% CI: 1.83-10.79), and ≥ 60 years (aHR = 13.63, 95% CI: 5.70-32.60) compared with those aged 20-39 years, with obesity (aHR = 2.30, 95% CI: 1.24-4.27), and with chronic kidney disease (aHR = 5.33, 95% CI: 1.85-15.35). In marginal structural model analysis, there was no statistically significant difference in odds of clinical improvement (adjusted odds ratio [aOR] = 1.53, 95% CI: 0.88-2.67, 	33009770	The American journal of tropical medicine and hygiene	1476-1645	10.4269/ajtmh.20-1240	Características clínicas e resultados de pacientes hospitalizados por COVID-19 na África: informações iniciais da República Democrática do Congo 	Pouco se sabe sobre as características clínicas e os resultados da infecção por SARS-CoV-2 na África. Realizamos um estudo de coorte retrospectivo de pacientes hospitalizados por COVID-19 entre 10 de março de 2020 e 31 de julho de 2020 em sete hospitais em Kinshasa, República Democrática do Congo (RDC). Os desfechos incluíram melhora clínica em 30 dias (primária) e mortalidade hospitalar (secundária). Dos 766 casos confirmados de COVID-19, 500 (65,6%) eram do sexo masculino, com idade mediana (intervalo interquartil [IQR]) de 46 (34-58) anos. Cento e noventa e um (25%) pacientes apresentavam doença grave/crítica com necessidade de internação na unidade de terapia intensiva (UTI). Seiscentos e vinte pacientes (80,9%) melhoraram e receberam alta em 30 dias da admissão. A mortalidade hospitalar geral foi de 13,2% (IC 95%: 10,9-15,8), e quase 50% entre aqueles na UTI. Os fatores de risco independentes para morte foram idade < 20 anos (taxa de risco ajustada [aHR] = 6,62, IC 95%: 1,85-23,64), 40-59 anos (aHR = 4,45, IC 95%: 1,83-10,79) e ≥ 60 anos (aHR = 13,63, IC 95%: 5,70-32,60) em comparação com os de 20-39 anos, com obesidade (aHR = 2,30, IC 95%: 1,24-4,27) e com doença renal crônica (aHR = 5,33, 95) % CI: 1,85-15,35). Na análise do modelo estrutural marginal, não houve diferença estatisticamente significativa nas chances de melhora clínica (razão de chances ajustada [aOR] = 1,53, IC 95%: 0,88-2,67,
Serum levels of Vitamin C and Vitamin D in a cohort of critically ill COVID-19 patients of a North American Community Hospital Intensive Care Unit in May 2020. A Pilot Study	https://doi.org/10.1016/j.medidd.2020.100064	18/09/2020	Artigo completo publicado em periódico científico	10.1016/j.medidd.2020.100064	2590-0986	25900986	Medicine in Drug Discovery	-	0.306	5	3.33	-	['Ácido ascórbico', 'Vitamina D (25-hidroxivitamina D)']	['Ascorbic acid', 'Vitamin D (25-hydroxyvitamin D)']	-	-	-	-	-	Níveis séricos de vitamina C e vitamina D em uma coorte de pacientes criticamente doentes com COVID-19 de uma Unidade de Terapia Intensiva de um Hospital Comunitário da América do Norte em maio de 2020. Um estudo piloto 	-
Therapeutic Anticoagulation Delays Death in COVID-19 Patients: Cross-Sectional Analysis of a Prospective Cohort	https://doi.org/10.1055/s-0040-1716721	26/09/2020	Artigo completo publicado em periódico científico	10.1055/s-0040-1716721	2512-9465	25129465	-	-	-	-	-	 Abstract A hypercoagulable state has been described in coronavirus disease 2019 (COVID-19) patients. Others have reported a survival advantage with prophylactic anticoagulation (pAC) and therapeutic anticoagulation (tAC), but these retrospective analyses have important limitations such as confounding by indication. We studied the impact of tAC and pAC compared with no anticoagulation (AC) on time to death in COVID-19. We performed a cross-sectional analysis of 127 deceased COVID-19 patients and compared time to death in those who received tAC (n = 67), pAC (n = 47), and no AC (n = 13). Median time to death was longer with higher doses of AC (11 days for tAC, 8 days for pAC, and 4 days for no AC, p &lt; 0.001). In multivariate analysis, AC was associated with longer time to death, both at prophylactic (hazard ratio [HR] = 0.29; 95% confidence interval [CI]: 0.15 to 0.58; p &lt; 0.001) and therapeutic doses (HR = 0.15; 95% CI: 0.07 to 0.32; p &lt; 0.001) compared with no AC. Bleeding rates were similar among tAC and remaining patients (19 vs. 18%; p = 0.877). In deceased COVID-19 patients, AC was associated with a delay in death in a dose-dependent manner. Randomized trials are required to prospectively investigate the benefit and safety of higher doses of AC in this population.	['Corticosteroides', 'Heparina']	['Corticosteroids', 'Heparin']	A hypercoagulable state has been described in coronavirus disease 2019 (COVID-19) patients. Others have reported a survival advantage with prophylactic anticoagulation (pAC) and therapeutic anticoagulation (tAC), but these retrospective analyses have important limitations such as confounding by indication. We studied the impact of tAC and pAC compared with no anticoagulation (AC) on time to death in COVID-19. We performed a cross-sectional analysis of 127 deceased COVID-19 patients and compared time to death in those who received tAC ( 	32995704	TH open : companion journal to thrombosis and haemostasis	2512-9465	10.1055/s-0040-1716721	A anticoagulação terapêutica atrasa a morte em pacientes com COVID-19: análise transversal de uma coorte prospectiva 	Um estado de hipercoagulabilidade foi descrito em pacientes com doença de coronavírus 2019 (COVID-19). Outros relataram uma vantagem de sobrevida com anticoagulação profilática (pAC) e anticoagulação terapêutica (tAC), mas essas análises retrospectivas têm limitações importantes, como confusão por indicação. Estudamos o impacto do tAC e pAC em comparação com a ausência de anticoagulação (AC) no tempo até a morte no COVID-19. Realizamos uma análise transversal de 127 pacientes falecidos com COVID-19 e comparamos o tempo até a morte naqueles que receberam tAC (
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study	https://doi.org/10.1053/j.gastro.2020.05.053	21/05/2020	Artigo completo publicado em periódico científico	10.1053/j.gastro.2020.05.053	0016-5085	165085	GASTROENTEROLOGY (NEW YORK, N.Y. 1943)	A1	7.689	423	10.76	-	['Famotidina']	['Famotidine']	Coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 continues to grow and spread throughout the world since being declared a pandemic. Despite extensive scientific research globally including repurposing of several existing drugs, there is no effective or proven therapy for this enigmatic disease which is still largely managed empirically This systematic review evaluated the role of hydroxychloroquine (HCQ) in the treatment of COVID-19 infection and was conducted using Cochrane methodology for systematic reviews of interventional studies including risk of bias assessment and grading of the quality of evidence. Only prospective clinical trials randomly assigning COVID-19 patients to HCQ plus standard of care therapy (test arm) versus placebo/standard of care (control arm) were included. Data were pooled using the random-effects model and expressed as risk ratio (RR) with 95% confidence interval (CI). A total of 10,492 patients from 19 randomised controlled trials were included. The use of HCQ was not associated with higher rates of clinical improvement (RR = 1.00, 95% CI: 0.96-1.03, p = 0.79) or reduction in all-cause mortality by Day14 (RR = 1.07, 95% CI: 0.97-1.19, p = 0.19) or Day28 (RR = 1.08, 95% CI: 0.99-1.19, p = 0.09) compared to placebo/standard of care. There was no significant difference in serious adverse events between the two arms (RR = 1.01, 95% CI: 0.85-1.19, p = 0.95). There is low-to-moderate certainty evidence that HCQ therapy is generally safe but does not reduce mortality or enhance recovery in patients with COVID-19 infection.	32446698	Gastroenterology	1528-0012	10.1053/j.gastro.2020.05.053	O uso de famotidina está associado a melhores resultados clínicos em pacientes hospitalizados com COVID-19: um estudo de coorte retrospectivo com pontuação de propensão A 	doença de coronavírus 2019 (COVID-19) causada pela nova síndrome respiratória aguda grave coronavírus 2 continua a crescer e se espalhar por todo o mundo desde que foi declarou uma pandemia. Apesar da extensa pesquisa científica global, incluindo o reaproveitamento de vários medicamentos existentes, não há terapia eficaz ou comprovada para esta doença enigmática que ainda é amplamente gerenciada empiricamente Esta revisão sistemática avaliou o papel da hidroxicloroquina (HCQ) no tratamento da infecção por COVID-19 e foi conduzido usando a metodologia Cochrane para revisões sistemáticas de estudos de intervenção, incluindo avaliação do risco de viés e classificação da qualidade da evidência. Apenas ensaios clínicos prospectivos que atribuíram aleatoriamente pacientes com COVID-19 a HCQ mais terapia padrão de tratamento (braço de teste) versus placebo/padrão de tratamento (braço de controle) foram incluídos. Os dados foram agrupados usando o modelo de efeitos aleatórios e expressos como razão de risco (RR) com intervalo de confiança de 95% (IC). Um total de 10.492 pacientes de 19 ensaios clínicos randomizados foram incluídos. O uso de HCQ não foi associado a maiores taxas de melhora clínica (RR = 1,00, IC 95%: 0,96-1,03, p = 0,79) ou redução na mortalidade por todas as causas no Dia 14 (RR = 1,07, IC 95%: 0,97- 1,19, p = 0,19) ou Dia 28 (RR = 1,08, IC 95%: 0,99-1,19, p = 0,09) em comparação com placebo/padrão de tratamento. Não houve diferença significativa em eventos adversos graves entre os dois braços (RR = 1,01, IC 95%: 0,85-1,19, p = 0,95). Há evidências de certeza baixa a moderada de que a terapia com HCQ é geralmente segura, mas não reduz a mortalidade ou melhora a recuperação em pacientes com infecção por COVID-19.
Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform	https://doi.org/10.1016/S2213-2600(20)30415-X	24/09/2020	Artigo completo publicado em periódico científico	10.1016/S2213-2600(20)30415-X	2213-2600	22132600	THE LANCET RESPIRATORY MEDICINE	A1	11.120	138	14.48	-	['Corticosteroides']	['Corticosteroids']	-	-	-	-	-	Risco de morte relacionada ao COVID-19 entre pacientes com doença pulmonar obstrutiva crônica ou asma prescritos com corticosteroides inalatórios: um estudo de coorte observacional usando a plataforma OpenSAFELY 	-
Effect of Corticosteroid Therapy on the Duration of SARS-CoV-2 Clearance in Patients with Mild COVID-19: A Retrospective Cohort Study.	https://doi.org/10.1007/s40121-020-00337-y	28/09/2020	Artigo completo publicado em periódico científico	10.1007/s40121-020-00337-y	2193-8229	21938229	INFECTIOUS DISEASES AND THERAPY	A4	1.141	33	4.82	-	['Corticosteroides']	['Corticosteroids']	-	-	-	-	-	Efeito da terapia com corticosteroides na duração da liberação de SARS-CoV-2 em pacientes com COVID-19 leve: um estudo de coorte retrospectivo. 	-
Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study	https://www.panafrican-med-journal.com/content/series/37/1/9/full/	15/09/2020	Artigo completo publicado em periódico científico	https://www.panafrican-med-journal.com/content/series/37/1/9/full/	-	-	-	-	-	-	-	-	['Azitromicina', 'Cloroquina', 'Hidroxicloroquina']	['Azithromycin', 'Chloroquine', 'Hydroxychloroquine']	-	-	-	-	-	Características clínicas, regime de tratamento e duração da hospitalização entre pacientes com COVID-19 em Gana: um estudo de coorte retrospectivo 	-
Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study	https://doi.org/10.1016/j.ebiom.2020.102999	16/09/2020	Artigo completo publicado em periódico científico	10.1016/j.ebiom.2020.102999	2352-3964	23523964	EBIOMEDICINE	A1	2.663	79	7.76	-	['Tocilizumabe']	['Tocilizumab']	Instituto de salud Carlos III (Spain).	32950003	EBioMedicine	2352-3964	10.1016/j.ebiom.2020.102999	Impacto do bloqueio de interleucina-6 com tocilizumab na cinética viral SARS-CoV-2 e respostas de anticorpos em pacientes com COVID-19: Um estudo de coorte prospectivo 	Instituto de salud Carlos III (Espanha).
Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study	https://doi.org/10.1016/S2665-9913(20)30305-2	21/09/2020	Artigo completo publicado em periódico científico	10.1016/S2665-9913(20)30305-2	2665-9913	26659913	Lancet Rheumatology, The	-	6.633	28	9.58	-	['Hidroxicloroquina']	['Hydroxychloroquine']	None.	32984847	The Lancet. Rheumatology	2665-9913	10.1016/S2665-9913(20)30305-2	Uso de hidroxicloroquina a longo prazo em pacientes com condições reumáticas e desenvolvimento de infecção por SARS-CoV-2: um estudo de coorte retrospectivo 	Nenhum.
Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Electrocardiogram Variability	https://doi.org/10.37616/2212-5043.1088	20/08/2020	Artigo completo publicado em periódico científico	10.37616/2212-5043.1088	2212-5043	22125043	Journal of the Saudi Heart Association	-	0.194	18	0.59	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']	During the COVID-19 pandemic, the effectiveness of the combination of hydroxychloroquine and azithromycin is widely discussed. This treatment can cause many severe cardiac side effects that makes us discuss its utility. The aim of this study is to describe the cardiovascular effect of hydroxychloroquine and azithromycin by analyzing surface ECG in patients with COVID-19. This observational cohort study included Moroccan patients with COVID-19 diagnosis and were hospitalized in Cheikh Khalifa International University Hospital, Casablanca, Morocco between March 26 and April 20, 2020. Patients were treated with a combination of hydroxychloroquine and azithromycin over a period of at least ten days. We were interested in the effects of this combination on the electrocardiogram. A total of 118 eligible patients were enrolled in the study. QT interval prolongation was observed in 19% of patients under the treatment. Only 5 patients required discontinuation of treatment. The factors associated with QT prolongation are male gender (P value 0,043), age over 68 years (P value 0,09), cardiovascular comorbidity (P value 0,013), tisdale score ≥11 (P value < 0,001), and a severe form of COVID-19 (P value < 0,001). First degree atrioventricular block was observed in 2 patients. No serious rhythm or conduction disorders were observed in this study. QT prolongation is a real risk with the combination of hydroxychloroquine and azithromycin. In the current context, it is necessary to select patients at high risk of severe rhythm disturbances that require closer ECG monitoring. Treatment should be discontinued if there are alarming signs such as QTc prolongation beyond 550 ms and the development of ventricular extrasystole or torsade de pointe.	33299775	Journal of the Saudi Heart Association	1016-7315	10.37616/2212-5043.1088	Hidroxicloroquina e Azitromicina como Tratamento da COVID-19: Variabilidade do Eletrocardiograma 	Durante a pandemia da COVID-19, a eficácia da combinação de hidroxicloroquina e azitromicina é amplamente discutida. Este tratamento pode causar muitos efeitos colaterais cardíacos graves que nos fazem discutir sua utilidade. O objetivo deste estudo é descrever o efeito cardiovascular da hidroxicloroquina e da azitromicina analisando o ECG de superfície em pacientes com COVID-19. Este estudo de coorte observacional incluiu pacientes marroquinos com diagnóstico de COVID-19 e foram hospitalizados no Hospital Universitário Internacional Cheikh Khalifa, Casablanca, Marrocos, entre 26 de março e 20 de abril de 2020. Os pacientes foram tratados com uma combinação de hidroxicloroquina e azitromicina por um período de pelo menos dez dias. Estávamos interessados nos efeitos dessa combinação no eletrocardiograma. Um total de 118 pacientes elegíveis foram incluídos no estudo. O prolongamento do intervalo QT foi observado em 19% dos pacientes em tratamento. Apenas 5 pacientes necessitaram de descontinuação do tratamento. Os fatores associados ao prolongamento do intervalo QT são sexo masculino (valor P 0,043), idade superior a 68 anos (valor P 0,09), comorbidade cardiovascular (valor P 0,013), escore tisdale ≥11 (valor P < 0,001) e uma forma grave de COVID-19 (valor P < 0,001). Bloqueio atrioventricular de primeiro grau foi observado em 2 pacientes. Nenhum ritmo grave ou distúrbios de condução foram observados neste estudo. O prolongamento do intervalo QT é um risco real com a combinação de hidroxicloroquina e azitromicina. No contexto atual, é necessário selecionar pacientes com alto risco de distúrbios graves do ritmo que requerem monitoramento mais próximo do ECG. O tratamento deve ser descontinuado se houver sinais alarmantes, como prolongamento do intervalo QTc além de 550 ms e desenvolvimento de extrassístole ventricular ou torsade de pointe.
Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19	https://www.mdpi.com/2077-0383/9/9/2961/htm	14/09/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2077-0383/9/9/2961/htm	-	-	-	-	-	-	-	-	['Colchicina']	['Colchicine']	The repurposing of colchicine for the treatment of COVID-19 was suggested based in its immunomodulatory, anti-inflammatory, and anti-viral properties. We performed a single-center propensity score matched cohort study, including all consecutive COVID-19 patients admitted to a community hospital between 1 March 2020 and 30 May 2020. Patients were stratified according to the receipt of colchicine. The primary endpoint was defined as in-hospital death within 28-days follow-up. Secondary endpoints included favorable change in the Ordinal Scale for Clinical Improvement on days 14 and 28 versus baseline, proportion of patients not requiring supplemental oxygen on days 14 and 28, and proportion of patients discharged by day 28. In total data for 303 PCR positive COVID-19 patients were extracted and 66 patients were included in the 1:1 matched cohort study. At the end of the 28 day follow-up, patients receiving colchicine were approximately five times more likely to be discharged (odds ratio, 5.0; 95% confidence interval, 1.25-20.1; 	32937800	Journal of clinical medicine	2077-0383	10.3390/jcm9092961	Colchicina para resistir à tempestade de citocinas em pacientes hospitalizados com COVID-19 	O reaproveitamento da colchicina para o tratamento de COVID-19 foi sugerido com base em suas propriedades imunomoduladoras, anti-inflamatórias e antivirais. Realizamos um estudo de coorte combinado com escore de propensão em um único centro, incluindo todos os pacientes consecutivos com COVID-19 admitidos em um hospital comunitário entre 1º de março de 2020 e 30 de maio de 2020. Os pacientes foram estratificados de acordo com o recebimento de colchicina. O desfecho primário foi definido como óbito hospitalar em 28 dias de seguimento. Os desfechos secundários incluíram mudança favorável na Escala Ordinal para Melhoria Clínica nos dias 14 e 28 em relação à linha de base, proporção de pacientes que não necessitaram de oxigênio suplementar nos dias 14 e 28 e proporção de pacientes que receberam alta no dia 28. No total de dados para 303 PCR positivo para COVID -19 pacientes foram extraídos e 66 pacientes foram incluídos no estudo de coorte 1:1 pareado. Ao final do seguimento de 28 dias, os pacientes que receberam colchicina tinham aproximadamente cinco vezes mais chances de receber alta (odds ratio, 5,0; intervalo de confiança de 95%, 1,25-20,1;
Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up	https://doi.org/10.1016/j.eclinm.2020.100459	17/07/2020	Artigo completo publicado em periódico científico	10.1016/j.eclinm.2020.100459	2589-5370	25895370	EClinicalMedicine	-	4.657	44	9.79	-	['Tocilizumabe']	['Tocilizumab']	none.	32838235	EClinicalMedicine	2589-5370	10.1016/j.eclinm.2020.100459	Uso precoce de baixa dose de tocilizumabe em pacientes com COVID-19: um estudo de coorte retrospectivo com nenhum acompanhamento completo 	.
Angiotensin converting enzyme inhibitors do not increase the risk of poor outcomes in COVID-19 disease. A multi-centre observational study	https://journals.sagepub.com/doi/full/10.1177/0036933020951926	01/09/2020	Artigo completo publicado em periódico científico	10.1177/0036933020951926	0036-9330	369330	Scottish Medical Journal	-	0.293	27	1.26	  Background and aims  Hypertension is associated with an increased risk of severe outcomes with COVID-19 disease. Angiotensin Converting Enzyme (ACE) inhibitors are widely used as a first line medication for the treatment of hypertension in the UK, although their use was suggested in early reports to increase the risk associated with SARS-CoV-2 infection.   Methods  A prospective cohort study of hospitalised patients with laboratory confirmed COVID-19 was conducted across three hospital sites with patients identified on the 9th April 2020. Demographic and other baseline data were extracted from electronic case records, and patients grouped depending on ACE inhibitor usage or not. The 60-day all-cause mortality and need for intubation compared.   Results  Of the 173 patients identified, 88 (50.8%) had hypertension. Of these 27 (30.7%) used ACE inhibitors. We did not find significant differences in 60-day all-cause mortality, the requirement for invasive ventilation or length of stay between our patient cohorts after adjusting for covariates.   Conclusion  This study contributes to the growing evidence supporting the continued use of ACE inhibitors in COVID-19 disease, although adequately powered randomised controlled trials will be needed to confirm effects. 	['Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	-	-	-	-	-	Os inibidores da enzima de conversão da angiotensina não aumentam o risco de resultados ruins na doença de COVID-19. Um estudo observacional multicêntrico 	-
COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study	https://doi.org/10.1186/s12979-020-00194-w	14/08/2020	Artigo completo publicado em periódico científico	10.1186/s12979-020-00194-w	1742-4933	17424933	IMMUNITY & AGEING	A2	1.697	50	7.3	 Abstract  Background The SARS-CoV-2 infection has widely spread to become the greatest public health challenge to date, the COVID-19 pandemic. Different fatality rates among countries are probably due to non-standardized records being carried out by local health authorities. The Spanish case-fatality rate is 11.22%, far higher than those reported in Asia or by other European countries. A multicentre retrospective study of demographic, clinical, laboratory and immunological features of 584 Spanish COVID-19 hospitalized patients and their outcomes was performed. The use of renin-angiotensin system blockers was also analysed as a risk factor.  Results In this study, 27.4% of cases presented a mild course, 42.1% a moderate one and for 30.5% of cases, the course was severe. Ages ranged from 18 to 98 (average 63). Almost 60 % (59.8%) of patients were male. Interleukin 6 was higher as severity increased. On the other hand, CD8 lymphocyte count was significantly lower as severity grew and subpopulations CD4, CD8, CD19, and NK showed concordant lowering trends. Severity-related natural killer percent descents were evidenced just within aged cases. A significant severity-related decrease of CD4 lymphocytes was found in males. The use of angiotensin-converting enzyme inhibitors was associated with a better prognosis. The angiotensin II receptor blocker use was associated with a more severe course.  Conclusions Age and age-related comorbidities, such as dyslipidaemia, hypertension or diabetes, determined more frequent severe forms of the disease in this study than in previous literature cohorts. Our cases are older than those so far reported and the clinical course of the disease is found to be impaired by age. Immunosenescence might be therefore a suitable explanation for the hampering of immune system effectors. The adaptive immunity would become exhausted and a strong but ineffective and almost deleterious innate response would account for COVID-19 severity. Angiotensin-converting enzyme inhibitors used by hypertensive patients have a protective effect in regards to COVID-19 severity in our series. Conversely, patients on angiotensin II receptor blockers showed a severer disease.	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	Age and age-related comorbidities, such as dyslipidaemia, hypertension or diabetes, determined more frequent severe forms of the disease in this study than in previous literature cohorts. Our cases are older than those so far reported and the clinical course of the disease is found to be impaired by age. Immunosenescence might be therefore a suitable explanation for the hampering of immune system effectors. The adaptive immunity would become exhausted and a strong but ineffective and almost deleterious innate response would account for COVID-19 severity. Angiotensin-converting enzyme inhibitors used by hypertensive patients have a protective effect in regards to COVID-19 severity in our series. Conversely, patients on angiotensin II receptor blockers showed a severer disease.	32802142	Immunity & ageing : I & A	1742-4933	10.1186/s12979-020-00194-w	COVID-19: idade, interleucina-6, proteína C reativa e linfócitos como pistas-chave de um estudo retrospectivo multicêntrico 	Idade e comorbidades relacionadas à idade, como dislipidemia, hipertensão ou diabetes, determinaram formas graves mais frequentes da doença neste estudo do que em coortes de literatura anteriores. Nossos casos são mais antigos do que os relatados até agora e o curso clínico da doença é prejudicado pela idade. A imunossenescência pode ser, portanto, uma explicação adequada para o impedimento dos efetores do sistema imunológico. A imunidade adaptativa se esgotaria e uma resposta inata forte, mas ineficaz e quase deletéria, seria responsável pela gravidade do COVID-19. Os inibidores da enzima conversora de angiotensina usados por pacientes hipertensos têm um efeito protetor em relação à gravidade da COVID-19 em nossa série. Por outro lado, os pacientes em uso de bloqueadores dos receptores da angiotensina II apresentaram uma doença mais grave.
Are the steroids a blanket solution for COVID‐19? a systematic review and meta‐analysis	https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26483	03/09/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26483	0146-6615	1466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Esteroides']	['Steroidal']	Steroids may play a critical role in the current pandemic of coronavirus disease-2019 (COVID-19), given the dearth of specific therapeutic options. This review was conducted to evaluate the impact of glucocorticoid therapy in patients with COVID-19 based on the publications reported to date. A comprehensive screening was conducted using electronic databases up to August 19, 2020. The randomized controlled trials (RCTs) and cohort studies evaluating the effectiveness and safety of steroids in patients with COVID-19 are included for the meta-analyses. Our search retrieved twelve studies, including two RCTs and 10 cohort studies, with a total of 15,754 patients. In patients with COVID-19, the use of systemic glucocorticoid neither reduce mortality (odds ratio [OR] = 1.94, 95% confidence interval [CI]: 1.11-3.4, I	32881007	Journal of medical virology	1096-9071	10.1002/jmv.26483	Os esteróides são uma solução geral para o COVID-19? uma revisão sistemática e meta-análise 	Os esteróides podem desempenhar um papel crítico na atual pandemia da doença por coronavírus-2019 (COVID-19), dada a escassez de opções terapêuticas específicas. Esta revisão foi realizada para avaliar o impacto da terapia com glicocorticóides em pacientes com COVID-19 com base nas publicações relatadas até o momento. Uma triagem abrangente foi realizada usando bancos de dados eletrônicos até 19 de agosto de 2020. Os ensaios clínicos randomizados (ECRs) e estudos de coorte que avaliam a eficácia e a segurança dos esteróides em pacientes com COVID-19 estão incluídos nas meta-análises. Nossa busca recuperou doze estudos, incluindo dois ECRs e 10 estudos de coorte, com um total de 15.754 pacientes. Em pacientes com COVID-19, o uso de glicocorticóide sistêmico não reduz a mortalidade (odds ratio [OR] = 1,94, intervalo de confiança de 95% [IC]: 1,11-3,4, I
Efficacy Evaluation of Early, Low-Dose, Short-Term Corticosteroids in Adults Hospitalized with Non-Severe COVID-19 Pneumonia: A Retrospective Cohort Study	https://link.springer.com/article/10.1007/s40121-020-00332-3	02/09/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s40121-020-00332-3	2193-8229	21938229	INFECTIOUS DISEASES AND THERAPY	A4	1.141	33	4.82	-	['Corticosteroides']	['Corticosteroids']	In adult patients with non-severe COVID-19 pneumonia, early, low-dose, and short-term corticosteroids therapy was associated with worse clinical outcomes.	32880102	Infectious diseases and therapy	2193-8229	10.1007/s40121-020-00332-3	Avaliação da eficácia de corticosteróides precoces, de baixa dose e de curto prazo em adultos hospitalizados com pneumonia não grave por COVID-19: um estudo de coorte retrospectivo 	Em pacientes adultos com pneumonia não grave por COVID-19, precoce, de baixa dose e curto a terapia com corticosteróides a termo foi associada a piores desfechos clínicos.
The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective cohort study	https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1111/cts.12880	03/09/2020	Artigo completo publicado em periódico científico	10.1111/cts.12880	1752-8054	17528054	Clinical and Translational Science	-	1.162	48	4.64	-	['Heparina']	['Heparin']	On March 11, 2020, the World Health Organization declared its assessment of coronavirus disease 2019 (COVID-19) as a global pandemic. However, specific anti-severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) drugs are still under development, and patients are managed by multiple complementary treatments. We performed a retrospective analysis to compare and evaluate the effect of low molecular weight heparin (LMWH) treatment on disease progression. For this purpose, the clinical records and laboratory indicators were extracted from electronic medical records of 42 patients with COVID-19 (21 of whom were treated with LMWH, and 21 without LMWH) hospitalized (Union Hospital of Huazhong University of Science and Technology) from February 1 to March 15, 2020. Changes in the percentage of lymphocytes before and after LMWH treatment were significantly different from those in the control group (P = 0.011). Likewise, changes in the levels of D-dimer and fibrinogen degradation products in the LMWH group before and after treatment were significantly different from those in the control group (P = 0.035). Remarkably, IL-6 levels were significantly reduced after LMWH treatment (P = 0.006), indicating that, besides other beneficial properties, LMWH may exert an anti-inflammatory effect and attenuate in part the "cytokine storm" induced by the virus. Our results support the use of LMWH as a potential therapeutic drug for the treatment of COVID-19, paving the way for a subsequent well-controlled clinical study.	32881340	Clinical and translational science	1752-8062	10.1111/cts.12880	O potencial da heparina de baixo peso molecular para mitigar a tempestade de citocinas em pacientes graves com COVID-19: um estudo de coorte retrospectivo 	Em 11 de março de 2020, a Organização Mundial da Saúde declarou sua avaliação da doença de coronavírus 2019 (COVID-19) como uma pandemia global. No entanto, medicamentos específicos contra a síndrome respiratória aguda grave-coronavírus 2 (SARS-CoV-2) ainda estão em desenvolvimento e os pacientes são tratados por vários tratamentos complementares. Realizamos uma análise retrospectiva para comparar e avaliar o efeito do tratamento com heparina de baixo peso molecular (HBPM) na progressão da doença. Para isso, os prontuários clínicos e indicadores laboratoriais foram extraídos de prontuários eletrônicos de 42 pacientes com COVID-19 (21 dos quais foram tratados com HBPM e 21 sem HBPM) hospitalizados (Union Hospital of Huazhong University of Science and Technology) de 1 de fevereiro a 15 de março de 2020. As alterações na porcentagem de linfócitos antes e após o tratamento com HBPM foram significativamente diferentes das do grupo controle (P = 0,011). Da mesma forma, as mudanças nos níveis de D-dímero e produtos de degradação do fibrinogênio no grupo HBPM antes e após o tratamento foram significativamente diferentes das do grupo controle (P = 0,035). Notavelmente, os níveis de IL-6 foram significativamente reduzidos após o tratamento com LMWH (P = 0,006), indicando que, além de outras propriedades benéficas, a LMWH pode exercer um efeito anti-inflamatório e atenuar em parte a "tempestade de citocinas" induzida pelo vírus. Nossos resultados apoiam o uso de HBPM como um potencial medicamento terapêutico para o tratamento de COVID-19, abrindo caminho para um estudo clínico subsequente bem controlado.
Empiric therapeutic anticoagulation and mortality in critically ill patients with respiratory failure from SARS-CoV-2: A retrospective cohort study	https://accp1.onlinelibrary.wiley.com/doi/abs/10.1002/jcph.1749	03/09/2020	Artigo completo publicado em periódico científico	10.1002/jcph.1749	0091-2700	912700	JOURNAL OF CLINICAL PHARMACOLOGY	A3	0.687	121	2.9	-	['Heparina']	['Heparin']	The pathophysiology of respiratory failure associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains under investigation. One hypothesis is that progressive endothelial damage from the virus leads to microvascular thrombosis. It is uncertain if empiric therapeutic anticoagulation provides benefit over standard deep vein thrombosis (DVT) prophylaxis in critically ill patients with SARS-CoV-2. A retrospective cohort study was performed to evaluate adult patients admitted to the intensive care unit at 3 hospitals with polymerase chain reaction-confirmed SARS-CoV-2-associated respiratory failure requiring invasive mechanical ventilation. A Kaplan-Meier survival analysis was used to compare patients who were initiated on therapeutic anticoagulation prior to the time of intubation and those receiving standard DVT prophylaxis doses. The primary outcome was the difference in the 28-day mortality of patients between the 2 groups. Twenty-eight-day mortality did not differ between groups, occurring in 26.1% of patients who received therapeutic anticoagulation and 29.5% of those who received a prophylactic dose only (hazard ratio, 0.52; P = .055). There was no difference in 28-day mortality between groups in patients who were admitted with a serum D-dimer ≥ 2 µg/mL (hazard ratio, 0.67; P = .41). Empiric therapeutic anticoagulation in patients who require invasive mechanical ventilation for confirmed SARS-CoV-2 infection does not improve 28-day mortality compared with standard DVT prophylaxis, even among those with elevated D-dimer levels.	32885463	Journal of clinical pharmacology	1552-4604	10.1002/jcph.1749	Anticoagulação terapêutica empírica e mortalidade em pacientes críticos com insuficiência respiratória por SARS-CoV-2: um estudo de coorte retrospectivo 	A fisiopatologia da insuficiência respiratória associada ao coronavírus 2 da síndrome respiratória aguda grave (SARS-CoV-2) permanece sob investigação. Uma hipótese é que o dano endotelial progressivo do vírus leva à trombose microvascular. É incerto se a anticoagulação terapêutica empírica oferece benefício sobre a profilaxia padrão de trombose venosa profunda (TVP) em pacientes criticamente enfermos com SARS-CoV-2. Um estudo de coorte retrospectivo foi realizado para avaliar pacientes adultos admitidos na unidade de terapia intensiva em 3 hospitais com insuficiência respiratória associada a SARS-CoV-2 confirmada por reação em cadeia da polimerase que requer ventilação mecânica invasiva. Uma análise de sobrevida de Kaplan-Meier foi usada para comparar pacientes que iniciaram anticoagulação terapêutica antes do momento da intubação e aqueles que receberam doses padrão de profilaxia para TVP. O desfecho primário foi a diferença na mortalidade em 28 dias dos pacientes entre os 2 grupos. A mortalidade em 28 dias não diferiu entre os grupos, ocorrendo em 26,1% dos pacientes que receberam anticoagulação terapêutica e 29,5% daqueles que receberam apenas uma dose profilática (hazard ratio, 0,52; P = 0,055). Não houve diferença na mortalidade em 28 dias entre os grupos em pacientes que foram admitidos com um dímero D sérico ≥ 2 µg/mL (razão de risco, 0,67; P = 0,41). A anticoagulação terapêutica empírica em pacientes que necessitam de ventilação mecânica invasiva para infecção confirmada por SARS-CoV-2 não melhora a mortalidade em 28 dias em comparação com a profilaxia de TVP padrão, mesmo entre aqueles com níveis elevados de dímero D.
Dual-Histamine Receptor Blockade with Cetirizine - Famotidine Reduces Pulmonary Symptoms in COVID-19 Patients	https://www.sciencedirect.com/science/article/pii/S1094553920301462?via%3Dihub	29/08/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S1094553920301462?via%3Dihub	-	-	-	-	-	-	-	-	['Cetirizina', 'Famotidina']	['Cetirizine', 'Famotidine']	This physician-sponsored cohort study of cetirizine and famotidine provides proof-of-concept of a safe and effective method to reduce the progression in symptom severity, presumably by minimizing the histamine-mediated cytokine storm. Further clinical studies in COVID-19 are warranted of the repurposed off-label combination of two historically-safe histamine receptor blockers.	32871242	Pulmonary pharmacology & therapeutics	1522-9629	10.1016/j.pupt.2020.101942	famotidina reduz os sintomas pulmonares em pacientes com COVID-19 	a tempestade de citocinas mediada por histamina. Outros estudos clínicos no COVID-19 são garantidos da combinação off-label reaproveitada de dois bloqueadores de receptores de histamina historicamente seguros.
Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19	https://doi.org/10.1016/j.ijantimicag.2020.106142	24/08/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.106142	0924-8579	9248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Hidroxicloroquina']	['Hydroxychloroquine']	This longitudinal, prospective cohort study aimed to assess risk of QTc interval prolongation and its predicting factors in subjects treated with combinations containing hydroxychloroquine (HCQ) for COVID-19. Moderate-to-severe QTc prolongation during therapy was defined as a QTc interval >470 ms in men or >480 ms in women. Patients were treated under strict cardiac supervision. A total of 105 adults were included [56% male; median (IQR) age 69 (57-79) years]. All patients received therapy with HCQ in combination with azithromycin (AZM), and 95 (90%) also with lopinavir/ritonavir (LPV/r). Concomitant medications classified as having risk of developing torsades de pointes (TdP) were simultaneously used in 81 patients (77%). Moderate-to-severe QTc prolongation was observed in 14 patients (13%), mostly at Days 3-5 from baseline, with 6 (6%) developing severe prolongation (>500 ms). There was no evidence of TdP arrhythmia or TdP-associated death. Adding LPV/r to HCQ+AZM did not significantly prolong the QTc interval. Multivariable Cox regression revealed that comedications with known risk of TdP (HR = 11.28, 95% CI 1.08-117.41), higher neutrophil-to-lymphocyte (NLR) ratio (HR = 1.10, 95% CI 1.03-1.18 per unit increase) and higher serum hs-cardiac troponin I (HR = 4.09, 95% CI 1.36-12.2 per unit increase) were major contributors to moderate-to-severe QTc prolongation. In this closely screened and monitored cohort, no complications derived from QTc prolongation were observed during pharmacological therapy containing HCQ for COVID-19. Evidence of myocardial injury with elevated troponin and strong inflammatory response, specifically higher NLR, are conditions requiring careful QTc interval monitoring.	32853675	International journal of antimicrobial agents	1872-7913	10.1016/j.ijantimicag.2020.106142	Fatores preditivos para anormalidades da condução cardíaca 	com combinações contendo hidroxicloroquina para COVID-19 O prolongamento QTc moderado a grave durante a terapia foi definido como um intervalo QTc > 470 ms em homens ou > 480 ms em mulheres. Os pacientes foram tratados sob estrita supervisão cardíaca. Um total de 105 adultos foram incluídos [56% do sexo masculino; mediana (IQR) idade 69 (57-79) anos]. Todos os pacientes receberam terapia com HCQ em combinação com azitromicina (AZM), e 95 (90%) também com lopinavir/ritonavir (LPV/r). Medicamentos concomitantes classificados como de risco para desenvolver torsades de pointes (TdP) foram usados simultaneamente em 81 pacientes (77%). Prolongamento QTc moderado a grave foi observado em 14 pacientes (13%), principalmente nos dias 3-5 da linha de base, com 6 (6%) desenvolvendo prolongamento grave (> 500 ms). Não houve evidência de arritmia TdP ou morte associada à TdP. A adição de LPV/r a HCQ+AZM não prolongou significativamente o intervalo QTc. A regressão multivariável de Cox revelou que os medicamentos com risco conhecido de TdP (HR = 11,28, IC 95% 1,08-117,41), razão neutrófilo-linfócito (NLR) mais alta (HR = 1,10, IC 95% 1,03-1,18 por unidade de aumento) e níveis séricos mais elevados de troponina I cardíaca (HR = 4,09, IC 95% 1,36-12,2 por unidade de aumento) foram os principais contribuintes para o prolongamento QTc moderado a grave. Nesta coorte rastreada e monitorada de perto, não foram observadas complicações derivadas do prolongamento do QTc durante a terapia farmacológica contendo HCQ para COVID-19. Evidência de lesão miocárdica com troponina elevada e forte resposta inflamatória, especificamente NLR mais alta, são condições que requerem monitoramento cuidadoso do intervalo QTc.
Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)	https://doi.org/10.1016/j.cmi.2020.08.010	26/08/2020	Artigo completo publicado em periódico científico	10.1016/j.cmi.2020.08.010	1198-743X	1198743X	CLINICAL MICROBIOLOGY AND INFECTION (PRINT)	A1	3.111	167	7.73	-	['Corticosteroides', 'Tocilizumabe']	['Corticosteroids', 'Tocilizumab']	Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situation.	32860964	Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases	1469-0691	10.1016/j.cmi.2020.08.010	Tratamento com tocilizumabe ou corticosteroides para pacientes com COVID-19 com estado hiperinflamatório: um estudo de coorte multicêntrico (SAM-COVID-19) O 	tocilizumabe pode ser útil em pacientes com COVID-19 com estado hiperinflamatório e deve ser priorizado para ensaios randomizados nessa situação.
Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients	https://doi.org/10.1007/s40264-020-00994-5	27/08/2020	Artigo completo publicado em periódico científico	10.1007/s40264-020-00994-5	0114-5916	1145916	Drug Safety	-	1.268	131	4.42	-	['Antagonistas do Receptor da Angiotensina II', 'Bloqueadores do Canal de Cálcio', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Calcium Channel Blockers', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	ACEI/ARB use is not associated with either an increased or decreased risk of all-cause mortality, compared with CCB use, in the largest cohort of hospitalised COVID-19 patients exposed to these drugs studied to date. The use of these drugs therefore does not affect the prognosis of COVID-19. This finding strengthens recommendations of international regulatory agencies about not withdrawing/switching ACEI/ARB treatments to modify COVID-19 prognosis.	32852721	Drug safety	1179-1942	10.1007/s40264-020-00994-5	Inibidores do sistema renina-angiotensina-aldosterona e risco de morte em pacientes hospitalizados com COVID-19: um estudo de coorte italiano retrospectivo de 43.000 pacientes O 	uso de IECA/BRA não está associado a um risco aumentado ou diminuído de mortalidade por todas as causas, em comparação com CCB uso, na maior coorte de pacientes hospitalizados com COVID-19 expostos a esses medicamentos estudados até o momento. O uso desses medicamentos, portanto, não afeta o prognóstico do COVID-19. Essa descoberta fortalece as recomendações das agências reguladoras internacionais sobre não retirar/trocar os tratamentos IECA/BRA para modificar o prognóstico da COVID-19.
High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients	https://doi.org/10.1016/j.jaut.2020.102537	20/08/2020	Artigo completo publicado em periódico científico	10.1016/j.jaut.2020.102537	0896-8411	8968411	JOURNAL OF AUTOIMMUNITY (PRINT)	A1	2.751	121	12.06	-	['Anakinra']	['Anakinra']	Overall, 55.6% of COVID-19 ARDS CSS patients treated with ANK exhibited favorable outcome, not inferior to a TCZ treated matched cohort. ANK may be a potential alternative to TCZ for patients with elevated aminotransferases, and may be useful in non-responders to TCZ.	32843231	Journal of autoimmunity	1095-9157	10.1016/j.jaut.2020.102537	Anakinra subcutâneo de alta dose para tratar a síndrome do desconforto respiratório agudo secundária à síndrome da tempestade de citocinas em pacientes com COVID-19 gravemente doentes 	No geral, 55,6% dos pacientes com COVID-19 ARDS CSS tratados com ANK exibiram resultado favorável, não inferior a uma coorte pareada tratada com TCZ. ANK pode ser uma alternativa potencial ao TCZ para pacientes com aminotransferases elevadas e pode ser útil em não respondedores ao TCZ.
Renin–angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study	https://doi.org/10.1038/s41440-020-00535-8	21/08/2020	Artigo completo publicado em periódico científico	10.1038/s41440-020-00535-8	0916-9636	9169636	HYPERTENSION RESEARCH	A2	1.119	95	3.97	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	Since the beginning of the coronavirus disease 2019 (COVID-19) outbreak initiated on the Diamond Princess Cruise Ship at Yokohama harbor in February 2020, we have been doing our best to treat COVID-19 patients. In animal experiments, angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor blockers (ARBs) are reported to suppress the downregulation of angiotensin converting enzyme 2 (ACE2), and they may inhibit the worsening of pathological conditions. We aimed to examine whether preceding use of ACEIs and ARBs affected the clinical manifestations and prognosis of COVID-19 patients. One hundred fifty-one consecutive patients (mean age 60 ± 19 years) with polymerase-chain-reaction proven severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who were admitted to six hospitals in Kanagawa Prefecture, Japan, were analyzed in this multicenter retrospective observational study. Among all COVID-19 patients, in the multiple regression analysis, older age (age ≥ 65 years) was significantly associated with the primary composite outcome (odds ratio (OR) 6.63, 95% confidence interval (CI) 2.28-22.78, P < 0.001), which consisted of (i) in-hospital death, (ii) extracorporeal membrane oxygenation, (iii) mechanical ventilation, including invasive and noninvasive methods, and (iv) admission to the intensive care unit. In COVID-19 patients with hypertension, preceding ACEI/ARB use was significantly associated with a lower occurrence of new-onset or worsening mental confusion (OR 0.06, 95% CI 0.002-0.69, P = 0.02), which was defined by the confusion criterion, which included mild disorientation or hallucination with an estimation of medical history of mental status, after adjustment for age, sex, and diabetes. In conclusion, older age was a significant contributor to a worse prognosis in COVID-19 patients, and ACEIs/ARBs could be beneficial for the prevention of confusion in COVID-19 patients with hypertension.	32820236	Hypertension research : official journal of the Japanese Society of Hypertension	1348-4214	10.1038/s41440-020-00535-8	Inibidores do sistema renina-angiotensina e a gravidade da doença de coronavírus 2019 em Kanagawa, Japão: um estudo de coorte 	retrospectivo temos feito o nosso melhor para tratar os pacientes com COVID-19. Em experimentos com animais, os inibidores da enzima de conversão da angiotensina (IECAs) e os bloqueadores dos receptores do tipo 1 da angiotensina II (BRAs) são relatados para suprimir a regulação negativa da enzima de conversão da angiotensina 2 (ACE2), e podem inibir o agravamento de condições patológicas. Nosso objetivo foi examinar se o uso anterior de IECAs e BRAs afetou as manifestações clínicas e o prognóstico de pacientes com COVID-19. Cento e cinquenta e um pacientes consecutivos (idade média de 60 ± 19 anos) com reação em cadeia da polimerase comprovada infecção por coronavírus 2 da síndrome respiratória aguda grave (SARS-CoV-2) que foram internados em seis hospitais na província de Kanagawa, Japão, foram analisados neste estudo observacional retrospectivo multicêntrico. Entre todos os pacientes com COVID-19, na análise de regressão múltipla, a idade mais avançada (idade ≥ 65 anos) foi significativamente associada ao resultado composto primário (razão de chances (OR) 6,63, intervalo de confiança de 95% (IC) 2,28-22,78, P < 0,001), que consistiu em (i) óbito hospitalar, (ii) oxigenação por membrana extracorpórea, (iii) ventilação mecânica, incluindo métodos invasivos e não invasivos, e (iv) internação em unidade de terapia intensiva. Em pacientes com COVID-19 com hipertensão, o uso anterior de IECA/BRA foi significativamente associado a uma menor ocorrência de novo início ou piora da confusão mental (OR 0,06, IC 95% 0,002-0,69, P = 0,02), que foi definida pela confusão critério, que incluiu leve desorientação ou alucinação com uma estimativa do histórico médico do estado mental, após ajuste para idade, sexo e diabetes. Em conclusão, a idade avançada foi um contribuinte significativo para um pior prognóstico em pacientes com COVID-19, e IECAs/BRAs podem ser benéficos para a prevenção de confusão em pacientes com COVID-19 com hipertensão.
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study	https://doi.org/10.1038/s41375-020-01018-y	19/08/2020	Artigo completo publicado em periódico científico	10.1038/s41375-020-01018-y	0887-6924	8876924	LEUKEMIA	A1	4.030	202	9.5	 Abstract Overwhelming inflammatory reactions contribute to respiratory distress in patients with COVID-19. Ruxolitinib is a JAK1/JAK2 inhibitor with potent anti-inflammatory properties. We report on a prospective, observational study in 34 patients with COVID-19 who received ruxolitinib on a compassionate-use protocol. Patients had severe pulmonary disease defined by pulmonary infiltrates on imaging and an oxygen saturation ≤ 93% in air and/or PaO2/FiO2 ratio ≤ 300 mmHg. Median age was 80.5 years, and 85.3% had ≥ 2 comorbidities. Median exposure time to ruxolitinib was 13 days, median dose intensity was 20 mg/day. Overall survival by day 28 was 94.1%. Cumulative incidence of clinical improvement of ≥2 points in the ordinal scale was 82.4% (95% confidence interval, 71–93). Clinical improvement was not affected by low-flow versus high-flow oxygen support but was less frequent in patients with PaO2/FiO2 &lt; 200 mmHg. The most frequent adverse events were anemia, urinary tract infections, and thrombocytopenia. Improvement of inflammatory cytokine profile and activated lymphocyte subsets was observed at day 14. In this prospective cohort of aged and high-risk comorbidity patients with severe COVID-19, compassionate-use ruxolitinib was safe and was associated with improvement of pulmonary function and discharge home in 85.3%. Controlled clinical trials are necessary to establish efficacy of ruxolitinib in COVID-19.	['Ruxolitinibe']	['Ruxolitinib']	Overwhelming inflammatory reactions contribute to respiratory distress in patients with COVID-19. Ruxolitinib is a JAK1/JAK2 inhibitor with potent anti-inflammatory properties. We report on a prospective, observational study in 34 patients with COVID-19 who received ruxolitinib on a compassionate-use protocol. Patients had severe pulmonary disease defined by pulmonary infiltrates on imaging and an oxygen saturation ≤ 93% in air and/or PaO2/FiO2 ratio ≤ 300 mmHg. Median age was 80.5 years, and 85.3% had ≥ 2 comorbidities. Median exposure time to ruxolitinib was 13 days, median dose intensity was 20 mg/day. Overall survival by day 28 was 94.1%. Cumulative incidence of clinical improvement of ≥2 points in the ordinal scale was 82.4% (95% confidence interval, 71-93). Clinical improvement was not affected by low-flow versus high-flow oxygen support but was less frequent in patients with PaO2/FiO2 < 200 mmHg. The most frequent adverse events were anemia, urinary tract infections, and thrombocytopenia. Improvement of inflammatory cytokine profile and activated lymphocyte subsets was observed at day 14. In this prospective cohort of aged and high-risk comorbidity patients with severe COVID-19, compassionate-use ruxolitinib was safe and was associated with improvement of pulmonary function and discharge home in 85.3%. Controlled clinical trials are necessary to establish efficacy of ruxolitinib in COVID-19.	32814839	Leukemia	1476-5551	10.1038/s41375-020-01018-y	Uso compassivo do inibidor de JAK1/2 ruxolitinibe para COVID-19 grave: um estudo observacional prospectivo 	Reações inflamatórias esmagadoras contribuem para o desconforto respiratório em pacientes com COVID-19. Ruxolitinib é um inibidor de JAK1/JAK2 com potentes propriedades anti-inflamatórias. Relatamos um estudo prospectivo e observacional em 34 pacientes com COVID-19 que receberam ruxolitinibe em um protocolo de uso compassivo. Os pacientes apresentavam doença pulmonar grave definida por infiltrados pulmonares na imagem e saturação de oxigênio ≤ 93% no ar e/ou relação PaO2/FiO2 ≤ 300 mmHg. A idade mediana foi de 80,5 anos e 85,3% tinham ≥ 2 comorbidades. O tempo médio de exposição ao ruxolitinib foi de 13 dias, a intensidade da dose média foi de 20 mg/dia. A sobrevida global no dia 28 foi de 94,1%. A incidência cumulativa de melhora clínica de ≥2 pontos na escala ordinal foi de 82,4% (intervalo de confiança de 95%, 71-93). A melhora clínica não foi afetada pelo suporte de oxigênio de baixo fluxo versus alto fluxo, mas foi menos frequente em pacientes com PaO2/FiO2 < 200 mmHg. Os eventos adversos mais frequentes foram anemia, infecções do trato urinário e trombocitopenia. A melhora do perfil de citocinas inflamatórias e subconjuntos de linfócitos ativados foi observada no dia 14. Nesta coorte prospectiva de pacientes idosos e com comorbidade de alto risco com COVID-19 grave, o uso compassivo de ruxolitinibe foi seguro e foi associado à melhora da função pulmonar e alta hospitalar em 85,3%. Ensaios clínicos controlados são necessários para estabelecer a eficácia do ruxolitinibe no COVID-19.
Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients	https://doi.org/10.1007/s11883-020-00880-6	24/08/2020	Artigo completo publicado em periódico científico	10.1007/s11883-020-00880-6	1523-3804	15233804	CURRENT ATHEROSCLEROSIS REPORTS	A4	1.284	79	5.21	 Abstract  Purpose of Review The role of renin-angiotensin-aldosterone system (RAAS) inhibitors, notably angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs), in the COVID-19 pandemic has not been fully evaluated. With an increasing number of COVID-19 cases worldwide, it is imperative to better understand the impact of RAAS inhibitors in hypertensive COVID patients. PubMed, Embase and the pre-print database Medrxiv were searched, and studies with data on patients on ACEi/ARB with COVID-19 were included. Random effects models were used to estimate the pooled mean difference with 95% confidence interval using Open Meta[Analyst] software.  Recent Findings A total of 28,872 patients were included in this meta-analysis. The use of any RAAS inhibition for any conditions showed a trend to lower risk of death/critical events (OR 0.671, CI 0.435 to 1.034,  p = 0.071). Within the hypertensive cohort, however, there was a significant lower association with deaths (OR 0.664, CI 0.458 to 0.964,  p = 0.031) or the combination of death/critical outcomes (OR 0.670, CI 0.495 to 0.908,  p = 0.010). There was no significant association of critical/death outcomes within ACEi vs non-ACEi (OR 1.008, CI 0.822 to 1.235,  p = 0.941) and ARB vs non-ARB (OR 0.946, CI 0.735 to 1.218,  p = 0.668).  Summary This is the largest meta-analysis including critical events and mortality data on patients prescribed ACEi/ARB and found evidence of beneficial effects of chronic ACEi/ARB use especially in hypertensive cohort with COVID-19. As such, we would strongly encourage patients to continue with RAAS inhibitor pharmacotherapy during the COVID-19 pandemic.	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	A total of 28,872 patients were included in this meta-analysis. The use of any RAAS inhibition for any conditions showed a trend to lower risk of death/critical events (OR 0.671, CI 0.435 to 1.034, p = 0.071). Within the hypertensive cohort, however, there was a significant lower association with deaths (OR 0.664, CI 0.458 to 0.964, p = 0.031) or the combination of death/critical outcomes (OR 0.670, CI 0.495 to 0.908, p = 0.010). There was no significant association of critical/death outcomes within ACEi vs non-ACEi (OR 1.008, CI 0.822 to 1.235, p = 0.941) and ARB vs non-ARB (OR 0.946, CI 0.735 to 1.218, p = 0.668). This is the largest meta-analysis including critical events and mortality data on patients prescribed ACEi/ARB and found evidence of beneficial effects of chronic ACEi/ARB use especially in hypertensive cohort with COVID-19. As such, we would strongly encourage patients to continue with RAAS inhibitor pharmacotherapy during the COVID-19 pandemic.	32830286	Current atherosclerosis reports	1534-6242	10.1007/s11883-020-00880-6	Efeito dos inibidores do sistema renina-angiotensina-aldosterona em pacientes com COVID-19: uma revisão sistemática e meta-análise de 28.872 pacientes 	Um total de 28.872 pacientes foram incluídos nesta meta-análise. O uso de qualquer inibição do SRAA para qualquer condição mostrou tendência a menor risco de morte/eventos críticos (OR 0,671, IC 0,435 a 1,034, p = 0,071). Dentro da coorte de hipertensos, no entanto, houve uma associação significativamente menor com óbitos (OR 0,664, IC 0,458 a 0,964, p = 0,031) ou a combinação de óbito/resultados críticos (OR 0,670, IC 0,495 a 0,908, p = 0,010). Não houve associação significativa de desfechos críticos/morte entre IECA vs não IECA (OR 1,008, IC 0,822 a 1,235, p = 0,941) e BRA vs não BRA (OR 0,946, IC 0,735 a 1,218, p = 0,668). Esta é a maior meta-análise que inclui eventos críticos e dados de mortalidade em pacientes com prescrição de IECA/BRA e encontrou evidências de efeitos benéficos do uso crônico de IECA/BRA, especialmente na coorte de hipertensos com COVID-19. Como tal, incentivamos fortemente os pacientes a continuarem com a farmacoterapia com inibidores de RAAS durante a pandemia de COVID-19.
Empiric Antibacterial Therapy and Community-onset Bacterial Co-infection in Patients Hospitalized with COVID-19: A Multi-Hospital Cohort Study	https://doi.org/10.1093/cid/ciaa1239	21/08/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa1239	1058-4838	10584838	CLINICAL INFECTIOUS DISEASES	A1	4.394	353	8.72	 Abstract                                   Background                   Antibacterials may be initiated out of concern for bacterial coinfection in coronavirus disease 2019 (COVID-19). We determined prevalence and predictors of empiric antibacterial therapy and community-onset bacterial coinfections in hospitalized patients with COVID-19.                                                  Methods                   A randomly sampled cohort of 1705 patients hospitalized with COVID-19 in 38 Michigan hospitals between 3/13/2020 and 6/18/2020. Data were collected on early (within 2 days of hospitalization) empiric antibacterial therapy and community-onset bacterial coinfections (positive microbiologic test ≤3 days). Poisson generalized estimating equation models were used to assess predictors.                                                  Results                   Of 1705 patients with COVID-19, 56.6% were prescribed early empiric antibacterial therapy; 3.5% (59/1705) had a confirmed community-onset bacterial infection. Across hospitals, early empiric antibacterial use varied from 27% to 84%. Patients were more likely to receive early empiric antibacterial therapy if they were older (adjusted rate ratio [ARR]: 1.04 [1.00–1.08] per 10 years); had a lower body mass index (ARR: 0.99 [0.99–1.00] per kg/m2), more severe illness (eg, severe sepsis; ARR: 1.16 [1.07–1.27]), a lobar infiltrate (ARR: 1.21 [1.04–1.42]); or were admitted to a for-profit hospital (ARR: 1.30 [1.15–1.47]). Over time, COVID-19 test turnaround time (returned ≤1 day in March [54.2%, 461/850] vs April [85.2%, 628/737], P &amp;lt; .001) and empiric antibacterial use (ARR: 0.71 [0.63–0.81] April vs March) decreased.                                                  Conclusions                   The prevalence of confirmed community-onset bacterial coinfections was low. Despite this, half of patients received early empiric antibacterial therapy. Antibacterial use varied widely by hospital. Reducing COVID-19 test turnaround time and supporting stewardship could improve antibacterial use.               	['Ampicilina', 'Antibióticos', 'Cefotaxima', 'Ceftarolina', 'Ceftriaxona', 'Levofloxacina', 'Moxifloxacina', 'Sulbactam']	['Ampicillin', 'Antibiotics', 'Cefotaxime', 'Ceftaroline', 'Ceftriaxone', 'Levofloxacin', 'Moxifloxacin', 'Sulbactam']	The prevalence of confirmed community-onset bacterial coinfections was low. Despite this, half of patients received early empiric antibacterial therapy. Antibacterial use varied widely by hospital. Reducing COVID-19 test turnaround time and supporting stewardship could improve antibacterial use.	32820807	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America	1537-6591	10.1093/cid/ciaa1239	Terapia antibacteriana empírica e coinfecção bacteriana de início na comunidade em pacientes hospitalizados com COVID-19: um estudo de coorte multi-hospitalar 	A prevalência de coinfecções bacterianas confirmadas de início na comunidade foi baixa. Apesar disso, metade dos pacientes recebeu terapia antibacteriana empírica precocemente. O uso de antibacterianos variou amplamente de acordo com o hospital. Reduzir o tempo de resposta do teste COVID-19 e apoiar a administração pode melhorar o uso de antibacterianos.
Finding the Best Antiviral Regimen for COVID-19: A Double-Center Retrospective Cohort Study of 207 Cases in Hunan, China	https://doi.org/10.1177/1559325820949740	14/08/2020	Artigo completo publicado em periódico científico	10.1177/1559325820949740	1559-3258	15593258	DOSE-RESPONSE	A2	0.453	41	2.52	  Objective:  To compare the efficacy of 3/4-drugs’ group with 1-drug’s or 2-drugs’ groups in coronavirus disease 2019 (COVID-19).   Methods:  We included 207 patients confirmed with COVID-19. We compared the viral clearance rate and discharge rate at day 7, 14, 21 and 28, and median time of viral clearance and length of hospitalization in patients treated with 3/4, 1 or 2 drugs.   Results:  The viral clearance rates of the 3/4-drugs group at day 7, 14 and 21 were significantly lower than those in the 1-drug’s or 2-drugs’ groups (P &lt; 0.05). The median viral clearance days in 3/4-drugs group (13.5 days) were longer than 1-drug’s or 2-drugs’ groups (both were 9 days) (P &lt; 0.001). The patients’ discharge rates in the 3/4-drugs group at day 14 and 21 were significantly lower than that in the 1-drug’s or 2 drugs’ group (P &lt; 0.05). The median length of hospitalization in the 3/4-drugs group was 17 days, which was significantly longer than 11 days in the 1-drug group and 13 days in the 2-drug group (P &lt; 0.05).   Conclusion:  The efficacy of 1 or 2 antiviral drugs was similar in COVID-19, and 3/4-drug regimens were not associated with clinical improvement. Corticosteroid treatment and more serious disease were also risk factors for viral clearance and patients’discharge. 	['Interferon alfa', 'Lopinavir', 'Novaferon', 'Ritonavir', 'Umifenovir']	['Interferon alpha', 'Lopinavir', 'Novaferon', 'Ritonavir', 'Umifenovir']	The efficacy of 1 or 2 antiviral drugs was similar in COVID-19, and 3/4-drug regimens were not associated with clinical improvement. Corticosteroid treatment and more serious disease were also risk factors for viral clearance and patients'discharge.	32855629	Dose-response : a publication of International Hormesis Society	1559-3258	10.1177/1559325820949740	Encontrando o melhor regime antiviral para COVID-19: um estudo de coorte retrospectivo em dois centros de 207 casos em Hunan, 	China melhora clínica. O tratamento com corticosteróides e doenças mais graves também foram fatores de risco para eliminação viral e alta dos pacientes.
COVID-19 and multisystem inflammatory syndrome in children and adolescents	https://doi.org/10.1016/S1473-3099(20)30651-4	17/08/2020	Artigo completo publicado em periódico científico	10.1016/S1473-3099(20)30651-4	1473-3099	14733099	LANCET. INFECTIOUS DISEASES (PRINT)	A1	10.236	255	13.38	-	['Ácido acetilsalicílico', 'Ácido acetilsalicílico', 'Ácido acetilsalicílico', 'Ácido acetilsalicílico', 'Ácido acetilsalicílico', 'Anakinra', 'Anakinra', 'Anakinra', 'Anakinra', 'Anakinra', 'Dexametasona', 'Dexametasona', 'Dexametasona', 'Dexametasona', 'Dexametasona', 'Dobutamina', 'Dobutamina', 'Dobutamina', 'Dobutamina', 'Dobutamina', 'Epinefrina', 'Epinefrina', 'Epinefrina', 'Epinefrina', 'Epinefrina', 'Heparina', 'Heparina', 'Heparina', 'Heparina', 'Heparina', 'Imunoglobulina', 'Imunoglobulina', 'Imunoglobulina', 'Imunoglobulina', 'Imunoglobulina', 'Infliximabe', 'Infliximabe', 'Infliximabe', 'Infliximabe', 'Infliximabe', 'Norepinefrina', 'Norepinefrina', 'Norepinefrina', 'Norepinefrina', 'Norepinefrina', 'Prednisona', 'Prednisona', 'Prednisona', 'Prednisona', 'Prednisona', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe']	['Acetylsalicylic acid', 'Acetylsalicylic acid', 'Acetylsalicylic acid', 'Acetylsalicylic acid', 'Acetylsalicylic acid', 'Anakinra', 'Anakinra', 'Anakinra', 'Anakinra', 'Anakinra', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Dobutamine', 'Dobutamine', 'Dobutamine', 'Dobutamine', 'Dobutamine', 'Epinephrine', 'Epinephrine', 'Epinephrine', 'Epinephrine ', 'Epinephrine', 'Heparin', 'Heparin', 'Heparin', 'Heparin', 'Heparin', 'Immunoglobulin', 'Immunoglobulin', 'Immunoglobulin', 'Immunoglobulin', 'Immunoglobulin', 'Infliximab', 'Infliximab', 'Infliximab', 'Infliximab', 'Infliximab', 'Norepinephrine', 'Norepinephrine', 'Norepinephrine', 'Norepinephrine', 'Norepinephrine', 'Prednisone', 'Prednisone', 'Prednisone', 'Prednisone ', 'Prednisone', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab']	In this cohort of 42 adolescents with a previous multisystem inflammatory syndrome (MIS-C) diagnosis, 32 (76.2%) were vaccinated with COVID-19 vaccines, with a low incidence of relevant adverse events. More importantly, no new MIS-C or myocarditis occurred after a median of 10 weeks (range 5.3-19.7) post-vaccination.	35904132	Journal of the Pediatric Infectious Diseases Society	2048-7207	10.1093/jpids/piac076	COVID-19 e síndrome inflamatória multissistêmica em crianças e adolescentes 	Nesta coorte de 42 adolescentes com diagnóstico prévio de síndrome inflamatória multissistêmica (MIS-C), 32 (76,2%) foram vacinados com vacinas COVID-19, com baixa incidência de efeitos adversos relevantes eventos. Mais importante, nenhum novo MIS-C ou miocardite ocorreu após uma mediana de 10 semanas (intervalo 5,3-19,7) pós-vacinação.
Impact of Tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients	https://doi.org/10.1016/j.ijid.2020.08.024	12/08/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.08.024	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Impacto do Tocilizumab na mortalidade e/ou necessidade de ventilação mecânica invasiva em uma coorte de 206 pacientes com COVID-19 	-
Thymosin α1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study	https://doi.org/10.1016/j.intimp.2020.106873	06/08/2020	Artigo completo publicado em periódico científico	10.1016/j.intimp.2020.106873	1567-5769	15675769	INTERNATIONAL IMMUNOPHARMACOLOGY (PRINT)	A2	1.059	119	5.61	-	['Timosina']	['Thymosin']	-	-	-	-	-	Terapia com timosina α1 em pacientes críticos com COVID-19: um estudo de coorte retrospectivo multicêntrico 	-
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational study	https://doi.org/10.1371/journal.pone.0237693	13/08/2020	Artigo completo publicado em periódico científico	10.1371/journal.pone.0237693	1932-6203	19326203	PLOS ONE	A1	0.852	367	3.8	-	['Hidroxicloroquina', 'Tocilizumabe']	['Hydroxychloroquine', 'Tocilizumab']	Hydroxychloroquine has been touted as a potential COVID-19 treatment. Tocilizumab, an inhibitor of IL-6, has also been proposed as a treatment of critically ill patients. In this retrospective observational cohort study drawn from electronic health records we sought to describe the association between mortality and hydroxychloroquine or tocilizumab therapy among hospitalized COVID-19 patients. Patients were hospitalized at a 13-hospital network spanning New Jersey USA between March 1, 2020 and April 22, 2020 with positive polymerase chain reaction results for SARS-CoV-2. Follow up was through May 5, 2020. Among 2512 hospitalized patients with COVID-19 there have been 547 deaths (22%), 1539 (61%) discharges and 426 (17%) remain hospitalized. 1914 (76%) received at least one dose of hydroxychloroquine and 1473 (59%) received hydroxychloroquine with azithromycin. After adjusting for imbalances via propensity modeling, compared to receiving neither drug, there were no significant differences in associated mortality for patients receiving any hydroxychloroquine during the hospitalization (HR, 0.99 [95% CI, 0.80-1.22]), hydroxychloroquine alone (HR, 1.02 [95% CI, 0.83-1.27]), or hydroxychloroquine with azithromycin (HR, 0.98 [95% CI, 0.75-1.28]). The 30-day unadjusted mortality for patients receiving hydroxychloroquine alone, azithromycin alone, the combination or neither drug was 25%, 20%, 18%, and 20%, respectively. Among 547 evaluable ICU patients, including 134 receiving tocilizumab in the ICU, an exploratory analysis found a trend towards an improved survival association with tocilizumab treatment (adjusted HR, 0.76 [95% CI, 0.57-1.00]), with 30 day unadjusted mortality with and without tocilizumab of 46% versus 56%. This observational cohort study suggests hydroxychloroquine, either alone or in combination with azithromycin, was not associated with a survival benefit among hospitalized COVID-19 patients. Tocilizumab demonstrated a trend association towards reduced mortality among ICU patients. Our findings are limited to hospitalized patients and must be interpreted with caution while awaiting results of randomized trials. Trial Registration: Clinicaltrials.gov Identifier: NCT04347993.	32790733	PloS one	1932-6203	10.1371/journal.pone.0237693	Terapia com hidroxicloroquina e tocilizumabe em pacientes com COVID-19 – Um estudo observacional A 	hidroxicloroquina foi apontada como um potencial tratamento para COVID-19. O tocilizumab, um inibidor de IL-6, também foi proposto como tratamento de pacientes críticos. Neste estudo de coorte observacional retrospectivo extraído de registros eletrônicos de saúde, procuramos descrever a associação entre mortalidade e terapia com hidroxicloroquina ou tocilizumabe entre pacientes hospitalizados com COVID-19. Os pacientes foram hospitalizados em uma rede de 13 hospitais em Nova Jersey, EUA, entre 1º de março de 2020 e 22 de abril de 2020, com resultados positivos de reação em cadeia da polimerase para SARS-CoV-2. O acompanhamento foi até 5 de maio de 2020. Entre 2.512 pacientes hospitalizados com COVID-19, houve 547 mortes (22%), 1.539 (61%) altas e 426 (17%) permanecem internados. 1.914 (76%) receberam pelo menos uma dose de hidroxicloroquina e 1.473 (59%) receberam hidroxicloroquina com azitromicina. Após o ajuste para desequilíbrios por meio de modelagem de propensão, em comparação a não receber nenhum medicamento, não houve diferenças significativas na mortalidade associada para pacientes que receberam qualquer hidroxicloroquina durante a hospitalização (HR, 0,99 [IC 95%, 0,80-1,22]), hidroxicloroquina isolada (HR, 1,02 [IC 95%, 0,83-1,27]), ou hidroxicloroquina com azitromicina (HR, 0,98 [IC 95%, 0,75-1,28]). A mortalidade não ajustada em 30 dias para pacientes que receberam hidroxicloroquina sozinha, azitromicina sozinha, a combinação ou nenhuma das drogas foi de 25%, 20%, 18% e 20%, respectivamente. Entre 547 pacientes de UTI avaliáveis, incluindo 134 recebendo tocilizumabe na UTI, uma análise exploratória encontrou uma tendência para uma melhor associação de sobrevida com o tratamento com tocilizumabe (HR ajustado, 0,76 [IC 95%, 0,57-1,00]), com mortalidade não ajustada em 30 dias com e sem tocilizumab de 46% versus 56%. Este estudo observacional de coorte sugere que a hidroxicloroquina, isoladamente ou em combinação com azitromicina, não foi associada a um benefício de sobrevida entre pacientes hospitalizados com COVID-19. O tocilizumabe demonstrou uma tendência de associação à redução da mortalidade entre os pacientes de UTI. Nossos achados são limitados a pacientes hospitalizados e devem ser interpretados com cautela enquanto aguardamos os resultados de estudos randomizados. Registro do teste: Clinicaltrials.gov Identificador: NCT04347993.
Efficacy of hydroxychloroquine and tocilizumab in patients with COVID-19: A single-center retrospective chart review	https://doi.org/10.2196/preprints.21758	13/08/2020	Artigo completo publicado em periódico científico	10.2196/preprints.21758	-	-	-	-	-	-	-	-	['Hidroxicloroquina', 'Tocilizumabe']	['Hydroxychloroquine', 'Tocilizumab']	In this cohort of patients with COVID-19, neither HCQ nor TCZ offered a significant reduction in in-hospital mortality, upgrade to intensive medical care, invasive mechanical ventilation, or acute renal failure needing dialysis. These results are similar to the recently published preliminary results of the HCQ arm of the Recovery trial, which showed no clinical benefit from the use of HCQ in hospitalized patients with COVID-19 (the TCZ arm is ongoing). Double-blinded randomized controlled trials are needed to further evaluate the impact of these drugs in larger patient samples so that data-driven guidelines can be deduced to combat this global pandemic.	32784192	Journal of medical Internet research	1438-8871	10.2196/21758	Eficácia da hidroxicloroquina e tocilizumabe em pacientes com COVID-19: uma revisão retrospectiva de prontuários em um único 	centro ventilação mecânica ou insuficiência renal aguda com necessidade de diálise. Esses resultados são semelhantes aos resultados preliminares publicados recentemente do braço HCQ do estudo Recovery, que não mostrou nenhum benefício clínico do uso de HCQ em pacientes hospitalizados com COVID-19 (o braço TCZ está em andamento). Ensaios controlados randomizados duplo-cegos são necessários para avaliar melhor o impacto desses medicamentos em amostras maiores de pacientes, para que diretrizes baseadas em dados possam ser deduzidas para combater essa pandemia global.
Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARSCoV-2 infection: a retrospective cohort study	https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26407	10/08/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26407	0146-6615	1466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Hydroxychloroquine', 'Lopinavir', 'Ritonavir']	As it has been shown that lopinavir (LPV) and hydroxychloroquine (HCQ) have in vitro activity against coronaviruses, they were used to treat COVID-19 during the first wave of the epidemic in Lombardy, Italy. To compare the rate of clinical improvement between those who started LPV/ritonavir (LPV/r)+HCQ within 5 days of symptom onset (early treatment, ET) and those who started later (delayed treatment, DT). This was a retrospective intent-to-treat analysis of the hospitalized patients who started LPV/r + HCQ between 21 February and 20 March 2020. The association between the timing of treatment and the probability of 30-day mortality was assessed using univariable and multivariable logistic models. The study involved 172 patients: 43 (25%) in the ET and 129 (75%) in the DT group. The rate of clinical improvement increased over time to 73.3% on day 30, without any significant difference between the two groups (Gray's test P = .213). After adjusting for potentially relevant clinical variables, there was no significant association between the timing of the start of treatment and the probability of 30-day mortality (adjusted odds ratio [aOR] ET vs DT = 1.45, 95% confidence interval 0.50-4.19). Eight percent of the patients discontinued the treatment becausebecause of severe gastrointestinal disorders attributable to LPV/r. The timing of the start of LPV/r + HCQ treatment does not seem to affect the clinical course of hospitalized patients with COVID-19. Together with the severe adverse events attributable to LPV/r, this raises concerns about the benefit of using this combination to treat COVID-19.	32776534	Journal of medical virology	1096-9071	10.1002/jmv.26407	A administração precoce de lopinavir/ritonavir mais hidroxicloroquina não altera o curso clínico da infecção por SARSCoV-2: um estudo de coorte 	retrospectivo tratar o COVID-19 durante a primeira onda da epidemia na Lombardia, Itália. Comparar a taxa de melhora clínica entre aqueles que iniciaram LPV/ritonavir (LPV/r)+HCQ dentro de 5 dias do início dos sintomas (tratamento precoce, TE) e aqueles que iniciaram mais tarde (tratamento tardio, DT). Esta foi uma análise retrospectiva de intenção de tratamento dos pacientes hospitalizados que iniciaram LPV/r + HCQ entre 21 de fevereiro e 20 de março de 2020. A associação entre o momento do tratamento e a probabilidade de mortalidade em 30 dias foi avaliada usando univariável e multivariável modelos logísticos. O estudo envolveu 172 pacientes: 43 (25%) no grupo TE e 129 (75%) no grupo DT. A taxa de melhora clínica aumentou ao longo do tempo para 73,3% no dia 30, sem qualquer diferença significativa entre os dois grupos (teste de Gray P = 0,213). Após o ajuste para variáveis clínicas potencialmente relevantes, não houve associação significativa entre o momento do início do tratamento e a probabilidade de mortalidade em 30 dias (odds ratio ajustado [aOR] ET vs DT = 1,45, intervalo de confiança de 95% 0,50-4,19) . Oito por cento dos pacientes interromperam o tratamento por causa de distúrbios gastrointestinais graves atribuíveis ao LPV/r. O momento do início do tratamento com LPV/r + HCQ não parece afetar o curso clínico de pacientes hospitalizados com COVID-19. Juntamente com os eventos adversos graves atribuíveis ao LPV/r, isso levanta preocupações sobre o benefício do uso dessa combinação para tratar o COVID-19.
Treatment of COVID-19 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality	https://doi.org/10.1016/j.ajpath.2020.08.001	10/08/2020	Artigo completo publicado em periódico científico	10.1016/j.ajpath.2020.08.001	0002-9440	29440	THE AMERICAN JOURNAL OF PATHOLOGY (PRINT)	A1	1.619	289	4.82	-	['Plasma convalescente']	['Convalescent Plasma']	Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, has spread globally, and proven treatments are limited. Transfusion of convalescent plasma collected from donors who have recovered from COVID-19 is among many approaches being studied as potentially efficacious therapy. We are conducting a prospective, propensity score-matched study assessing the efficacy of COVID-19 convalescent plasma transfusion versus standard of care as treatment for severe and/or critical COVID-19. We present herein the results of an interim analysis of 316 patients enrolled at Houston Methodist hospitals from March 28 to July 6, 2020. Of the 316 transfused patients, 136 met a 28-day outcome and were matched to 251 non-transfused control COVID-19 patients. Matching criteria included age, sex, body mass index, comorbidities, and baseline ventilation requirement 48 hours from admission, and in a second matching analysis, ventilation status at day 0. Variability in the timing of transfusion relative to admission and titer of antibodies of plasma transfused allowed for analysis in specific matched cohorts. The analysis showed a significant reduction (P = 0.047) in mortality within 28 days, specifically in patients transfused within 72 hours of admission with plasma with an anti-spike protein receptor binding domain titer of ≥1:1350. These data suggest that treatment of COVID-19 with high anti-receptor binding domain IgG titer convalescent plasma is efficacious in early-disease patients.	32795424	The American journal of pathology	1525-2191	10.1016/j.ajpath.2020.08.001	Tratamento de pacientes com COVID-19 com plasma convalescente revela um sinal de mortalidade significativamente diminuída A 	doença por coronavírus 2019 (COVID-19), causada pela síndrome respiratória aguda grave coronavírus 2, se espalhou globalmente e os tratamentos comprovados são limitados. A transfusão de plasma convalescente coletado de doadores que se recuperaram do COVID-19 está entre as muitas abordagens que estão sendo estudadas como terapia potencialmente eficaz. Estamos realizando um estudo prospectivo, com pontuação de propensão, avaliando a eficácia da transfusão de plasma convalescente de COVID-19 versus o padrão de atendimento como tratamento para COVID-19 grave e/ou crítico. Apresentamos aqui os resultados de uma análise interina de 316 pacientes matriculados nos hospitais Metodistas de Houston de 28 de março a 6 de julho de 2020. Dos 316 pacientes transfundidos, 136 obtiveram um resultado de 28 dias e foram pareados com 251 controles não transfundidos COVID- 19 pacientes. Os critérios de correspondência incluíram idade, sexo, índice de massa corporal, comorbidades e necessidade de ventilação basal 48 horas após a admissão e, em uma segunda análise de correspondência, status de ventilação no dia 0. Variabilidade no momento da transfusão em relação à admissão e título de anticorpos do plasma transfundido permitiu a análise em coortes pareadas específicas. A análise mostrou uma redução significativa (P = 0,047) na mortalidade em 28 dias, especificamente em pacientes transfundidos dentro de 72 horas da admissão com plasma com um título de domínio de ligação ao receptor de proteína anti-pico de ≥1:1350. Esses dados sugerem que o tratamento de COVID-19 com plasma convalescente de alto título de domínio de ligação anti-receptor é eficaz em pacientes com doença precoce.
Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients - Results from a real-life patient cohort	https://doi.org/10.1007/s00508-020-01720-y	10/08/2020	Artigo completo publicado em periódico científico	10.1007/s00508-020-01720-y	0043-5325	435325	Wiener Klinische Wochenschrift	-	0.497	54	1.65	-	['Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Hydroxychloroquine', 'Lopinavir', 'Ritonavir']	No statistically significant differences were observed in outcome parameters in patients treated with HCQ or LPV/RTV but patients in the LPV/RTV group showed a numerically lower hospital mortality rate. Additionally, in comparison to other studies we demonstrated a lower mortality in patients treated with LPV/RTV despite having similar patient groups, perhaps due to early initiation of treatment.	32776298	Wiener klinische Wochenschrift	1613-7671	10.1007/s00508-020-01720-y	Hidroxicloroquina versus lopinavir/ritonavir em pacientes graves com COVID-19 - Resultados de uma coorte de pacientes da vida real 	Não foram observadas diferenças estatisticamente significativas nos parâmetros de resultados em pacientes tratados com HCQ ou LPV/RTV, mas os pacientes do grupo LPV/RTV mostraram um valor numericamente menor taxa de mortalidade hospitalar. Além disso, em comparação com outros estudos, demonstramos menor mortalidade em pacientes tratados com LPV/RTV apesar de ter grupos de pacientes semelhantes, talvez devido ao início precoce do tratamento.
Convalescent plasma a clutch at straws in COVID-19 management! A systematic review and meta-analysis	https://doi.org/10.1002/jmv.26408	10/08/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26408	0146-6615	1466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Plasma convalescente']	['Convalescent Plasma']	In the absence of definitive therapy for coronavirus disease (COVID-19), convalescent plasma therapy (CPT) may be a critical therapeutic option. This review was conducted to evaluate the impact of CPT in COVID-19 patients based on the publications reported to date. A robust screening of electronic databases was conducted up to 10th July 2020. Randomized controlled trials (RCTs), cohort studies, and case series with a control group evaluating the effectiveness and safety of CPT in patients with COVID-19 are included for the meta-analyses. Our search retrieved seven studies, including two RCTs and five cohort studies, with a total of 5444 patients. In patients with COVID-19, the use of CPT reduces mortality (odd's ratio [OR] 0.44; 95% CI, 0.25-0.77), increases viral clearance (OR, 11.29; 95% CI, 4.9-25.9) and improves clinically (OR, 2.06; 95% CI, 0.8 to 4.9). However, the evidence is of low quality (mortality reduction, and viral clearance), and very low quality (clinical improvement). CPT may be beneficial for reducing mortality, viral shedding and improving clinical conditions in COVID-19 patients. However, further randomized control trials (RCT) are required to substantiate the safety margin, initiation, optimal dosage, titre and duration of CPT.	32776573	Journal of medical virology	1096-9071	10.1002/jmv.26408	Plasma convalescente uma embreagem em canudos no gerenciamento de COVID-19! Uma revisão sistemática e meta-análise 	Na ausência de terapia definitiva para a doença de coronavírus (COVID-19), a terapia com plasma convalescente (CPT) pode ser uma opção terapêutica crítica. Esta revisão foi realizada para avaliar o impacto da CPT em pacientes com COVID-19 com base nas publicações relatadas até o momento. Uma triagem robusta de bancos de dados eletrônicos foi realizada até 10 de julho de 2020. Ensaios controlados randomizados (ECRs), estudos de coorte e séries de casos com um grupo de controle avaliando a eficácia e a segurança da CPT em pacientes com COVID-19 estão incluídos para o meta- análises. Nossa busca recuperou sete estudos, incluindo dois ECRs e cinco estudos de coorte, com um total de 5.444 pacientes. Em pacientes com COVID-19, o uso de CPT reduz a mortalidade (odd's ratio [OR] 0,44; IC 95%, 0,25-0,77), aumenta a depuração viral (OR, 11,29; IC 95%, 4,9-25,9) e melhora clinicamente ( OR, 2,06; IC 95%, 0,8 a 4,9). No entanto, a evidência é de baixa qualidade (redução da mortalidade e eliminação viral) e muito baixa (melhoria clínica). A CPT pode ser benéfica para reduzir a mortalidade, a disseminação viral e melhorar as condições clínicas em pacientes com COVID-19. No entanto, mais ensaios clínicos randomizados (RCT) são necessários para fundamentar a margem de segurança, início, dosagem ideal, título e duração da CPT.
Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study	https://doi.org/10.1016/j.eclinm.2020.100418	20/06/2020	Artigo completo publicado em periódico científico	10.1016/j.eclinm.2020.100418	2589-5370	25895370	EClinicalMedicine	-	4.657	44	9.79	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Tocilizumab para tratamento de pacientes com COVID-19 grave: um estudo de coorte retrospectivo 	-
Clinical outcomes of COVID‑19 in Wuhan, China: a large cohort study	https://doi.org/10.1186/s13613-020-00706-3	31/07/2020	Artigo completo publicado em periódico científico	10.1186/s13613-020-00706-3	2110-5820	21105820	ANNALS OF INTENSIVE CARE	A1	2.219	60	7.23	 Abstract  Background Since December 2019, an outbreak of Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) initially emerged in Wuhan, China, and has spread worldwide now. Clinical features of patients with COVID-19 have been described. However, risk factors leading to in-hospital deterioration and poor prognosis in COVID-19 patients with severe disease have not been well identified.  Methods In this retrospective, single-center cohort study, 1190 adult inpatients (≥ 18 years old) with laboratory-confirmed COVID-19 and determined outcomes (discharged or died) were included from Wuhan Infectious Disease Hospital from December 29, 2019 to February 28, 2020. The final follow-up date was March 2, 2020. Clinical data including characteristics, laboratory and imaging information as well as treatments were extracted from electronic medical records and compared. A multivariable logistic regression model was used to explore the potential predictors associated with in-hospital deterioration and death.  Results 1190 patients with confirmed COVID-19 were included. Their median age was 57 years (interquartile range 47–67 years). Two hundred and sixty-one patients (22%) developed a severe illness after admission. Multivariable logistic regression demonstrated that higher SOFA score (OR 1.32, 95% CI 1.22–1.43, per score increase,  p &lt; 0.001 for deterioration and OR 1.30, 95% CI 1.11–1.53, per score increase,  p = 0.001 for death), lymphocytopenia (OR 1.81, 95% CI 1.13–2.89  p = 0.013 for deterioration; OR 4.44, 95% CI 1.26–15.87,  p = 0.021 for death) on admission were independent risk factors for in-hospital deterioration from not severe to severe disease and for death in severe patients. On admission D-dimer greater than 1 μg/L (OR 3.28, 95% CI 1.19–9.04,  p = 0.021), leukocytopenia (OR 5.10, 95% CI 1.25–20.78), thrombocytopenia (OR 8.37, 95% CI 2.04–34.44) and history of diabetes (OR 11.16, 95% CI 1.87–66.57,  p = 0.008) were also associated with higher risks of in-hospital death in severe COVID-19 patients. Shorter time interval from illness onset to non-invasive mechanical ventilation in the survivors with severe disease was observed compared with non-survivors (10.5 days, IQR 9.25–11.0 vs. 16.0 days, IQR 11.0–19.0 days,  p = 0.030). Treatment with glucocorticoids increased the risk of progression from not severe to severe disease (OR 3.79, 95% CI 2.39–6.01,  p &lt; 0.001). Administration of antiviral drugs especially oseltamivir or ganciclovir is associated with a decreased risk of death in severe patients (OR 0.17, 95% CI 0.05–0.64,  p &lt; 0.001).  Conclusions High SOFA score and lymphocytopenia on admission could predict that not severe patients would develop severe disease in-hospital. On admission elevated D-dimer, leukocytopenia, thrombocytopenia and diabetes were independent risk factors of in-hospital death in severe patients with COVID-19. Administration of oseltamivir or ganciclovir might be beneficial for reducing mortality in severe patients.	['Corticosteroides', 'Ganciclovir', 'Oseltamivir']	['Corticosteroids', 'Ganciclovir', 'Oseltamivir']	-	-	-	-	-	Resultados clínicos do COVID-19 em Wuhan, China: um grande estudo de coorte 	-
Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection	https://doi.org/10.1016/j.mayocp.2020.05.005	19/05/2020	Artigo completo publicado em periódico científico	10.1016/j.mayocp.2020.05.005	0025-6196	256196	MAYO CLINIC PROCEEDINGS	A1	2.186	191	4.51	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']	Among candidate drugs to treat coronavirus disease 2019 (COVID-19), the combination of hydroxychloroquine (HCQ) and azithromycin (AZ) has received intense worldwide attention. Even as the efficacy of this combination is under evaluation, clinicians have begun to use it largely. As these medications are known to prolong the QT interval, we analyzed serial electrocardiograms recorded in patients hospitalized for COVID-19 pneumonia and treated with HCQ + AZ. Fifty consecutive patients received the combination of HCQ (600 mg/d for 10 days) and AZ (500 mg/d on day 1 and 250 mg/d from day 2 to day 5). Twelve-lead electrocardiograms were recorded before treatment, at day 3, at day 5, and at discharge. The median age of patients was 68 years (interquartile range, 53-81 years); 28 (56%) were men. The main comorbidities were hypertension (36%; n=18) and diabetes (16%; n=8). The mean corrected QT (QTc) interval was 408 ms at baseline and increased up to 437 ms at day 3 and to 456 ms at day 5. Thirty-eight patients (76%) presented short-term modifications of the QTc duration (>30 ms). Treatment discontinuation was decided in 6 patients (12%), leading to QTc normalization in 5 of them. No deaths and no cardiac arrhythmic events were observed in this cohort. Our report confirms that a short duration treatment with HCQ + AZ modifies the QTc interval. The treatment had to be discontinued for QTc modifications in 12% of patients. Nevertheless, in inpatients hospitalized for COVID-19, we did not observe any clinically relevant consequences of these transitory modifications. In conclusion, when patients are treated with HCQ + AZ, cardiac monitoring should be regularly performed and hospital settings allow monitoring under in safe conditions.	32753141	Mayo Clinic proceedings	1942-5546	10.1016/j.mayocp.2020.05.005	Modificações agudas do intervalo QT durante o tratamento com hidroxicloroquina-azitromicina no contexto da infecção por COVID- 	19 Mesmo que a eficácia dessa combinação esteja sendo avaliada, os médicos começaram a usá-la amplamente. Como esses medicamentos são conhecidos por prolongar o intervalo QT, analisamos eletrocardiogramas seriados registrados em pacientes hospitalizados por pneumonia por COVID-19 e tratados com HCQ + AZ. Cinquenta pacientes consecutivos receberam a combinação de HCQ (600 mg/d por 10 dias) e AZ (500 mg/d no dia 1 e 250 mg/d do dia 2 ao dia 5). Eletrocardiogramas de doze derivações foram registrados antes do tratamento, no dia 3, no dia 5 e na alta. A idade mediana dos pacientes foi de 68 anos (intervalo interquartil, 53-81 anos); 28 (56%) eram homens. As principais comorbidades foram hipertensão (36%; n=18) e diabetes (16%; n=8). A média do intervalo QT corrigido (QTc) foi de 408 ms na linha de base e aumentou para 437 ms no dia 3 e para 456 ms no dia 5. Trinta e oito pacientes (76%) apresentaram modificações de curto prazo na duração do QTc (>30 EM). A descontinuação do tratamento foi decidida em 6 pacientes (12%), levando à normalização do QTc em 5 deles. Nenhuma morte e nenhum evento arrítmico cardíaco foram observados nesta coorte. Nosso relato confirma que um tratamento de curta duração com HCQ + AZ modifica o intervalo QTc. O tratamento teve que ser descontinuado para modificações do QTc em 12% dos pacientes. No entanto, em pacientes internados por COVID-19, não observamos nenhuma consequência clinicamente relevante dessas modificações transitórias. Em conclusão, quando os pacientes são tratados com HCQ + AZ, o monitoramento cardíaco deve ser realizado regularmente e as configurações hospitalares permitem o monitoramento em condições seguras.
Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study	https://onlinelibrary.wiley.com/doi/abs/10.1111/joim.13162	03/08/2020	Artigo completo publicado em periódico científico	10.1111/joim.13162	0954-6820	9546820	JOURNAL OF INTERNAL MEDICINE (PRINT)	A1	3.193	170	9.41	-	['Tocilizumabe']	['Tocilizumab']	Treatment with COX-2 inhibitors was not associated with an increase in adverse outcomes. Its potential for therapeutic use as an immune modulator warrants further evaluation in a large randomised controlled trial.	32744399	Journal of internal medicine	1365-2796	10.1111/joim.13162	O tocilizumab reduz o tempo de ventilação mecânica e o tempo de internação hospitalar em pacientes com COVID-19 grave: um estudo de coorte retrospectivo 	O tratamento com inibidores de COX-2 não foi associado a um aumento de desfechos adversos. Seu potencial para uso terapêutico como modulador imunológico merece avaliação adicional em um grande estudo controlado randomizado.
Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome	https://pubmed.ncbi.nlm.nih.gov/32732245/	30/07/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32732245/	-	-	-	-	-	-	-	-	['Colchicina']	['Colchicine']	-	-	-	-	-	Associação entre tratamento com colchicina e melhora da sobrevida em uma coorte de um único centro de pacientes adultos hospitalizados com pneumonia por COVID-19 e síndrome do desconforto respiratório agudo 	-
The Association of Interleukin-6 value, Interleukin inhibitors and Outcomes of Patients with COVID-19 in New York City	https://onlinelibrary.wiley.com/doi/10.1002/jmv.26365	28/07/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26365	0146-6615	1466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Tocilizumabe']	['Tocilizumab']	Since cytokine release syndrome with elevation of interleukin-6 (IL-6) is considered to be associated with severe cases of coronavirus disease 2019 (COVID-19); IL-6 inhibitors, such as tocilizumab, are expected to be effective for its treatment. This was a retrospective study using a consecutive cohort of 224 patients hospitalized with COVID-19 in March 2020. Patients were divided into those admitted to the intensive care unit (ICU group) and those not (no ICU group), and clinical data including usage of tocilizumab were compared. Correlation between IL-6 value at admission and at peak, and tocilizumab use, as well as clinical outcomes were also investigated. The ICU group had higher rates of pre-existing comorbidities such as hypertension, diabetes, and coronary disease, and higher IL-6 than no ICU group (all P < .05). Age, peak IL-6, and peak d-dimer were significant predictors of in-hospital mortality (1.05 [1.01-1.09], P = .012; 1.001 [1.000-1.002], P = .002; 1.10 [1.03-1.18], P = .008). Receiver operating characteristics curve showed higher predictability of in-hospital mortality with IL-6 at peak than others (area under curve; IL-6 at peak: 0.875 [0.87-0.942], IL-6 at admission: 0.794 [0.699-0.889], d-dimer at peak 0.787 [0.690-0.883], d-dimer at admission 0.726 [0.625-0.827]). Incidence of fungal infections was significantly higher in patients who were given tocilizumab than those who were not (13.0% vs 1.1%, P < .001). Notably, tocilizumab did not affect in-hospital mortality after adjustment including IL-6 (odds ratio [95% confidential interval]: 1.00 [0.27-3.72, P = .998]). Age, peak IL-6, and peak d-dimer levels were significant predictors of in-hospital mortality. Tocilizumab did not decrease in-hospital mortality in our cohort.	32720702	Journal of medical virology	1096-9071	10.1002/jmv.26365	COVID -19 in New York City 	COVID-19); Espera-se que os inibidores de IL-6, como o tocilizumab, sejam eficazes para o seu tratamento. Este foi um estudo retrospectivo usando uma coorte consecutiva de 224 pacientes hospitalizados com COVID-19 em março de 2020. Os pacientes foram divididos em internados na unidade de terapia intensiva (grupo UTI) e não internados (grupo sem UTI) e dados clínicos, incluindo uso de tocilizumab foram comparados. A correlação entre o valor de IL-6 na admissão e no pico, e uso de tocilizumab, bem como os resultados clínicos também foram investigados. O grupo de UTI teve taxas mais altas de comorbidades pré-existentes, como hipertensão, diabetes e doença coronariana, e IL-6 mais alta do que nenhum grupo de UTI (todos P < 0,05). Idade, pico de IL-6 e pico d-dímero foram preditores significativos de mortalidade hospitalar (1,05 [1,01-1,09], P = 0,012; 1,001 [1,000-1,002], P = 0,002; 1,10 [1,03-1,18] ], P = 0,008). A curva de características operacionais do receptor mostrou maior previsibilidade de mortalidade hospitalar com IL-6 no pico do que outros (área sob a curva; IL-6 no pico: 0,875 [0,87-0,942], IL-6 na admissão: 0,794 [0,699-0,889] , d-dímero no pico 0,787 [0,690-0,883], d-dímero na admissão 0,726 [0,625-0,827]). A incidência de infecções fúngicas foi significativamente maior em pacientes que receberam tocilizumabe do que aqueles que não receberam (13,0% vs 1,1%, P < 0,001). Notavelmente, o tocilizumabe não afetou a mortalidade intra-hospitalar após o ajuste, incluindo IL-6 (odds ratio [intervalo confidencial de 95%]: 1,00 [0,27-3,72, P = 0,998]). A idade, o pico de IL-6 e os níveis de pico de dímero d foram preditores significativos de mortalidade intra-hospitalar. O tocilizumabe não diminuiu a mortalidade hospitalar em nossa coorte.
Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people	https://heart.bmj.com/content/heartjnl/early/2020/07/31/heartjnl-2020-317393.full.pdf	13/07/2020	Artigo completo publicado em periódico científico	https://heart.bmj.com/content/heartjnl/early/2020/07/31/heartjnl-2020-317393.full.pdf	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	Since cytokine release syndrome with elevation of interleukin-6 (IL-6) is considered to be associated with severe cases of coronavirus disease 2019 (COVID-19); IL-6 inhibitors, such as tocilizumab, are expected to be effective for its treatment. This was a retrospective study using a consecutive cohort of 224 patients hospitalized with COVID-19 in March 2020. Patients were divided into those admitted to the intensive care unit (ICU group) and those not (no ICU group), and clinical data including usage of tocilizumab were compared. Correlation between IL-6 value at admission and at peak, and tocilizumab use, as well as clinical outcomes were also investigated. The ICU group had higher rates of pre-existing comorbidities such as hypertension, diabetes, and coronary disease, and higher IL-6 than no ICU group (all P < .05). Age, peak IL-6, and peak d-dimer were significant predictors of in-hospital mortality (1.05 [1.01-1.09], P = .012; 1.001 [1.000-1.002], P = .002; 1.10 [1.03-1.18], P = .008). Receiver operating characteristics curve showed higher predictability of in-hospital mortality with IL-6 at peak than others (area under curve; IL-6 at peak: 0.875 [0.87-0.942], IL-6 at admission: 0.794 [0.699-0.889], d-dimer at peak 0.787 [0.690-0.883], d-dimer at admission 0.726 [0.625-0.827]). Incidence of fungal infections was significantly higher in patients who were given tocilizumab than those who were not (13.0% vs 1.1%, P < .001). Notably, tocilizumab did not affect in-hospital mortality after adjustment including IL-6 (odds ratio [95% confidential interval]: 1.00 [0.27-3.72, P = .998]). Age, peak IL-6, and peak d-dimer levels were significant predictors of in-hospital mortality. Tocilizumab did not decrease in-hospital mortality in our cohort.	33153994	Heart (British Cardiac Society)	1468-201X	10.1136/heartjnl-2020-318312	COVID -19 com inibidores da ECA e bloqueadores dos receptores de angiotensina: estudo de coorte incluindo 8,3 milhões de pessoas 	-19); Espera-se que os inibidores de IL-6, como o tocilizumab, sejam eficazes para o seu tratamento. Este foi um estudo retrospectivo usando uma coorte consecutiva de 224 pacientes hospitalizados com COVID-19 em março de 2020. Os pacientes foram divididos em internados na unidade de terapia intensiva (grupo UTI) e não internados (grupo sem UTI) e dados clínicos, incluindo uso de tocilizumab foram comparados. A correlação entre o valor de IL-6 na admissão e no pico, e uso de tocilizumab, bem como os resultados clínicos também foram investigados. O grupo de UTI teve taxas mais altas de comorbidades pré-existentes, como hipertensão, diabetes e doença coronariana, e IL-6 mais alta do que nenhum grupo de UTI (todos P < 0,05). Idade, pico de IL-6 e pico d-dímero foram preditores significativos de mortalidade hospitalar (1,05 [1,01-1,09], P = 0,012; 1,001 [1,000-1,002], P = 0,002; 1,10 [1,03-1,18] ], P = 0,008). A curva de características operacionais do receptor mostrou maior previsibilidade de mortalidade intra-hospitalar com IL-6 no pico do que outras (área sob a curva; IL-6 no pico: 0,875 [0,87-0,942], IL-6 na admissão: 0,794 [0,699-0,889] , d-dímero no pico 0,787 [0,690-0,883], d-dímero na admissão 0,726 [0,625-0,827]). A incidência de infecções fúngicas foi significativamente maior em pacientes que receberam tocilizumabe do que aqueles que não receberam (13,0% vs 1,1%, P < 0,001). Notavelmente, o tocilizumabe não afetou a mortalidade intra-hospitalar após o ajuste, incluindo IL-6 (odds ratio [intervalo confidencial de 95%]: 1,00 [0,27-3,72, P = 0,998]). A idade, o pico de IL-6 e os níveis de pico de dímero d foram preditores significativos de mortalidade intra-hospitalar. O tocilizumabe não diminuiu a mortalidade hospitalar em nossa coorte.
Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients	https://doi.org/10.1016/j.jaut.2020.102511	08/07/2020	Artigo completo publicado em periódico científico	10.1016/j.jaut.2020.102511	0896-8411	8968411	JOURNAL OF AUTOIMMUNITY (PRINT)	A1	2.751	121	12.06	-	['Tocilizumabe']	['Tocilizumab']	In cases of COVID-19 acute respiratory distress syndrome, an excessive host inflammatory response has been reported, with elevated serum interleukin-6 levels. In this multicenter retrospective cohort study we included adult patients with COVID-19, need of respiratory support, and elevated C-reactive protein who received intravenous tocilizumab in addition to standard of care. Control patients not receiving tocilizumab were matched for sex, age and respiratory support. We selected survival as the primary endpoint, along with need for invasive ventilation, thrombosis, hemorrhage, and infections as secondary endpoints at 30 days. We included 64 patients with COVID-19 in the tocilizumab group and 64 matched controls. At baseline the tocilizumab group had longer symptom duration (13 ± 5 vs. 9 ± 5 days) and received hydroxychloroquine more often than controls (100% vs. 81%). The mortality rate was similar between groups (27% with tocilizumab vs. 38%) and at multivariable analysis risk of death was not significantly influenced by tocilizumab (hazard ratio 0.61, 95% confidence interval 0.33-1.15), while being associated with the use at baseline of non invasive mechanical or invasive ventilation, and the presence of comorbidities. Among secondary outcomes, tocilizumab was associated with a lower probability of requiring invasive ventilation (hazard ratio 0.36, 95% confidence interval 0.16-0.83; P = 0.017) but not with the risk of thrombosis, bleeding, or infections. The use of intravenous tocilizumab was not associated with changes in 30-day mortality in patients with COVID-19 severe respiratory impairment. Among the secondary outcomes there was less use of invasive ventilation in the tocilizumab group.	32713677	Journal of autoimmunity	1095-9157	10.1016/j.jaut.2020.102511	Bloqueio do receptor de interleucina-6 com tocilizumabe intravenoso na síndrome do desconforto respiratório agudo COVID-19: Uma análise retrospectiva de sobrevida de 128 pacientes 	Em casos de síndrome do desconforto respiratório agudo COVID-19, uma resposta inflamatória excessiva do hospedeiro foi relatada, com níveis séricos de interleucina-6. Neste estudo de coorte retrospectivo multicêntrico, incluímos pacientes adultos com COVID-19, necessidade de suporte respiratório e proteína C reativa elevada que receberam tocilizumabe intravenoso além do tratamento padrão. Os pacientes controle que não receberam tocilizumabe foram pareados por sexo, idade e suporte respiratório. Selecionamos a sobrevivência como o desfecho primário, juntamente com a necessidade de ventilação invasiva, trombose, hemorragia e infecções como desfechos secundários em 30 dias. Incluímos 64 pacientes com COVID-19 no grupo tocilizumabe e 64 controles pareados. No início do estudo, o grupo de tocilizumab teve maior duração dos sintomas (13 ± 5 vs. 9 ± 5 dias) e recebeu hidroxicloroquina com mais frequência do que os controles (100% vs. 81%). A taxa de mortalidade foi semelhante entre os grupos (27% com tocilizumab vs. 38%) e na análise multivariada o risco de morte não foi significativamente influenciado pelo tocilizumab (hazard ratio 0,61, intervalo de confiança de 95% 0,33-1,15), estando associado ao uso na linha de base de ventilação mecânica não invasiva ou invasiva e a presença de comorbidades. Entre os desfechos secundários, o tocilizumabe foi associado a uma menor probabilidade de necessitar de ventilação invasiva (taxa de risco 0,36, intervalo de confiança de 95% 0,16-0,83; P = 0,017), mas não com o risco de trombose, sangramento ou infecções. O uso de tocilizumabe intravenoso não foi associado a alterações na mortalidade em 30 dias em pacientes com insuficiência respiratória grave por COVID-19. Entre os desfechos secundários houve menor uso de ventilação invasiva no grupo tocilizumab.
Safety and efficacy of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus-2 pneumonia: A retrospective cohort study	http://www.ijmm.org/text.asp?2020/38/1/117/290693	25/07/2020	Artigo completo publicado em periódico científico	http://www.ijmm.org/text.asp?2020/38/1/117/290693	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Segurança e eficácia do tocilizumab no tratamento da pneumonia por coronavírus-2 da síndrome respiratória aguda grave: um estudo de coorte retrospectivo 	-
Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients	https://doi.org/10.1016/j.chom.2020.07.005	18/07/2020	Artigo completo publicado em periódico científico	10.1016/j.chom.2020.07.005	1931-3128	19313128	CELL HOST & MICROBE	A1	9.373	201	19.72	-	['Interferon alfa']	['Interferon alpha']	Interferons (IFNs) are widely used in treating coronavirus disease 2019 (COVID-19) patients. However, a recent report of ACE2, the host factor mediating SARS-Cov-2 infection, identifying it as interferon-stimulated raised considerable safety concern. To examine the association between the use and timing of IFN-α2b and clinical outcomes, we analyzed in a retrospective multicenter cohort study of 446 COVID-19 patients in Hubei, China. Regression models estimated that early administration (≤5 days after admission) of IFN-α2b was associated with reduced in-hospital mortality in comparison with no admission of IFN-α2b, whereas late administration of IFN-α2b was associated with increased mortality. Among survivors, early IFN-α2b was not associated with hospital discharge or computed tomography (CT) scan improvement, whereas late IFN-α2b was associated with delayed recovery. Additionally, early IFN-α2b and umifenovir alone or together were associated with reduced mortality and accelerated recovery in comparison with treatment with lopinavir/ritonavir (LPV/r) alone. We concluded that administration of IFN-α2b during the early stage of COVID-19 could induce favorable clinical responses.	32707096	Cell host & microbe	1934-6069	10.1016/j.chom.2020.07.005	Estudo de coorte multicêntrico retrospectivo mostra que a terapia precoce com interferon está associada a respostas clínicas favoráveis em pacientes com COVID-19 Os 	interferons (IFNs) são amplamente utilizados no tratamento de pacientes com doença de coronavírus 2019 (COVID-19). No entanto, um relatório recente do ACE2, o fator do hospedeiro mediando a infecção por SARS-Cov-2, identificando-o como estimulado por interferon, levantou uma preocupação de segurança considerável. Para examinar a associação entre o uso e o momento do IFN-α2b e os resultados clínicos, analisamos em um estudo de coorte multicêntrico retrospectivo de 446 pacientes com COVID-19 em Hubei, China. Modelos de regressão estimaram que a administração precoce (≤ 5 dias após a admissão) de IFN-α2b foi associada à redução da mortalidade hospitalar em comparação com a não admissão de IFN-α2b, enquanto a administração tardia de IFN-α2b foi associada a aumento da mortalidade. Entre os sobreviventes, o IFN-α2b precoce não foi associado à alta hospitalar ou melhora na tomografia computadorizada (TC), enquanto o IFN-α2b tardio foi associado à recuperação tardia. Além disso, IFN-α2b precoce e umifenovir sozinhos ou em conjunto foram associados com mortalidade reduzida e recuperação acelerada em comparação com o tratamento com lopinavir/ritonavir (LPV/r) sozinho. Concluímos que a administração de IFN-α2b durante o estágio inicial de COVID-19 pode induzir respostas clínicas favoráveis.
Successful treatment of two Japanese ESRD cases with severe COVID‐19 pneumonia	https://doi.org/10.1007/s13730-020-00512-7	26/07/2020	Artigo completo publicado em periódico científico	10.1007/s13730-020-00512-7	2192-4449	21924449	-	-	-	-	-	-	['Imunoglobulina', 'Tocilizumabe']	['Immunoglobulin', 'Tocilizumab']	Novel coronavirus disease 2019 (COVID-19) is a highly infectious and deadly disease, spreading worldwide. There are limited data about the clinical course of end-stage renal disease (ESRD) patients infected with COVID-19. However, previous cohort studies showed a high mortality rate of ESRD patients infected with COVID-19. We report here two Japanese ESRD patients confirmed with severe COVID-19 pneumonia. Case 1 was a 60-year-old man with ESRD due to diabetic nephropathy who were infected with COVID-19 and exhibited acute respiratory distress syndrome (ARDS) requiring mechanical ventilation and intensive care unit (ICU) admission. He was treated with tocilizumab and intravenous immunoglobulin (IVIG). After 6 days of treatment in ICU, he was extubated. Case 2 was a 68-year-old woman undergoing maintenance hemodialysis for 17 years who also exhibited ARDS due to COVID-19. Her clinical course resembles case 1. Our experience of these two cases indicates that anti-cytokine therapy might be effective for severe COVID-19 pneumonia in ESRD patients.	32715376	CEN case reports	2192-4449	10.1007/s13730-020-00512-7	O tratamento bem-sucedido de dois casos japoneses de DRT com pneumonia grave por COVID-19 A nova 	doença de coronavírus 2019 (COVID-19) é uma doença altamente infecciosa e mortal, que se espalha em todo o mundo. Existem dados limitados sobre o curso clínico de pacientes com doença renal terminal (ESRD) infectados com COVID-19. No entanto, estudos de coorte anteriores mostraram uma alta taxa de mortalidade de pacientes com insuficiência renal terminal infectados com COVID-19. Relatamos aqui dois pacientes japoneses com insuficiência renal terminal confirmados com pneumonia grave por COVID-19. O caso 1 era um homem de 60 anos com ESRD devido a nefropatia diabética que estava infectado com COVID-19 e exibia síndrome do desconforto respiratório agudo (SDRA) com necessidade de ventilação mecânica e internação em unidade de terapia intensiva (UTI). Foi tratado com tocilizumabe e imunoglobulina intravenosa (IGIV). Após 6 dias de tratamento na UTI, foi extubado. O caso 2 era uma mulher de 68 anos em hemodiálise de manutenção há 17 anos que também apresentava SDRA por COVID-19. Seu curso clínico se assemelha ao caso 1. Nossa experiência desses dois casos indica que a terapia anticitocina pode ser eficaz para pneumonia grave por COVID-19 em pacientes com insuficiência renal terminal.
Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study	https://cancerdiscovery.aacrjournals.org/content/early/2020/07/21/2159-8290.CD-20-0941	22/07/2020	Artigo completo publicado em periódico científico	https://cancerdiscovery.aacrjournals.org/content/early/2020/07/21/2159-8290.CD-20-0941	-	-	-	-	-	-	-	-	['Corticosteroides', 'Hidroxicloroquina', 'Remdesivir', 'Tocilizumabe']	['Corticosteroids', 'Hydroxychloroquine', 'Remdesivir', 'Tocilizumab']	NCT04354701.	33746047	Annals of oncology : official journal of the European Society for Medical Oncology	1569-8041	10.1016/j.annonc.2021.02.024	Utilização de tratamentos com COVID-19 e resultados clínicos entre pacientes com câncer: um estudo de coorte COVID-19 e Cancer Consortium (CCC19) 	NCT04354701.
Ribavirin Therapy For Severe COVID-19: A Retrospective Cohort Study	https://doi.org/10.1016/j.ijantimicag.2020.106114	23/07/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.106114	0924-8579	9248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Ribavirina']	['Ribavirin']	-	-	-	-	-	Terapia com ribavirina para COVID-19 grave: um estudo de coorte retrospectivo 	-
Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care	https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa1041/5876045	24/07/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa1041/5876045	-	-	-	-	-	-	-	-	['Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir']	['Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir']	-	-	-	-	-	Remdesivir para COVID-19 grave versus um padrão de atendimento de coorte recebendo 	-
Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study	https://doi.org/10.1016/j.jaut.2020.102523	16/07/2020	Artigo completo publicado em periódico científico	10.1016/j.jaut.2020.102523	0896-8411	8968411	JOURNAL OF AUTOIMMUNITY (PRINT)	A1	2.751	121	12.06	-	['Tocilizumabe']	['Tocilizumab']	In a Mediterranean cohort, use of tocilizumab for severe COVID-19 show 12.9% of mortality. Early TCZ-response by BCRSS and low comorbidity were associated with increased survival. Early TCZ-response was related to shorter median hospital stay.	32690352	Journal of autoimmunity	1095-9157	10.1016/j.jaut.2020.102523	Experiência com tocilizumabe em pneumonia grave por COVID-19 após 80 dias de acompanhamento: um estudo de coorte retrospectivo 	Em uma coorte mediterrânea, o uso de tocilizumabe para COVID-19 grave mostra 12,9% de mortalidade. A resposta precoce ao TCZ pelo BCRSS e a baixa comorbidade foram associadas ao aumento da sobrevida. A resposta precoce ao TCZ foi relacionada a uma mediana de internação hospitalar mais curta.
Neuromuscular blocking agents (NMBA) for COVID-19 acute respiratory distress syndrome: a multicenter observational study	https://doi.org/10.1186/s13054-020-03164-2	19/07/2020	Artigo completo publicado em periódico científico	10.1186/s13054-020-03164-2	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Agentes bloqueadores neuromusculares']	['Neuromuscular blocking agents']	In a Mediterranean cohort, use of tocilizumab for severe COVID-19 show 12.9% of mortality. Early TCZ-response by BCRSS and low comorbidity were associated with increased survival. Early TCZ-response was related to shorter median hospital stay.	32684169	Critical care (London, England)	1466-609X	10.1186/s13054-020-03164-2	Agentes bloqueadores neuromusculares (NMBA) para síndrome do desconforto respiratório agudo de COVID-19: um estudo observacional multicêntrico 	Em uma coorte do Mediterrâneo, o uso de tocilizumabe para COVID-19 grave mostra 12,9% de mortalidade. A resposta precoce ao TCZ pelo BCRSS e a baixa comorbidade foram associadas ao aumento da sobrevida. A resposta precoce ao TCZ foi relacionada a uma mediana de internação hospitalar mais curta.
Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19	http://www.pnas.org/content/early/2020/07/21/2009017117.abstract	22/07/2020	Artigo completo publicado em periódico científico	http://www.pnas.org/content/early/2020/07/21/2009017117.abstract	-	-	-	-	-	-	-	-	['Anakinra']	['Anakinra']	In a Mediterranean cohort, use of tocilizumab for severe COVID-19 show 12.9% of mortality. Early TCZ-response by BCRSS and low comorbidity were associated with increased survival. Early TCZ-response was related to shorter median hospital stay.	32868435	Proceedings of the National Academy of Sciences of the United States of America	1091-6490	10.1073/pnas.2017202117	Bloqueio precoce do receptor de IL-1 em insuficiência respiratória inflamatória grave complicando COVID- 	19 A resposta precoce ao TCZ pelo BCRSS e a baixa comorbidade foram associadas ao aumento da sobrevida. A resposta precoce ao TCZ foi relacionada a uma mediana de internação hospitalar mais curta.
A possible benefit from therapeutic anticoagulation in COVID-19: the Dolo hospital experience in Veneto, Italy	https://pubmed.ncbi.nlm.nih.gov/32628001/	06/07/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32628001/	-	-	-	-	-	-	-	-	['Anti-inflamatórios', 'Anticorpos', 'Cloroquina', 'Enoxaparina', 'Fondaparinux', 'Heparina', 'Hidroxicloroquina', 'Lopinavir', 'Oxigenoterapia', 'Ritonavir', 'Tocilizumabe', 'Varfarina']	['Anti-inflammatory', 'Antibodies', 'Chloroquine', 'Enoxaparin', 'Fondaparinux', 'Heparin', 'Hydroxychloroquine', 'Lopinavir', 'Oxygen Therapy', 'Ritonavir', 'Tocilizumab', 'Warfarin' ]	Extracorporeal membrane oxygenation (ECMO) is an established part of the treatment algorithm for coronavirus disease 2019 (COVID-19)-related acute respiratory distress syndrome. An intense inflammatory response may cause an imbalance in the coagulation cascade making both thrombosis and bleeding common and notable features of the clinical management of these patients. Large observational and retrospective studies provide a better understanding of the pathophysiology and management of bleeding and thrombosis in COVID-19 patients requiring ECMO. Clinically significant bleeding, including intracerebral hemorrhage, is an independent predictor of mortality, and thrombosis (particularly pulmonary embolism) is associated with mortality, especially if occurring with right ventricular dysfunction. The incidence of heparin-induced thrombocytopenia is higher than the general patient cohort with acute respiratory distress syndrome or other indications for ECMO. The use of laboratory parameters to predict bleeding or thrombosis has a limited role. In this review, the authors discuss the complex pathophysiology of bleeding and thrombosis observed in patients with COVID-19 during ECMO support, and their effects on outcomes.	32628001	Kardiologia polska	1897-4279	10.33963/KP.15489	Um possível benefício da anticoagulação terapêutica no COVID-19: a experiência do hospital Dolo em Veneto, Itália A oxigenação por 	membrana extracorpórea (ECMO) é uma parte estabelecida do algoritmo de tratamento para a síndrome do desconforto respiratório agudo relacionada à doença de coronavírus 2019 (COVID-19). Uma resposta inflamatória intensa pode causar um desequilíbrio na cascata de coagulação, tornando a trombose e o sangramento características comuns e notáveis no manejo clínico desses pacientes. Grandes estudos observacionais e retrospectivos fornecem uma melhor compreensão da fisiopatologia e manejo de sangramento e trombose em pacientes com COVID-19 que necessitam de ECMO. Sangramento clinicamente significativo, incluindo hemorragia intracerebral, é um preditor independente de mortalidade, e trombose (particularmente embolia pulmonar) está associada à mortalidade, especialmente se ocorrer com disfunção ventricular direita. A incidência de trombocitopenia induzida por heparina é maior do que a coorte geral de pacientes com síndrome do desconforto respiratório agudo ou outras indicações para ECMO. O uso de parâmetros laboratoriais para prever sangramento ou trombose tem um papel limitado. Nesta revisão, os autores discutem a complexa fisiopatologia do sangramento e da trombose observada em pacientes com COVID-19 durante o suporte com ECMO e seus efeitos nos resultados.
Outcome of a patient with refractory Hodgkin lymphoma on pembrolizumab, infected with SARS-CoV-2	https://onlinelibrary.wiley.com/doi/10.1111/bjh.16798	07/05/2020	Artigo completo publicado em periódico científico	10.1111/bjh.16798	0007-1048	71048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Pembrolizumabe']	['Pembrolizumab']	Extracorporeal membrane oxygenation (ECMO) is an established part of the treatment algorithm for coronavirus disease 2019 (COVID-19)-related acute respiratory distress syndrome. An intense inflammatory response may cause an imbalance in the coagulation cascade making both thrombosis and bleeding common and notable features of the clinical management of these patients. Large observational and retrospective studies provide a better understanding of the pathophysiology and management of bleeding and thrombosis in COVID-19 patients requiring ECMO. Clinically significant bleeding, including intracerebral hemorrhage, is an independent predictor of mortality, and thrombosis (particularly pulmonary embolism) is associated with mortality, especially if occurring with right ventricular dysfunction. The incidence of heparin-induced thrombocytopenia is higher than the general patient cohort with acute respiratory distress syndrome or other indications for ECMO. The use of laboratory parameters to predict bleeding or thrombosis has a limited role. In this review, the authors discuss the complex pathophysiology of bleeding and thrombosis observed in patients with COVID-19 during ECMO support, and their effects on outcomes.	32379903	British journal of haematology	1365-2141	10.1111/bjh.16798	O resultado de um paciente com linfoma de Hodgkin refratário em pembrolizumab, infectado com SARS-CoV-2 A oxigenação por 	membrana extracorpórea (ECMO) é uma parte estabelecida do algoritmo de tratamento para a síndrome do desconforto respiratório agudo relacionado à doença de coronavírus 2019 (COVID-19). Uma resposta inflamatória intensa pode causar um desequilíbrio na cascata de coagulação, tornando a trombose e o sangramento características comuns e notáveis no manejo clínico desses pacientes. Grandes estudos observacionais e retrospectivos fornecem uma melhor compreensão da fisiopatologia e manejo de sangramento e trombose em pacientes com COVID-19 que necessitam de ECMO. Sangramento clinicamente significativo, incluindo hemorragia intracerebral, é um preditor independente de mortalidade, e trombose (particularmente embolia pulmonar) está associada à mortalidade, especialmente se ocorrer com disfunção ventricular direita. A incidência de trombocitopenia induzida por heparina é maior do que a coorte geral de pacientes com síndrome do desconforto respiratório agudo ou outras indicações para ECMO. O uso de parâmetros laboratoriais para prever sangramento ou trombose tem um papel limitado. Nesta revisão, os autores discutem a complexa fisiopatologia do sangramento e da trombose observada em pacientes com COVID-19 durante o suporte com ECMO e seus efeitos nos resultados.
Efficacy of ACEIs/ARBs versus CCBs on the progression of COVID-19 patients with hypertension in Wuhan: A hospital-based retrospective cohort study	https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26315	20/07/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26315	0146-6615	1466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Antagonistas do Receptor da Angiotensina II', 'Bloqueadores do Canal de Cálcio', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Calcium Channel Blockers', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	-	-	-	-	-	Eficácia de IECAs/BRA versus BCCs na progressão de pacientes com COVID-19 com hipertensão em Wuhan: Um estudo de coorte retrospectivo de base hospitalar 	-
A pandemic center's experience of managing pregnant women with COVID-19 infection in Turkey: A prospective cohort study	https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1002/ijgo.13318	18/07/2020	Artigo completo publicado em periódico científico	10.1002/ijgo.13318	0020-7292	207292	INTERNATIONAL JOURNAL OF GYNAECOLOGY AND OBSTETRICS	A3	0.956	103	3.59	-	['Azitromicina', 'Heparina', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Azithromycin', 'Heparin', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir']	The clinical course of COVID 19 during pregnancy appears to be mild in the present study.	32682342	International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics	1879-3479	10.1002/ijgo.13318	A experiência de um centro pandêmico no manejo de mulheres grávidas com infecção por COVID-19 na Turquia: um estudo de coorte prospectivo 	O curso clínico do COVID 19 durante a gravidez parece ser leve no presente estudo.
Tocilizumab for the treatment of adult patients with severe COVID‐19 pneumonia: a single‐center cohort study	https://doi.org/10.1002/jmv.26308	16/07/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26308	0146-6615	1466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Tocilizumab para o tratamento de pacientes adultos com pneumonia grave por COVID-19: um estudo de coorte de centro único 	-
Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study	https://doi.org/10.1186/s13054-020-03154-4	14/07/2020	Artigo completo publicado em periódico científico	10.1186/s13054-020-03154-4	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Atorvastatina']	['Atorvastatin']	-	-	-	-	-	Atorvastatina associada à diminuição do risco de morte em pacientes com COVID-19 internados em uma UTI: um estudo de coorte retrospectivo 	-
Subcutaneous tocilizumab treatment in patients with severe COVID-19-related cytokine release syndrome: An observational cohort study	https://doi.org/10.1016/j.eclinm.2020.100410	15/07/2020	Artigo completo publicado em periódico científico	10.1016/j.eclinm.2020.100410	2589-5370	25895370	EClinicalMedicine	-	4.657	44	9.79	-	['Tocilizumabe']	['Tocilizumab']	Tocilizumab administered subcutaneously to patients with COVID-19 and CRS is a promising treatment for reduction in disease activity and improvement in lung function. The effect of tocilizumab should be confirmed in a randomised controlled trial.	32766535	EClinicalMedicine	2589-5370	10.1016/j.eclinm.2020.100410	Tratamento subcutâneo com tocilizumabe em pacientes com síndrome grave de liberação de citocinas relacionada à COVID-19: um estudo de coorte observacional 	Tocilizumabe administrado por via subcutânea a pacientes com COVID-19 e SRC é um tratamento promissor para redução da atividade da doença e melhora da função pulmonar. O efeito do tocilizumab deve ser confirmado em um estudo controlado randomizado.
Clinical Features of COVID-19 in Patients With Essential Hypertension and the Impacts of Renin-angiotensin-aldosterone System Inhibitors on the Prognosis of COVID-19 Patients	https://doi.org/10.1161/HYPERTENSIONAHA.120.15289	13/07/2020	Artigo completo publicado em periódico científico	10.1161/HYPERTENSIONAHA.120.15289	0194-911X	0194911X	HYPERTENSION (DALLAS, TEX. 1979)	A1	3.395	276	7.36	             Hypertension is one of the most common comorbidities in patients with coronavirus disease 2019 (COVID-19). This study aimed to clarify the impact of hypertension on COVID-19 and investigate whether the prior use of renin-angiotensin-aldosterone system (RAAS) inhibitors affects the prognosis of COVID-19. A total of 996 patients with COVID-19 were enrolled, including 282 patients with hypertension and 714 patients without hypertension. Propensity score-matched analysis (1:1 matching) was used to adjust the imbalanced baseline variables between the 2 groups. Patients with hypertension were further divided into the RAAS inhibitor group (n=41) and non-RAAS inhibitor group (n=241) according to their medication history. The results showed that COVID-19 patients with hypertension had more severe secondary infections, cardiac and renal dysfunction, and depletion of CD8             +            cells on admission. Patients with hypertension were more likely to have comorbidities and complications and were more likely to be classified as critically ill than those without hypertension. Cox regression analysis revealed that hypertension (hazard ratio, 95% CI, unmatched cohort [1.80, 1.20–2.70]; matched cohort [2.24, 1.36–3.70]) was independently associated with all-cause mortality in patients with COVID-19. In addition, hypertensive patients with a history of RAAS inhibitor treatment had lower levels of C-reactive protein and higher levels of CD4             +            cells. The mortality of patients in the RAAS inhibitor group (9.8% versus 26.1%) was significantly lower than that of patients in the non-RAAS inhibitor group. In conclusion, hypertension may be an independent risk factor for all-cause mortality in patients with COVID-19. Patients who previously used RAAS inhibitors may have a better prognosis.          	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	Hypertension is one of the most common comorbidities in patients with coronavirus disease 2019 (COVID-19). This study aimed to clarify the impact of hypertension on COVID-19 and investigate whether the prior use of renin-angiotensin-aldosterone system (RAAS) inhibitors affects the prognosis of COVID-19. A total of 996 patients with COVID-19 were enrolled, including 282 patients with hypertension and 714 patients without hypertension. Propensity score-matched analysis (1:1 matching) was used to adjust the imbalanced baseline variables between the 2 groups. Patients with hypertension were further divided into the RAAS inhibitor group (n=41) and non-RAAS inhibitor group (n=241) according to their medication history. The results showed that COVID-19 patients with hypertension had more severe secondary infections, cardiac and renal dysfunction, and depletion of CD8	32654555	Hypertension (Dallas, Tex. : 1979)	1524-4563	10.1161/HYPERTENSIONAHA.120.15289	Características clínicas da COVID-19 em pacientes com hipertensão essencial e os impactos dos inibidores do sistema renina-angiotensina-aldosterona no prognóstico de pacientes com COVID-19 A 	hipertensão é uma das comorbidades mais comuns em pacientes com doença por coronavírus 2019 (COVID-19). Este estudo teve como objetivo esclarecer o impacto da hipertensão na COVID-19 e investigar se o uso prévio de inibidores do sistema renina-angiotensina-aldosterona (SRAA) afeta o prognóstico da COVID-19. Um total de 996 pacientes com COVID-19 foram inscritos, incluindo 282 pacientes com hipertensão e 714 pacientes sem hipertensão. A análise de correspondência de pontuação de propensão (correspondência de 1:1) foi usada para ajustar as variáveis basais desequilibradas entre os 2 grupos. Os pacientes com hipertensão foram divididos em grupo inibidor de RAAS (n=41) e grupo não inibidor de RAAS (n=241) de acordo com seu histórico de medicação. Os resultados mostraram que pacientes com COVID-19 com hipertensão tiveram infecções secundárias mais graves, disfunção cardíaca e renal e depleção de CD8
Bacillus Calmette–Guérin vaccination and clinical characteristics and outcomes of COVID-19 in Rhode Island, United States: a cohort study	https://www.cambridge.org/core/journals/epidemiology-and-infection/article/bacillus-calmetteguerin-vaccination-and-clinical-characteristics-and-outcomes-of-covid19-in-rhode-island-united-states-a-cohort-study/2A472746C49A1AB2C6AC698711C5049F	09/07/2020	Artigo completo publicado em periódico científico	https://www.cambridge.org/core/journals/epidemiology-and-infection/article/bacillus-calmetteguerin-vaccination-and-clinical-characteristics-and-outcomes-of-covid19-in-rhode-island-united-states-a-cohort-study/2A472746C49A1AB2C6AC698711C5049F	-	-	-	-	-	-	-	-	['Vacina BCG']	['BCG vaccine']	Coronavirus disease 2019 (COVID-19) has resulted in a global pandemic, and there is limited data on effective therapies. Bacillus Calmette-Guérin (BCG) vaccine, a live-attenuated strain derived from an isolate of Mycobacterium bovis and originally designed to prevent tuberculosis, has shown some efficacy against infection with unrelated pathogens. In this study, we reviewed 120 consecutive adult patients (≥18 years old) with COVID-19 at a major federally qualified health centre in Rhode Island, United States from 19 March to 29 April 2020. Median age was 39.5 years (interquartile range, 27.0-50.0), 30% were male and 87.5% were Latino/Hispanics. Eighty-two (68.3%) patients had BCG vaccination. Individuals with BCG vaccination were less likely to require hospital admission during the disease course (3.7% vs. 15.8%, P = 0.019). This association remained unchanged after adjusting for demographics and comorbidities (P = 0.017) using multivariate regression analysis. The finding from our study suggests the potential of BCG in preventing more severe COVID-19.	32641191	Epidemiology and infection	1469-4409	10.1017/S0950268820001569	Vacinação com Bacillus Calmette-Guérin e características clínicas e resultados da COVID-19 em Rhode Island, Estados Unidos: um estudo de coorte 	A doença de coronavírus 2019 (COVID-19) resultou em uma pandemia global e há dados limitados sobre terapias eficazes. A vacina Bacillus Calmette-Guérin (BCG), uma cepa viva atenuada derivada de um isolado de Mycobacterium bovis e originalmente projetada para prevenir a tuberculose, mostrou alguma eficácia contra a infecção por patógenos não relacionados. Neste estudo, revisamos 120 pacientes adultos consecutivos (≥18 anos) com COVID-19 em um importante centro de saúde federal qualificado em Rhode Island, Estados Unidos, de 19 de março a 29 de abril de 2020. A idade média foi de 39,5 anos (intervalo interquartil, 27,0-50,0), 30% eram do sexo masculino e 87,5% eram latinos/hispânicos. Oitenta e dois (68,3%) pacientes foram vacinados com BCG. Indivíduos com vacinação BCG foram menos propensos a necessitar de internação hospitalar durante o curso da doença (3,7% vs. 15,8%, P = 0,019). Essa associação permaneceu inalterada após o ajuste para dados demográficos e comorbidades (P = 0,017) usando análise de regressão multivariada. A descoberta do nosso estudo sugere o potencial do BCG na prevenção de COVID-19 mais grave.
Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab	https://doi.org/10.1016/j.jaut.2020.102512	03/07/2020	Artigo completo publicado em periódico científico	10.1016/j.jaut.2020.102512	0896-8411	8968411	JOURNAL OF AUTOIMMUNITY (PRINT)	A1	2.751	121	12.06	-	['Tocilizumabe']	['Tocilizumab']	Coronavirus disease 2019 (COVID-19) can progress to cytokine storm that is associated with organ dysfunction and death. The purpose of the present study is to determine clinical characteristics associated with 28 day in-hospital survival in patients with coronavirus disease 2019 (COVID-19) that received tocilizumab. This was a retrospective observational cohort study conducted at a five hospital health system in Michigan, United States. Adult patients with confirmed COVID-19 that were admitted to the hospital and received tocilizumab for cytokine storm from March 1, 2020 through April 3, 2020 were included. Patients were grouped into survivors and non-survivors based on 28 day in-hospital mortality. Study day 0 was defined as the day tocilizumab was administered. Factors independently associated with in-hospital survival at 28 days after tocilizumab administration were assessed. Epidemiologic, demographic, laboratory, prognostic scores, treatment, and outcome data were collected and analyzed. Clinical response was collected and defined as a decline of two levels on a six-point ordinal scale of clinical status or discharged alive from the hospital. Of the 81 patients included, the median age was 64 (58-71) years and 56 (69.1%) were male. The 28 day in-hospital mortality was 43.2%. There were 46 (56.8%) patients in the survivors and 35 (43.2%) in the non-survivors group. On study day 0 no differences were noted in demographics, clinical characteristics, severity of illness scores, or treatments received between survivors and non-survivors. C-reactive protein was significantly higher in the non-survivors compared to survivors. Compared to non-survivors, recipients of tocilizumab within 12 days of symptom onset was independently associated with survival (adjusted OR: 0.296, 95% CI: 0.098-0.889). SOFA score ≥8 on day 0 was independently associated with mortality (adjusted OR: 2.842, 95% CI: 1.042-7.753). Clinical response occurred more commonly in survivors than non-survivors (80.4% vs. 5.7%; p < 0.001). Improvements in the six-point ordinal scale and SOFA score were observed in survivors after tocilizumab. Early receipt of tocilizumab in patients with severe COVID-19 was an independent predictor for in-hospital survival at 28 days.	32646770	Journal of autoimmunity	1095-9157	10.1016/j.jaut.2020.102512	Características clínicas e preditores de sobrevivência em adultos com doença de coronavírus 2019 recebendo tocilizumab 	A doença de coronavírus 2019 (COVID-19) pode progredir para tempestade de citocinas associada à disfunção orgânica e morte. O objetivo do presente estudo é determinar as características clínicas associadas à sobrevida hospitalar de 28 dias em pacientes com doença por coronavírus 2019 (COVID-19) que receberam tocilizumabe. Este foi um estudo de coorte observacional retrospectivo realizado em um sistema de saúde de cinco hospitais em Michigan, Estados Unidos. Pacientes adultos com COVID-19 confirmado que foram admitidos no hospital e receberam tocilizumab para tempestade de citocinas de 1º de março de 2020 a 3 de abril de 2020 foram incluídos. Os pacientes foram agrupados em sobreviventes e não sobreviventes com base na mortalidade hospitalar em 28 dias. O dia 0 do estudo foi definido como o dia em que o tocilizumabe foi administrado. Fatores independentemente associados à sobrevida hospitalar em 28 dias após a administração de tocilizumab foram avaliados. Dados epidemiológicos, demográficos, laboratoriais, prognósticos, tratamento e resultados foram coletados e analisados. A resposta clínica foi coletada e definida como um declínio de dois níveis em uma escala ordinal de seis pontos do estado clínico ou alta viva do hospital. Dos 81 pacientes incluídos, a mediana de idade foi de 64 (58-71) anos e 56 (69,1%) eram do sexo masculino. A mortalidade hospitalar em 28 dias foi de 43,2%. Havia 46 (56,8%) pacientes no grupo de sobreviventes e 35 (43,2%) no grupo de não sobreviventes. No dia 0 do estudo, não foram observadas diferenças nos dados demográficos, características clínicas, gravidade dos escores da doença ou tratamentos recebidos entre sobreviventes e não sobreviventes. A proteína C reativa foi significativamente maior nos não sobreviventes em comparação com os sobreviventes. Em comparação com os não sobreviventes, os receptores de tocilizumabe dentro de 12 dias do início dos sintomas foram independentemente associados à sobrevida (OR ajustado: 0,296, IC 95%: 0,098-0,889). A pontuação SOFA ≥8 no dia 0 foi independentemente associada à mortalidade (OR ajustado: 2,842, IC 95%: 1,042-7,753). A resposta clínica ocorreu mais comumente em sobreviventes do que não sobreviventes (80,4% vs. 5,7%; p < 0,001). Melhorias na escala ordinal de seis pontos e pontuação SOFA foram observadas em sobreviventes após tocilizumab. O recebimento precoce de tocilizumabe em pacientes com COVID-19 grave foi um preditor independente de sobrevida hospitalar em 28 dias.
Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases	https://ard.bmj.com/content/early/2020/06/30/annrheumdis-2020-218054	30/06/2020	Artigo completo publicado em periódico científico	https://ard.bmj.com/content/early/2020/06/30/annrheumdis-2020-218054	-	-	-	-	-	-	-	-	['Drogas antirreumáticas modificadoras de doenças', 'Hidroxicloroquina', 'Prednisona']	['Disease-modifying anti-rheumatic drugs', 'Hydroxychloroquine', 'Prednisone']	-	-	-	-	-	Curso clínico, gravidade e mortalidade em uma coorte de pacientes com COVID-19 com doenças reumáticas 	-
An Observational Cohort Study of Hydroxychloroquine and Azithromycin for COVID-19: (Can’t Get No) Satisfaction	https://doi.org/10.1016/j.ijid.2020.06.095	02/07/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.06.095	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']	COVID-19 patients (n = 34) suffering from ARDS were treated with tocilizumab (TCZ). Outcome was classified in two groups: "Death" and "Recovery". Predictive factors of mortality were studied. Mean age was 75.3, mean oxygen (O	32623080	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases	1878-3511	10.1016/j.ijid.2020.06.095	Um estudo de coorte observacional de hidroxicloroquina e azitromicina para COVID-19: (não é possível obter não) Satisfação 	Pacientes com COVID-19 (n = 34) que sofrem de SDRA foram tratados com tocilizumab (TCZ). O desfecho foi classificado em dois grupos: "Morte" e "Recuperação". Fatores preditivos de mortalidade foram estudados. A média de idade foi de 75,3 anos, a média de oxigênio (O
Incidence and clinical profiles of COVID-19 pneumonia in pregnant women: A single-centre cohort study from Spain	https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30151-6/fulltext	15/06/2020	Artigo completo publicado em periódico científico	https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30151-6/fulltext	-	-	-	-	-	-	-	-	['Amoxicilina', 'Azitromicina', 'Ceftriaxona', 'Esteroides', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir', 'Tocilizumabe']	['Amoxicillin', 'Azithromycin', 'Ceftriaxone', 'Ssteroids', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir', 'Tocilizumab']	Instituto de Salud Carlos III (COV20/00,181), Spanish Ministry of Science and Innovation.	32632417	EClinicalMedicine	2589-5370	10.1016/j.eclinm.2020.100407	Incidência e perfis clínicos de pneumonia por COVID-19 em mulheres grávidas: Um estudo de coorte de centro único do 	Instituto de Salud Carlos III da Espanha (COV20/00,181), Ministério da Ciência e Inovação da Espanha.
Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: a retrospective matched-pair cohort study	https://doi.org/10.1002/jmv.26260	04/07/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26260	0146-6615	1466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']	During the early stages of the pandemic, some coronavirus disease (COVID-19) patients were misdiagnosed as having influenza, which aroused the concern that some deaths attributed to influenza were actually COVID-19-related. However, little is known about whether coinfection with influenza contributes to severity of COVID-19 pneumonia, and the optimal therapeutic strategy for these patients. We retrospectively studied 128 hospitalized patients with COVID-19 pneumonia. All patients were positive severe acute respiratory syndrome coronavirus 2 positive by nucleic acid detection. Sixty-four cases were coinfected with influenza A/B and the other 64 were influenza negative, matched by age, sex, and days from onset of symptoms. Among the 64 coinfected patients, 54 (84.4%) were coinfected with influenza A, and 10 (15.6%) with influenza B. The median duration of viral shedding time from admission was longer for patients with influenza coinfection (17.0 days) than for those without influenza coinfection (12.0 days) (P < .001). The multivariable Cox proportional hazards model showed that the hazards ratio of resolution in lung involvement was 1.878 (P = .020) for patients administered lopinavir/ritonavir, compared with those not administered lopinavir/ritonavir (95% confidence interval: 1.103-3.196). Among influenza coinfected patients, those treated with lopinavir/ritonavir exhibited faster pneumonia resolution within 2 weeks after symptom onset (37% vs 1%; P = .001). There was no difference in lung involvement between influenza coinfected and noninfected groups. Lopinavir/ritonavir eliminated the difference of lung involvement between influenza coinfected and noninfected groups, indicating that lopinavir/ritonavir is associated with pneumonia resolution in COVID-19.	32621621	Journal of medical virology	1096-9071	10.1002/jmv.26260	COVID -19 com coinfecção por influenza: um estudo de coorte retrospectivo de pares pareados 	preocupação de que algumas mortes atribuídas à gripe estivessem realmente relacionadas ao COVID-19. No entanto, pouco se sabe se a coinfecção com influenza contribui para a gravidade da pneumonia por COVID-19 e a estratégia terapêutica ideal para esses pacientes. Estudamos retrospectivamente 128 pacientes hospitalizados com pneumonia por COVID-19. Todos os pacientes foram positivos para síndrome respiratória aguda grave coronavírus 2 positivo por detecção de ácido nucleico. Sessenta e quatro casos foram coinfectados com influenza A/B e os outros 64 foram negativos para influenza, pareados por idade, sexo e dias do início dos sintomas. Entre os 64 pacientes coinfectados, 54 (84,4%) foram coinfectados com influenza A e 10 (15,6%) com influenza B. A duração mediana do tempo de disseminação viral desde a admissão foi maior para pacientes com coinfecção por influenza (17,0 dias) do que para aqueles sem coinfecção por influenza (12,0 dias) (P < 0,001). O modelo multivariável de risco proporcional de Cox mostrou que a razão de risco de resolução no envolvimento pulmonar foi de 1,878 (P = 0,020) para pacientes que receberam lopinavir/ritonavir, em comparação com aqueles que não receberam lopinavir/ritonavir (intervalo de confiança de 95%: 1,103-3,196). Entre os pacientes coinfectados com influenza, aqueles tratados com lopinavir/ritonavir apresentaram resolução mais rápida da pneumonia dentro de 2 semanas após o início dos sintomas (37% vs 1%; P = 0,001). Não houve diferença no envolvimento pulmonar entre os grupos coinfectados e não infectados por influenza. Lopinavir/ritonavir eliminou a diferença de envolvimento pulmonar entre os grupos coinfectados e não infectados por influenza, indicando que lopinavir/ritonavir está associado à resolução da pneumonia no COVID-19.
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study	https://pubmed.ncbi.nlm.nih.gov/32620597/	03/07/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32620597/	-	-	-	-	-	-	-	-	['Sarilumabe']	['Sarilumab']	During the early stages of the pandemic, some coronavirus disease (COVID-19) patients were misdiagnosed as having influenza, which aroused the concern that some deaths attributed to influenza were actually COVID-19-related. However, little is known about whether coinfection with influenza contributes to severity of COVID-19 pneumonia, and the optimal therapeutic strategy for these patients. We retrospectively studied 128 hospitalized patients with COVID-19 pneumonia. All patients were positive severe acute respiratory syndrome coronavirus 2 positive by nucleic acid detection. Sixty-four cases were coinfected with influenza A/B and the other 64 were influenza negative, matched by age, sex, and days from onset of symptoms. Among the 64 coinfected patients, 54 (84.4%) were coinfected with influenza A, and 10 (15.6%) with influenza B. The median duration of viral shedding time from admission was longer for patients with influenza coinfection (17.0 days) than for those without influenza coinfection (12.0 days) (P < .001). The multivariable Cox proportional hazards model showed that the hazards ratio of resolution in lung involvement was 1.878 (P = .020) for patients administered lopinavir/ritonavir, compared with those not administered lopinavir/ritonavir (95% confidence interval: 1.103-3.196). Among influenza coinfected patients, those treated with lopinavir/ritonavir exhibited faster pneumonia resolution within 2 weeks after symptom onset (37% vs 1%; P = .001). There was no difference in lung involvement between influenza coinfected and noninfected groups. Lopinavir/ritonavir eliminated the difference of lung involvement between influenza coinfected and noninfected groups, indicating that lopinavir/ritonavir is associated with pneumonia resolution in COVID-19.	32816702	Annals of the rheumatic diseases	1468-2060	10.1136/annrheumdis-2020-218724	sarilumabe na pneumonia grave por COVID-19 com hiperinflamação sistêmica: um estudo de coorte aberto 	algumas mortes atribuídas à gripe foram, na verdade, relacionadas ao COVID-19. No entanto, pouco se sabe se a coinfecção com influenza contribui para a gravidade da pneumonia por COVID-19 e a estratégia terapêutica ideal para esses pacientes. Estudamos retrospectivamente 128 pacientes hospitalizados com pneumonia por COVID-19. Todos os pacientes foram positivos para síndrome respiratória aguda grave coronavírus 2 positivo por detecção de ácido nucleico. Sessenta e quatro casos foram coinfectados com influenza A/B e os outros 64 foram negativos para influenza, pareados por idade, sexo e dias do início dos sintomas. Entre os 64 pacientes coinfectados, 54 (84,4%) foram coinfectados com influenza A e 10 (15,6%) com influenza B. A duração mediana do tempo de disseminação viral desde a admissão foi maior para pacientes com coinfecção por influenza (17,0 dias) do que para aqueles sem coinfecção por influenza (12,0 dias) (P < 0,001). O modelo multivariável de risco proporcional de Cox mostrou que a razão de risco de resolução no envolvimento pulmonar foi de 1,878 (P = 0,020) para pacientes que receberam lopinavir/ritonavir, em comparação com aqueles que não receberam lopinavir/ritonavir (intervalo de confiança de 95%: 1,103-3,196). Entre os pacientes coinfectados com influenza, aqueles tratados com lopinavir/ritonavir apresentaram resolução mais rápida da pneumonia dentro de 2 semanas após o início dos sintomas (37% vs 1%; P = 0,001). Não houve diferença no envolvimento pulmonar entre os grupos coinfectados e não infectados por influenza. Lopinavir/ritonavir eliminou a diferença de envolvimento pulmonar entre os grupos coinfectados e não infectados por influenza, indicando que lopinavir/ritonavir está associado à resolução da pneumonia no COVID-19.
Use of Baricitinib in Patients with Moderate and Severe COVID-19	https://doi.org/10.1093/cid/ciaa879	29/06/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa879	1058-4838	10584838	CLINICAL INFECTIOUS DISEASES	A1	4.394	353	8.72	 Abstract                Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized, controlled clinical trials.	['Baricitinibe', 'Hidroxicloroquina']	['Baricitinib', 'Hydroxychloroquine']	-	-	-	-	-	Uso de Baricitinibe em Pacientes com COVID-19 Moderado e Grave 	-
Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors.	https://ard.bmj.com/content/early/2020/06/25/annrheumdis-2020-218152	25/06/2020	Artigo completo publicado em periódico científico	https://ard.bmj.com/content/early/2020/06/25/annrheumdis-2020-218152	-	-	-	-	-	-	-	-	['Azitromicina', 'Colchicina', 'Drogas antirreumáticas modificadoras de doenças', 'Hidroxicloroquina', 'Inibidores de Janus Kinase (JAK)', 'Prednisona']	['Azithromycin', 'Colchicine', 'Disease-modifying anti-rheumatic drugs', 'Hydroxychloroquine', 'Janus Kinase Inhibitors (JAK)', 'Prednisone']	-	-	-	-	-	Incidência de COVID-19 grave em uma coorte espanhola de 1.037 pacientes com doenças reumáticas tratados com biológicos e inibidores de JAK. 	-
Tocilizumab in patients with severe COVID-19: a retrospective cohort study	https://doi.org/10.1016/S2665-9913(20)30173-9	24/06/2020	Artigo completo publicado em periódico científico	10.1016/S2665-9913(20)30173-9	2665-9913	26659913	Lancet Rheumatology, The	-	6.633	28	9.58	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Tocilizumab em pacientes com COVID-19 grave: um estudo de coorte retrospectivo 	-
Investigational therapies for the treatment of COVID-19: updates from ongoing clinical trials.	https://doi.org/10.1016/j.euf.2020.05.019	05/06/2020	Artigo completo publicado em periódico científico	10.1016/j.euf.2020.05.019	2405-4569	24054569	European Urology Focus	-	1.453	34	4.27	-	['Cloroquina', 'Hidroxicloroquina', 'Inibidores de interleucina-6', 'Plasma convalescente', 'Remdesivir']	['Chloroquine', 'Hydroxychloroquine', 'Interleukin-6 Inhibitors', 'Convalescent Plasma', 'Remdesivir']	Determinants of the acquisition and maintenance of maternal microchimerism (MMc) during infancy and the impact of MMc on infant immune responses are unknown. We examined factors that influence MMc detection and level across infancy and the effect of MMc on T cell responses to bacillus Calmette-Guérin (BCG) vaccination in a cohort of HIV-exposed, uninfected and HIV-unexposed infants in South Africa. MMc was measured in whole blood from 58 infants using a panel of quantitative PCR assays at day 1, and 7, 15, and 36 weeks of life. Infants received BCG at birth, and selected whole blood samples from infancy were stimulated in vitro with BCG and assessed for polyfunctional CD4+ T cell responses. MMc was present in most infants across infancy, with levels ranging from 0 to 1,193/100,000 genomic equivalents and was positively impacted by absence of maternal HIV, maternal and infant HLA compatibility, infant female sex, and exclusive breastfeeding. Initiation of maternal antiretroviral therapy prior to pregnancy partially restored MMc level in HIV-exposed, uninfected infants. Birth MMc was associated with an improved polyfunctional CD4+ T cell response to BCG. These data emphasize that both maternal and infant factors influence the level of MMc, which may subsequently affect infant T cell responses.	32563675	European urology focus	2405-4569	10.1016/j.euf.2020.05.019	Terapias de investigação para o tratamento de COVID-19: atualizações de ensaios clínicos em andamento. 	Os determinantes da aquisição e manutenção do microquimerismo materno (MMc) durante a infância e o impacto do MMc nas respostas imunes infantis são desconhecidos. Examinamos os fatores que influenciam a detecção e o nível de MMc na infância e o efeito do MMc nas respostas das células T à vacinação do bacilo Calmette-Guérin (BCG) em uma coorte de bebês expostos, não infectados e não expostos ao HIV na África do Sul. O MMc foi medido no sangue total de 58 crianças usando um painel de ensaios quantitativos de PCR no dia 1 e 7, 15 e 36 semanas de vida. Os bebês receberam BCG ao nascimento e amostras de sangue total selecionadas da infância foram estimuladas in vitro com BCG e avaliadas para respostas de células T CD4+ polifuncionais. O MMc estava presente na maioria dos bebês ao longo da primeira infância, com níveis variando de 0 a 1.193/100.000 equivalentes genômicos e foi impactado positivamente pela ausência de HIV materno, compatibilidade HLA materno-infantil, sexo feminino infantil e amamentação exclusiva. O início da terapia antirretroviral materna antes da gravidez restaurou parcialmente o nível de MMc em bebês não infectados expostos ao HIV. O nascimento MMc foi associado a uma resposta melhorada de células T CD4+ polifuncionais ao BCG. Esses dados enfatizam que fatores maternos e infantis influenciam o nível de MMc, o que pode afetar subsequentemente as respostas das células T infantis.
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study.	https://doi.org/10.1016/S2665-9913(20)30170-3	16/06/2020	Artigo completo publicado em periódico científico	10.1016/S2665-9913(20)30170-3	2665-9913	26659913	Lancet Rheumatology, The	-	6.633	28	9.58	-	['Mavrilimumabe']	['Mavrilimumab']	IRCCS San Raffaele Scientific Institute.	32835256	The Lancet. Rheumatology	2665-9913	10.1016/S2665-9913(20)30170-3	Bloqueio de GM-CSF com mavrilimumab em pneumonia grave por COVID-19 e hiperinflamação sistêmica: um estudo de coorte prospectivo em um único centro. 	Instituto Científico IRCCS San Raffaele.
Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian cohort of 133 hypertensives.	https://doi.org/10.1093/ajh/hpaa096	08/06/2020	Artigo completo publicado em periódico científico	10.1093/ajh/hpaa096	0895-7061	8957061	AMERICAN JOURNAL OF HYPERTENSION	A3	0.862	141	2.38	 Abstract                                   BACKGROUND                   The effect of chronic use of renin–angiotensin–aldosterone system (RAAS) inhibitors on the severity of COVID-19 infection is still unclear in patients with hypertension. We aimed to investigate the association between chronic use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) and COVID-19-related outcomes in hypertensive patients.                                                  METHODS                   A single-center study was conducted on 133 consecutive hypertensive subjects presenting to the emergency department with acute respiratory symptoms and/or fever who were diagnosed with COVID-19 infection between 9 and 31 March 2020.                                                  RESULTS                   All patients were grouped according to their chronic antihypertensive medications (ACEIs, N = 40; ARBs, N = 42; not on RAAS inhibitors, N = 51). There was no statistical difference between ACEIs and ARBs groups in terms of hospital admission rate, oxygen therapy, and need for noninvasive ventilation. Patients chronically treated with RAAS inhibitors showed a significantly lower rate of admission to semi-intensive/intensive care units, when compared with the non-RAAS population (odds ratio (OR) 0.25, confidence interval (CI) 95% 0.09–0.66, P = 0.006). Similarly, the risk of mortality was lower in the former group, although not reaching statistical significance (OR 0.56, CI 95% 0.17–1.83, P = 0.341).                                                  CONCLUSIONS                   Our data suggest that chronic use of RAAS inhibitors does not negatively affect clinical course of COVID-19 in hypertensive patients. Further studies are needed to confirm this finding and determine whether RAAS inhibitors may have a protective effect on COVID-19-related morbidity and mortality.               	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	Our data suggest that chronic use of RAAS inhibitors does not negatively affect clinical course of COVID-19 in hypertensive patients. Further studies are needed to confirm this finding and determine whether RAAS inhibitors may have a protective effect on COVID-19-related morbidity and mortality.	32511678	American journal of hypertension	1941-7225	10.1093/ajh/hpaa096	Uso de inibidores de RAAS e risco de deterioração clínica no COVID-19: resultados de uma coorte italiana de 133 hipertensos. 	Nossos dados sugerem que o uso crônico de inibidores do SRAA não afeta negativamente o curso clínico da COVID-19 em pacientes hipertensos. Mais estudos são necessários para confirmar esse achado e determinar se os inibidores do SRAA podem ter um efeito protetor na morbidade e mortalidade relacionadas ao COVID-19.
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study.	https://doi.org/10.1016/j.ejim.2020.05.021	01/06/2020	Artigo completo publicado em periódico científico	10.1016/j.ejim.2020.05.021	0953-6205	9536205	EUROPEAN JOURNAL OF INTERNAL MEDICINE (LEICESTER)	A2	1.210	79	3.28	-	['Tocilizumabe']	['Tocilizumab']	At day 28, clinical improvement and mortality were not statistically different between tocilizumab and standard treatment patients in our cohort. Bacterial or fungal infections were recorded in 13% of tocilizumab patients and in 12% of standard treatment patients. Confirmation of efficacy and safety will require ongoing controlled trials.	32482597	European journal of internal medicine	1879-0828	10.1016/j.ejim.2020.05.021	Eficácia e segurança do tocilizumab em pacientes graves com COVID-19: um estudo de coorte retrospectivo de centro único. 	No dia 28, a melhora clínica e a mortalidade não foram estatisticamente diferentes entre o tocilizumabe e os pacientes do tratamento padrão em nossa coorte. Infecções bacterianas ou fúngicas foram registradas em 13% dos pacientes com tocilizumabe e em 12% dos pacientes com tratamento padrão. A confirmação da eficácia e segurança exigirá estudos controlados em andamento.
Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients with Inflammatory Bowel Disease.	https://doi.org/10.1053/j.gastro.2020.05.066	23/05/2020	Artigo completo publicado em periódico científico	10.1053/j.gastro.2020.05.066	0016-5085	165085	GASTROENTEROLOGY (NEW YORK, N.Y. 1943)	A1	7.689	423	10.76	-	['Corticosteroides']	['Corticosteroids']	At day 28, clinical improvement and mortality were not statistically different between tocilizumab and standard treatment patients in our cohort. Bacterial or fungal infections were recorded in 13% of tocilizumab patients and in 12% of standard treatment patients. Confirmation of efficacy and safety will require ongoing controlled trials.	32479824	Gastroenterology	1528-0012	10.1053/j.gastro.2020.05.066	Atividade da doença basal e terapia com esteróides estratificam o risco de COVID-19 em pacientes com doença inflamatória intestinal. 	No dia 28, a melhora clínica e a mortalidade não foram estatisticamente diferentes entre o tocilizumabe e os pacientes do tratamento padrão em nossa coorte. Infecções bacterianas ou fúngicas foram registradas em 13% dos pacientes com tocilizumabe e em 12% dos pacientes com tratamento padrão. A confirmação da eficácia e segurança exigirá estudos controlados em andamento.
Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis.	https://doi.org/10.1016/j.phrs.2020.104872	30/04/2020	Artigo completo publicado em periódico científico	10.1016/j.phrs.2020.104872	1043-6618	10436618	PHARMACOLOGICAL RESEARCH	A1	1.738	147	8.88	-	['Cloroquina', 'Hidroxicloroquina', 'Interferon', 'Lopinavir', 'Remdesivir', 'Ribavirina', 'Ritonavir', 'Umifenovir']	['Chloroquine', 'Hydroxychloroquine', 'Interferon', 'Lopinavir', 'Remdesivir', 'Ribavirin', 'Ritonavir', 'Umifenovir']	The rapidly progressing of coronavirus disease 2019 (COVID-19) pandemic has become a global concern. This meta-analysis aimed at evaluating the efficacy and safety of current option of therapies for severe acute respiratory syndrome (SARS), Middle Eastern respiratory syndrome (MERS) besides COVID-19, in an attempt to identify promising therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients. We searched PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), and WANFANG DATA for randomized controlled trials (RCTs), prospective cohort, and retrospective cohort studies that evaluated therapies (hydroxychloroquine, lopinavir/ritonavir-based therapy, and ribavirin-based therapy, etc.) for SARS, MERS, and COVID-19. The primary outcomes were mortality, virological eradication and clinical improvement, and secondary outcomes were improvement of symptoms and chest radiography results, incidence of acute respiratory disease syndrome (ARDS), utilization of mechanical ventilation, and adverse events (AEs). Summary relative risks (RRs) and 95% confidence intervals (CIs) were calculated using random-effects models, and the quality of evidence was appraised using GRADEpro. Eighteen articles (5 RCTs, 2 prospective cohort studies, and 11 retrospective cohort studies) involving 4,941 patients were included. Compared with control treatment, anti-coronary virus interventions significantly reduced mortality (RR 0.65, 95% CI 0.44-0.96; I	32360583	Pharmacological research	1096-1186	10.1016/j.phrs.2020.104872	Eficácia e segurança das opções terapêuticas atuais para COVID-19 - lições a serem aprendidas com a epidemia de SARS e MERS: uma revisão sistemática e meta-análise. 	A rápida progressão da pandemia da doença de coronavírus 2019 (COVID-19) tornou-se uma preocupação global. Esta meta-análise teve como objetivo avaliar a eficácia e segurança da opção atual de terapias para síndrome respiratória aguda grave (SARS), síndrome respiratória do Oriente Médio (MERS) além de COVID-19, na tentativa de identificar terapia promissora para síndrome respiratória aguda grave coronavírus 2 (SARS-CoV-2) pacientes infectados. Pesquisamos PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP) e WANFANG DATA para estudos controlados randomizados (RCTs), coorte prospectiva e estudos de coorte retrospectivos que avaliaram terapias (hidroxicloroquina , terapia à base de lopinavir/ritonavir e terapia à base de ribavirina, etc.) para SARS, MERS e COVID-19. Os desfechos primários foram mortalidade, erradicação virológica e melhora clínica, e os desfechos secundários foram melhora dos sintomas e resultados da radiografia de tórax, incidência de síndrome da doença respiratória aguda (SDRA), utilização de ventilação mecânica e eventos adversos (EAs). Riscos relativos resumidos (RRs) e intervalos de confiança de 95% (ICs) foram calculados usando modelos de efeitos aleatórios, e a qualidade da evidência foi avaliada usando GRADEpro. Dezoito artigos (5 ECRs, 2 estudos de coorte prospectivos e 11 estudos de coorte retrospectivos) envolvendo 4.941 pacientes foram incluídos. Em comparação com o tratamento de controle, as intervenções anti-vírus coronarianos reduziram significativamente a mortalidade (RR 0,65, IC 95% 0,44-0,96; I
Potential of Arbidol for Post-exposure Prophylaxis of COVID-19 Transmission—A Preliminary Report of a Retrospective Cohort Study.	https://doi.org/10.1007/s11596-020-2203-3	30/05/2020	Artigo completo publicado em periódico científico	10.1007/s11596-020-2203-3	2096-5230	20965230	Current Medical Science	-	0.538	32	2.61	-	['Umifenovir']	['Umifenovir']	The efficient transmission of severe acute respiratory syndrome-2 coronavirus (SARS-CoV-2) from patients to health care workers or family members has been a worrisome and prominent feature of the ongoing outbreak. On the basis of clinical practice and in-vitro studies, we postulated that post-exposure prophylaxis (PEP) using Arbidol is associated with decreased infection among individuals exposed to confirmed cases of COVID-19 infection. We conducted a retrospective cohort study on family members and health care workers who were exposed to patients confirmed to have SARS-CoV-2 infection by real-time RT-PCR and chest computed tomography (CT) from January 1 to January 16, 2020. The last follow-up date was Feb. 26, 2020. The emergence of fever and/or respiratory symptoms after exposure to the primary case was collected. The correlations between post-exposure prophylaxis and infection in household contacts and health care workers were respectively analyzed. A total of 66 members in 27 families and 124 health care workers had evidence of close exposure to patients with confirmed COVID-19. The Cox regression based on the data of the family members and health care workers with Arbidol or not showed that Arbidol PEP was a protective factor against the development of COVID-19 (HR 0.025, 95% CI 0.003-0.209, P=0.0006 for family members and HR 0.056, 95% CI 0.005-0.662, P=0.0221 for health care workers). Our findings suggest Arbidol could reduce the infection risk of the novel coronavirus in hospital and family settings. This treatment should be promoted for PEP use and should be the subject of further investigation.	32474860	Current medical science	2523-899X	10.1007/s11596-020-2203-3	Potencial do Arbidol para Profilaxia Pós-Exposição da Transmissão COVID-19 - Um Relatório Preliminar de um Estudo de Coorte Retrospectivo. 	A transmissão eficiente do coronavírus da síndrome respiratória aguda grave-2 (SARS-CoV-2) de pacientes para profissionais de saúde ou familiares tem sido uma característica preocupante e proeminente do surto em andamento. Com base na prática clínica e estudos in vitro, postulamos que a profilaxia pós-exposição (PEP) usando Arbidol está associada à diminuição da infecção entre indivíduos expostos a casos confirmados de infecção por COVID-19. Realizamos um estudo de coorte retrospectivo em familiares e profissionais de saúde que foram expostos a pacientes com infecção confirmada por SARS-CoV-2 por RT-PCR em tempo real e tomografia computadorizada (TC) de tórax de 1º de janeiro a 16 de janeiro de 2020. A última data de acompanhamento foi 26 de fevereiro de 2020. Foi coletado o surgimento de febre e/ou sintomas respiratórios após a exposição ao caso primário. Foram analisadas as correlações entre profilaxia pós-exposição e infecção em contatos domiciliares e profissionais de saúde, respectivamente. Um total de 66 membros em 27 famílias e 124 profissionais de saúde tiveram evidências de exposição próxima a pacientes com COVID-19 confirmado. A regressão de Cox com base nos dados dos familiares e profissionais de saúde com Arbidol ou não mostrou que Arbidol PEP foi um fator de proteção contra o desenvolvimento de COVID-19 (HR 0,025, IC 95% 0,003-0,209, P=0,0006 para membros e HR 0,056, IC 95% 0,005-0,662, P=0,0221 para profissionais de saúde). Nossas descobertas sugerem que o Arbidol pode reduzir o risco de infecção do novo coronavírus em ambientes hospitalares e familiares. Este tratamento deve ser promovido para uso de PEP e deve ser objeto de investigação adicional.
Lack of viral clearance by the combination of hydroxychloroquine and azithromycin or lopinavir and ritonavir in SARS-CoV-2-related acute respiratory distress syndrome.	https://doi.org/10.1186/s13613-020-00678-4	24/05/2020	Artigo completo publicado em periódico científico	10.1186/s13613-020-00678-4	2110-5820	21105820	ANNALS OF INTENSIVE CARE	A1	2.219	60	7.23	-	['Azitromicina', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Azithromycin', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir']	The efficient transmission of severe acute respiratory syndrome-2 coronavirus (SARS-CoV-2) from patients to health care workers or family members has been a worrisome and prominent feature of the ongoing outbreak. On the basis of clinical practice and in-vitro studies, we postulated that post-exposure prophylaxis (PEP) using Arbidol is associated with decreased infection among individuals exposed to confirmed cases of COVID-19 infection. We conducted a retrospective cohort study on family members and health care workers who were exposed to patients confirmed to have SARS-CoV-2 infection by real-time RT-PCR and chest computed tomography (CT) from January 1 to January 16, 2020. The last follow-up date was Feb. 26, 2020. The emergence of fever and/or respiratory symptoms after exposure to the primary case was collected. The correlations between post-exposure prophylaxis and infection in household contacts and health care workers were respectively analyzed. A total of 66 members in 27 families and 124 health care workers had evidence of close exposure to patients with confirmed COVID-19. The Cox regression based on the data of the family members and health care workers with Arbidol or not showed that Arbidol PEP was a protective factor against the development of COVID-19 (HR 0.025, 95% CI 0.003-0.209, P=0.0006 for family members and HR 0.056, 95% CI 0.005-0.662, P=0.0221 for health care workers). Our findings suggest Arbidol could reduce the infection risk of the novel coronavirus in hospital and family settings. This treatment should be promoted for PEP use and should be the subject of further investigation.	32449091	Annals of intensive care	2110-5820	10.1186/s13613-020-00678-4	Falta de depuração viral pela combinação de hidroxicloroquina e azitromicina ou lopinavir e ritonavir na síndrome do desconforto respiratório agudo relacionada ao SARS-CoV-2. 	A transmissão eficiente do coronavírus da síndrome respiratória aguda grave-2 (SARS-CoV-2) de pacientes para profissionais de saúde ou familiares tem sido uma característica preocupante e proeminente do surto em andamento. Com base na prática clínica e estudos in vitro, postulamos que a profilaxia pós-exposição (PEP) usando Arbidol está associada à diminuição da infecção entre indivíduos expostos a casos confirmados de infecção por COVID-19. Realizamos um estudo de coorte retrospectivo em familiares e profissionais de saúde que foram expostos a pacientes com infecção confirmada por SARS-CoV-2 por RT-PCR em tempo real e tomografia computadorizada (TC) de tórax de 1º de janeiro a 16 de janeiro de 2020. A última data de acompanhamento foi 26 de fevereiro de 2020. Foi coletado o surgimento de febre e/ou sintomas respiratórios após a exposição ao caso primário. Foram analisadas as correlações entre profilaxia pós-exposição e infecção em contatos domiciliares e profissionais de saúde, respectivamente. Um total de 66 membros em 27 famílias e 124 profissionais de saúde tiveram evidências de exposição próxima a pacientes com COVID-19 confirmado. A regressão de Cox com base nos dados dos familiares e profissionais de saúde com Arbidol ou não mostrou que Arbidol PEP foi um fator de proteção contra o desenvolvimento de COVID-19 (HR 0,025, IC 95% 0,003-0,209, P=0,0006 para membros e HR 0,056, IC 95% 0,005-0,662, P=0,0221 para profissionais de saúde). Nossas descobertas sugerem que o Arbidol pode reduzir o risco de infecção do novo coronavírus em ambientes hospitalares e familiares. Este tratamento deve ser promovido para uso de PEP e deve ser objeto de investigação adicional.
Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors.	http://www.ncbi.nlm.nih.gov/pubmed/32451823	02/06/2020	Artigo completo publicado em periódico científico	http://www.ncbi.nlm.nih.gov/pubmed/32451823	-	-	-	-	-	-	-	-	['Profilaxia para tromboembolismo']	['Prophylaxis for thromboembolism']	Coagulopathy in COVID-19 is a burning issue and strategies to prevent thromboembolic events are debated and highly heterogeneous. The objective was to determine incidence and risk factors of venous thromboembolism (VTE) in COVID-19 inpatients receiving thromboprophylaxis. In this retrospective French cohort study, patients hospitalized in medical wards non-ICU with confirmed COVID-19 and adequate thromboprophylaxis were included. A systematic low limb venous duplex ultrasonography was performed at hospital discharge or earlier if deep venous thrombosis (DVT) was clinically suspected. Chest angio-CT scan was performed when pulmonary embolism (PE) was suspected. Of 71 patients, 16 developed VTE (22.5%) and 7 PE (10%) despite adequate thromboprophylaxis. D-dimers at baseline were significantly higher in patients with DVT (p < 0.001). Demographics, comorbidities, disease manifestations, severity score, and other biological parameters, including inflammatory markers, were similar in patients with and without VTE. The negative predictive value of a baseline D-dimer level < 1.0 µg/ml was 90% for VTE and 98% for PE. The positive predictive value for VTE was 44% and 67% for D-dimer level ≥ 1.0 µg/ml and ≥ 3 µg/ml, respectively. The association between D-dimer level and VTE risk increased by taking into account the latest available D-dimer level prior to venous duplex ultrasonography for the patients with monitoring of D-dimer. Despite thromboprophylaxis, the risk of VTE is high in COVID-19 non-ICU inpatients. Increased D-dimer concentrations of more than 1.0 μg/ml predict the risk of venous thromboembolism. D-dimer level-guided aggressive thromboprophylaxis regimens using higher doses of heparin should be evaluated in prospective studies.	32451823	Journal of thrombosis and thrombolysis	1573-742X	10.1007/s11239-020-02146-z	Avaliação sistemática do tromboembolismo venoso em pacientes com COVID-19 recebendo tromboprofilaxia: incidência e papel do dímero D como fatores preditivos. 	A coagulopatia na COVID-19 é uma questão candente e as estratégias para prevenir eventos tromboembólicos são debatidas e altamente heterogêneas. O objetivo foi determinar a incidência e os fatores de risco de tromboembolismo venoso (TEV) em pacientes internados com COVID-19 recebendo tromboprofilaxia. Neste estudo de coorte francês retrospectivo, foram incluídos pacientes hospitalizados em enfermarias médicas sem UTI com COVID-19 confirmado e tromboprofilaxia adequada. Uma ultrassonografia duplex venosa de membros inferiores sistemática foi realizada na alta hospitalar ou mais cedo se houver suspeita clínica de trombose venosa profunda (TVP). A angiotomografia de tórax foi realizada quando houve suspeita de embolia pulmonar (EP). Dos 71 pacientes, 16 desenvolveram TEV (22,5%) e 7 EP (10%) apesar da tromboprofilaxia adequada. D-dímeros no início do estudo foram significativamente maiores em pacientes com TVP (p <0,001). Demografia, comorbidades, manifestações da doença, escore de gravidade e outros parâmetros biológicos, incluindo marcadores inflamatórios, foram semelhantes em pacientes com e sem TEV. O valor preditivo negativo de um nível basal de dímero D < 1,0 µg/ml foi de 90% para TEV e 98% para EP. O valor preditivo positivo para TEV foi de 44% e 67% para nível de D-dímero ≥ 1,0 µg/ml e ≥ 3 µg/ml, respectivamente. A associação entre o nível de D-dímero e o risco de TEV aumentou levando em consideração o último nível de D-dímero disponível antes da ultrassonografia duplex venosa para os pacientes com monitoramento de D-dímero. Apesar da tromboprofilaxia, o risco de TEV é alto em pacientes com COVID-19 não internados em UTI. Concentrações aumentadas de dímero D de mais de 1,0 μg/ml predizem o risco de tromboembolismo venoso. Regimes de tromboprofilaxia agressivos guiados por nível de dímero D usando doses mais altas de heparina devem ser avaliados em estudos prospectivos.
Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort	https://doi.org/10.1016/S2352-3018(20)30164-8	28/05/2020	Artigo completo publicado em periódico científico	10.1016/S2352-3018(20)30164-8	2352-3018	23523018	THE LANCET HIV	A1	5.296	62	4.76	-	['Azitromicina', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Azithromycin', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir']	None.	32473657	The lancet. HIV	2352-3018	10.1016/S2352-3018(20)30164-8	Descrição do COVID-19 em indivíduos infectados pelo HIV: uma coorte prospectiva de centro único 	Nenhum.
Anakinra for severe forms of COVID-19 : a cohort study	https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30164-8/fulltext	29/05/2020	Artigo completo publicado em periódico científico	https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30164-8/fulltext	-	-	-	-	-	-	-	-	['Anakinra']	['Anakinra']	-	-	-	-	-	Anakinra para formas graves de COVID-19: um estudo de coorte 	-
Arbidol/IFN-α2b Therapy for Patients With Corona Virus Disease 2019: A Retrospective Multicenter Cohort Study	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238991/	20/05/2020	Artigo completo publicado em periódico científico	PMC:PMC7238991/	-	-	-	-	-	-	-	-	['Interferon alfa', 'Umifenovir']	['Interferon alpha', 'Umifenovir']	The spread of COVID-19 is accelerating. At present, there is no specific antiviral drugs for COVID-19 outbreak. This is a multicenter retrospective cohort study of patients with laboratory-confirmed COVID-19 infection pneumonia from 3 hospitals in Hubei and Guangdong province, 141 adults (aged ≥18 years) without ventilation were included. Combined group patients were given Arbidol and IFN-α2b, monotherapy group patients inhaled IFN-α2b for 10-14 days. Of 141 COVID-19 patients, baseline clinical and laboratory characteristics were similar between combined group and monotherapy group, that 30% of the patients leucocytes counts were below the normal range and 36.4% of the patients experienced lymphocytopenia. The duration of viral RNA of respiratory tract in the monotherapy group was not longer than that in the combined therapy group. There was no significant differences between two groups. The absorption of pneumonia in the combined group was faster than that in the monotherapy group. We inferred that Arbidol/IFN - 2 b therapy can be used as an effective method to improve the COVID-19 pneumonia of mild patients, although it helpless with accelerating the virus clearance. These results should be verified in a larger prospective randomized environment.	32445881	Microbes and infection	1769-714X	10.1016/j.micinf.2020.05.012	Terapia Arbidol/IFN-α2b para pacientes com doença do vírus Corona 2019: um estudo de coorte multicêntrico retrospectivo 	A disseminação do COVID-19 está acelerando. Atualmente, não há medicamentos antivirais específicos para o surto de COVID-19. Este é um estudo de coorte retrospectivo multicêntrico de pacientes com pneumonia por infecção por COVID-19 confirmada em laboratório de 3 hospitais na província de Hubei e Guangdong, 141 adultos (idade ≥18 anos) sem ventilação foram incluídos. Os pacientes do grupo combinado receberam Arbidol e IFN-α2b, os pacientes do grupo monoterapia inalaram IFN-α2b por 10-14 dias. Dos 141 pacientes com COVID-19, as características clínicas e laboratoriais basais foram semelhantes entre o grupo combinado e o grupo de monoterapia, que 30% das contagens de leucócitos dos pacientes estavam abaixo da faixa normal e 36,4% dos pacientes apresentaram linfocitopenia. A duração do RNA viral do trato respiratório no grupo de monoterapia não foi maior do que no grupo de terapia combinada. Não houve diferenças significativas entre os dois grupos. A absorção da pneumonia no grupo combinado foi mais rápida do que no grupo monoterapia. Inferimos que a terapia com Arbidol/IFN - 2 b pode ser usada como um método eficaz para melhorar a pneumonia por COVID-19 de pacientes leves, embora seja impotente para acelerar a eliminação do vírus. Esses resultados devem ser verificados em um ambiente prospectivo randomizado maior.
Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study	https://doi.org/10.1093/cid/ciaa624	22/05/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa624	1058-4838	10584838	CLINICAL INFECTIOUS DISEASES	A1	4.394	353	8.72	 Abstract                                   Background                   Renin-angiotensin-aldosterone system (RAAS) inhibitors may facilitate host cell entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or attenuate organ injury via RAAS blockade. We aimed to assess the associations between prior use of RAAS inhibitors and clinical outcomes among Korean patients with coronavirus disease 2019 (COVID-19).                                                  Methods                   We performed a nationwide population-based cohort study using the Korean Health Insurance Review and Assessment database. Claim records were screened for 69 793 individuals who were tested for COVID-19 until 8 April 2020. Adjusted odds ratios (ORs) were used to compare the clinical outcomes between RAAS inhibitor users and nonusers.                                                  Results                   Among 5179 confirmed COVID-19 cases, 762 patients were RAAS inhibitor users and 4417 patients were nonusers. Relative to nonusers, RAAS inhibitor users were more likely to be older, male, and have comorbidities. Among 1954 hospitalized patients with COVID-19, 377 patients were RAAS inhibitor users, and 1577 patients were nonusers. In-hospital mortality was observed for 33 RAAS inhibitor users (9%) and 51 nonusers (3%) (P &amp;lt; .001). However, after adjustment for age, sex, Charlson comorbidity index, immunosuppression, and hospital type, the use of RAAS inhibitors was not associated with a higher risk of mortality (adjusted OR, 0.88; 95% confidence interval, 0.53–1.44; P = .60). No significant differences were observed between RAAS inhibitor users and nonusers in terms of vasopressor use, modes of ventilation, extracorporeal membrane oxygenation, renal replacement therapy, and acute cardiac events.                                                  Conclusions                   Our findings suggest that prior use of RAAS inhibitors was not independently associated with mortality among COVID-19 patients in Korea.               	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	Our findings suggest that prior use of RAAS inhibitors was not independently associated with mortality among COVID-19 patients in Korea.	32442285	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America	1537-6591	10.1093/cid/ciaa624	Associação de inibidores do sistema renina-angiotensina-aldosterona com desfechos relacionados ao COVID-19 na Coreia: um estudo de coorte nacional de base 	populacional
SARS2-CoV-2 and Stroke in a New York Healthcare System	https://www.ahajournals.org/doi/10.1161/STROKEAHA.120.030335	20/05/2020	Artigo completo publicado em periódico científico	10.1161/STROKEAHA.120.030335	0039-2499	392499	STROKE (DALLAS. 1970)	A1	3.245	330	6.52	              Background and Purpose:             With the spread of coronavirus disease 2019 (COVID-19) during the current worldwide pandemic, there is mounting evidence that patients affected by the illness may develop clinically significant coagulopathy with thromboembolic complications including ischemic stroke. However, there is limited data on the clinical characteristics, stroke mechanism, and outcomes of patients who have a stroke and COVID-19.                                  Methods:             We conducted a retrospective cohort study of consecutive patients with ischemic stroke who were hospitalized between March 15, 2020, and April 19, 2020, within a major health system in New York, the current global epicenter of the pandemic. We compared the clinical characteristics of stroke patients with a concurrent diagnosis of COVID-19 to stroke patients without COVID-19 (contemporary controls). In addition, we compared patients to a historical cohort of patients with ischemic stroke discharged from our hospital system between March 15, 2019, and April 15, 2019 (historical controls).                                  Results:                           During the study period in 2020, out of 3556 hospitalized patients with diagnosis of COVID-19 infection, 32 patients (0.9%) had imaging proven ischemic stroke. Cryptogenic stroke was more common in patients with COVID-19 (65.6%) as compared to contemporary controls (30.4%,               P              =0.003) and historical controls (25.0%,               P              &lt;0.001). When compared with contemporary controls, COVID-19 positive patients had higher admission National Institutes of Health Stroke Scale score and higher peak D-dimer levels. When compared with historical controls, COVID-19 positive patients were more likely to be younger men with elevated troponin, higher admission National Institutes of Health Stroke Scale score, and higher erythrocyte sedimentation rate. Patients with COVID-19 and stroke had significantly higher mortality than historical and contemporary controls.                                              Conclusions:             We observed a low rate of imaging-confirmed ischemic stroke in hospitalized patients with COVID-19. Most strokes were cryptogenic, possibly related to an acquired hypercoagulability, and mortality was increased. Studies are needed to determine the utility of therapeutic anticoagulation for stroke and other thrombotic event prevention in patients with COVID-19.          	['Anticoagulantes']	['Anticoagulants']	-	-	-	-	-	SARS2-CoV-2 e acidente vascular cerebral em um sistema de saúde de Nova York 	-
Deep Vein Thrombosis in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: Prevalence, Risk Factors, and Outcome	https://doi.org/10.1161/CIRCULATIONAHA.120.046702	18/05/2020	Artigo completo publicado em periódico científico	10.1161/CIRCULATIONAHA.120.046702	0009-7322	97322	CIRCULATION (NEW YORK, N.Y.)	A1	8.281	630	12.78	              Background:             To investigate deep vein thrombosis (DVT) in hospitalized patients with coronavirus disease 2019 (COVID-19), we performed a single institutional study to evaluate its prevalence, risk factors, prognosis, and potential thromboprophylaxis strategies in a large referral and treatment center.                                  Methods:             We studied a total of 143 patients with COVID-19 from January 29, 2020 to February 29, 2020. Demographic and clinical data, laboratory data, including ultrasound scans of the lower extremities, and outcome variables were obtained, and comparisons were made between groups with and without DVT.                                  Results:                           Of the 143 patients hospitalized with COVID-19 (age 63±14 years, 74 [51.7%] men), 66 patients developed lower extremity DVT (46.1%: 23 [34.8%] with proximal DVT and 43 [65.2%] with distal DVT). Compared with patients who did not have DVT, patients with DVT were older and had a lower oxygenation index, a higher rate of cardiac injury, and worse prognosis, including an increased proportion of deaths (23 [34.8%] versus 9 [11.7%];               P              =0.001) and a decreased proportion of patients discharged (32 [48.5%] versus 60 [77.9%];               P              &lt;0.001). Multivariant analysis showed an association only between CURB-65 (confusion status, urea, respiratory rate, and blood pressure) score 3 to 5 (odds ratio, 6.122;               P              =0.031), Padua prediction score ≥4 (odds ratio, 4.016;               P              =0.04), D-dimer &gt;1.0 μg/mL (odds ratio, 5.818;               P              &lt;0.014), and DVT in this cohort, respectively. The combination of a CURB-65 score 3 to 5, a Padua prediction score ≥4, and D-dimer &gt;1.0 μg/mL has a sensitivity of 88.52% and a specificity of 61.43% for screening for DVT. In the subgroup of patients with a Padua prediction score ≥4 and whose ultrasound scans were performed &gt;72 hours after admission, DVT was present in 18 (34.0%) patients in the subgroup receiving venous thromboembolism prophylaxis versus 35 (66.0%) patients in the nonprophylaxis group (               P              =0.010).                                              Conclusions:             The prevalence of DVT is high and is associated with adverse outcomes in hospitalized patients with COVID-19. Prophylaxis for venous thromboembolism may be protective in patients with a Padua protection score ≥4 after admission. Our data seem to suggest that COVID-19 is probably an additional risk factor for DVT in hospitalized patients.          	['Antagonistas do Receptor da Angiotensina II', 'Antivirais', 'Heparina', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Antivirals', 'Heparin', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	The treatment of psoriasis is mainly based on anti-inflammatory and/or anti-hyperproliferative agents. The topical steroids appeared in the fifties and were the first therapeutic breakthrough for psoriasis, followed by methotrexate and phototherapy in the sixties, photochemotherapy (PUVA) in the seventies and acitretin and cyclosporine in the eighties. The targeted biologic therapies represent a whole new era of therapeutic possibilities with a highly beneficial safety record. The choice of treatment depends on a large series of factors, including the type and extend of the psoriasis, the patient's preferences, co-medications, comorbidities and drug tolerance. This overview presents the currently available topical and systemic agents for treating psoriasis, including topical corticosteroids, vitamin D derivatives, UV-light based therapies, methotrexate, cyclosporine, acitretin, and the biologic agents such as the TNF antagonists etanercept, adalimumab and infliximab, as well as the anti-p40 IL12/23 agent ustekinumab. Newer, very promising, agents aiming the Th17 pathway are under development for psoriasis. 	33523727	Circulation	1524-4539	10.1161/CIRCULATIONAHA.120.050551	Trombose Venosa Profunda em Pacientes Hospitalizados com Doença de Coronavírus 2019 (COVID-19) em Wuhan, China: Prevalência, Fatores de Risco e Resultado 	O tratamento da psoríase é baseado principalmente em agentes anti-inflamatórios e/ou anti-hiperproliferativos. Os esteróides tópicos surgiram na década de 50 e foram o primeiro avanço terapêutico para a psoríase, seguidos pelo metotrexato e fototerapia na década de 60, fotoquimioterapia (PUVA) na década de 70 e acitretina e ciclosporina na década de 80. As terapias biológicas direcionadas representam uma nova era de possibilidades terapêuticas com um histórico de segurança altamente benéfico. A escolha do tratamento depende de uma grande série de fatores, incluindo o tipo e extensão da psoríase, preferências do paciente, co-medicações, comorbidades e tolerância medicamentosa. Esta visão geral apresenta os agentes tópicos e sistêmicos atualmente disponíveis para o tratamento da psoríase, incluindo corticosteroides tópicos, derivados da vitamina D, terapias à base de luz UV, metotrexato, ciclosporina, acitretina e os agentes biológicos, como os antagonistas do TNF etanercept, adalimumabe e infliximabe, como bem como o agente anti-p40 IL12/23 ustekinumab. Agentes mais novos e muito promissores visando a via Th17 estão em desenvolvimento para a psoríase.
Neurologically Devastating Intraparenchymal Hemorrhage in COVID-19 Patients on Extracorporeal Membrane Oxygenation: A Case Series	https://academic.oup.com/neurosurgery/article/doi/10.1093/neuros/nyaa198/5840444	19/05/2020	Artigo completo publicado em periódico científico	10.1093/neuros/nyaa198/5840444	-	-	-	-	-	-	-	-	['Oxigenação por membrana extracorpórea (ECMO)']	['Extracorporeal membrane oxygenation (ECMO)']	Understanding the complications of ECMO in this cohort and developing therapeutic algorithms to aid in optimal patient selection will be critical in the limited resource setting experienced as a result of global pandemic. We propose the use of head computed tomography (CT) to identify devastating neurological complications as early as possible, aiding in the resource allocation of ECMO machines to the most appropriately selected patients.	32424429	Neurosurgery	1524-4040	10.1093/neuros/nyaa198	Hemorragia intraparenquimatosa neurologicamente devastadora em pacientes com COVID-19 em oxigenação por membrana extracorpórea: uma série 	de casos . Propomos o uso de tomografia computadorizada (TC) de crânio para identificar complicações neurológicas devastadoras o mais precocemente possível, auxiliando na alocação de recursos de máquinas de ECMO para os pacientes selecionados mais adequadamente.
Coronavirus Disease 2019 in Heart Transplant Recipients in Southeastern Michigan – Case Series	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224667/	14/05/2020	Artigo completo publicado em periódico científico	PMC:PMC7224667/	-	-	-	-	-	-	-	-	['Corticosteroides', 'Hidroxicloroquina', 'Tocilizumabe']	['Corticosteroids', 'Hydroxychloroquine', 'Tocilizumab']	Black men may be at increased risk for COVID-19 among patients with OHT. Presenting signs and symptoms in this cohort are similar to those in the general population. Elevated inflammatory markers on presentation appear to be associated with more severe illness.	32417380	Journal of cardiac failure	1532-8414	10.1016/j.cardfail.2020.05.008	Doença de Coronavírus 2019 em Receptores de Transplante de Coração no Sudeste de Michigan – Série de Casos 	Homens negros podem estar em maior risco de COVID-19 entre pacientes com OHT. Os sinais e sintomas apresentados nesta coorte são semelhantes aos da população geral. Marcadores inflamatórios elevados na apresentação parecem estar associados a doenças mais graves.
First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study	https://doi.org/10.1111/ajt.16062	15/05/2020	Artigo completo publicado em periódico científico	10.1111/ajt.16062	1600-6135	16006135	AMERICAN JOURNAL OF TRANSPLANTATION (PRINT)	A1	3.311	198	6.32	-	['Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Hydroxychloroquine', 'Lopinavir', 'Ritonavir']	-	-	-	-	-	Primeira experiência de infecções por SARS-CoV-2 em receptores de transplante de órgãos sólidos no Swiss Transplant Cohort Study 	-
An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31103-X/fulltext	13/05/2020	Artigo completo publicado em periódico científico	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31103-X/fulltext	-	-	-	-	-	-	-	-	['Imunoglobulina', 'Prednisona']	['Immunoglobulin', 'Prednisone']	None.	32410760	Lancet (London, England)	1474-547X	10.1016/S0140-6736(20)31103-X	Um surto de doença grave semelhante a Kawasaki no epicentro italiano da epidemia de SARS-CoV-2: um estudo de coorte observacional 	Nenhum.
Successful COVID-19 rescue therapy by extra-corporeal membrane oxygenation (ECMO) for respiratory failure: a case report	https://doi.org/10.1186/s13037-020-00245-7	08/05/2020	Artigo completo publicado em periódico científico	10.1186/s13037-020-00245-7	1754-9493	17549493	PATIENT SAFETY IN SURGERY	B1	0.845	26	2.9	 Abstract  Background The value of extracorporeal membrane oxygenation (ECMO) for patients suffering from novel coronavirus disease 2019 (COVID-19) as a rescue therapy for respiratory failure remains controversial and associated with high mortality rates of 50 to 82% in early reports from Wuhan, China. We hypothesized that patient outcomes would be improved at our tertiary cardiothoracic surgery referral center with a protocolized team-approach for ECMO treatment of patients with severe COVID-19 disease.  Case presentation A 51-year-old healthy female developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) bilateral pneumonia while vacationing in Colorado with her family. She was transferred to our facility for a higher level of care. Her respiratory status continued to deteriorate despite maximized critical care, including prone positioning ventilation and nitric oxide inhalation therapy. Veno-venous ECMO was initiated on hospital day 7 in conjunction with a 10-day course of compassionate use antiviral treatment with remdesivir. The patient’s condition improved significantly and she was decannulated from ECMO on hospital day 17 (ECMO day 11). She was successfully extubated and eventually discharged to rehabilitation on hospital day 28.  Conclusion This case report demonstrates a positive outcome in a young patient with COVID-19 treated by the judicious application of ECMO in conjunction with compassionate use antiviral treatment (remdesivir). Future prospective multi-center studies are needed to validate these findings in a larger cohort of patients.	['Oxigenação por membrana extracorpórea (ECMO)', 'Remdesivir']	['Extracorporeal membrane oxygenation (ECMO)', 'Remdesivir']	This case report demonstrates a positive outcome in a young patient with COVID-19 treated by the judicious application of ECMO in conjunction with compassionate use antiviral treatment (remdesivir). Future prospective multi-center studies are needed to validate these findings in a larger cohort of patients.	32395179	Patient safety in surgery	1754-9493	10.1186/s13037-020-00245-7	Terapia de resgate bem-sucedida de COVID-19 por oxigenação por membrana extracorpórea (ECMO) para insuficiência respiratória: relato de 	caso Este relato de caso demonstra um resultado positivo em um paciente jovem com COVID-19 tratado pela aplicação criteriosa de ECMO em conjunto com antiviral de uso compassivo tratamento (remdesivir). Futuros estudos multicêntricos prospectivos são necessários para validar esses achados em uma coorte maior de pacientes.
Clinical course of severe and critical COVID-19 in hospitalized pregnancies: a US cohort study	https://pubmed.ncbi.nlm.nih.gov/32391519/	08/05/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32391519/	-	-	-	-	-	-	-	-	['Anticoagulantes', 'Esteroides', 'Hidroxicloroquina', 'Plasma convalescente', 'Remdesivir']	['Anticoagulants', 'Ssteroids', 'Hydroxychloroquine', 'Convalescent Plasma', 'Remdesivir']	In pregnant women with severe or critical coronavirus disease 2019, admission into the hospital typically occurred about 7 days after symptom onset, and the duration of hospitalization was 6 days (6 [severe group] vs 12 [critical group]). Women with critical disease had a high rate of acute respiratory distress syndrome, and there was 1 case of cardiac arrest, but there were no cases of cardiomyopathy or maternal mortality. Hospitalization of pregnant women with severe or critical coronavirus disease 2019 resulted in delivery during the clinical course of the disease in 50% of this cohort, usually in the third trimester. There were no perinatal deaths in this cohort.	32391519	American journal of obstetrics & gynecology MFM	2589-9333	10.1016/j.ajogmf.2020.100134	Curso clínico de COVID-19 grave e crítico em gestações hospitalizadas: um estudo de coorte nos EUA 	Em mulheres grávidas com doença grave ou crítica por coronavírus 2019, a admissão no hospital ocorreu normalmente cerca de 7 dias após o início dos sintomas e a duração da hospitalização foi de 6 dias ( 6 [grupo grave] vs 12 [grupo crítico]). As mulheres com doença crítica apresentaram alta taxa de síndrome do desconforto respiratório agudo e houve 1 caso de parada cardíaca, mas não houve casos de cardiomiopatia ou mortalidade materna. A hospitalização de gestantes com doença grave ou crítica por coronavírus 2019 resultou em parto durante o curso clínico da doença em 50% dessa coorte, geralmente no terceiro trimestre. Não houve óbitos perinatais nesta coorte.
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study	https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30127-2/fulltext	07/05/2020	Artigo completo publicado em periódico científico	https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30127-2/fulltext	-	-	-	-	-	-	-	-	['Anakinra', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Anakinra', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir']	None.	32501454	The Lancet. Rheumatology	2665-9913	10.1016/S2665-9913(20)30127-2	Bloqueio de interleucina-1 com anakinra em altas doses em pacientes com COVID-19, síndrome do desconforto respiratório agudo e hiperinflamação: um estudo de coorte retrospectivo 	Nenhum.
Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19	https://www.sciencedirect.com/science/article/pii/S2211383520305529	20/04/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S2211383520305529	-	-	-	-	-	-	-	-	['Dipiridamol']	['Dipyridamole']	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can cause acute respiratory distress syndrome, hypercoagulability, hypertension, and multiorgan dysfunction. Effective antivirals with safe clinical profile are urgently needed to improve the overall prognosis. In an analysis of a randomly collected cohort of 124 patients with COVID-19, we found that hypercoagulability as indicated by elevated concentrations of D-dimers was associated with disease severity. By virtual screening of a U.S. FDA approved drug library, we identified an anticoagulation agent dipyridamole (DIP) 	32318327	Acta pharmaceutica Sinica. B	2211-3835	10.1016/j.apsb.2020.04.008	Os potenciais efeitos terapêuticos do dipiridamol em pacientes gravemente enfermos com COVID-19 Infecção por 	coronavírus 2 da síndrome respiratória aguda grave (SARS-CoV-2) podem causar síndrome do desconforto respiratório agudo, hipercoagulabilidade, hipertensão e disfunção de múltiplos órgãos. Antivirais eficazes com perfil clínico seguro são urgentemente necessários para melhorar o prognóstico geral. Em uma análise de uma coorte coletada aleatoriamente de 124 pacientes com COVID-19, descobrimos que a hipercoagulabilidade indicada por concentrações elevadas de dímeros D estava associada à gravidade da doença. Por triagem virtual de uma biblioteca de medicamentos aprovada pela FDA dos EUA, identificamos um agente anticoagulante dipiridamol (DIP)
Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers	http://www.ncbi.nlm.nih.gov/pubmed/32283499%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7144598	09/04/2020	Artigo completo publicado em periódico científico	http://www.ncbi.nlm.nih.gov/pubmed/32283499%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7144598	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II']	['Angiotensin II Receptor Antagonists']	Covid-19 disease is caused by SARS-CoV-2, a virus belonging to the coronavirus family. Covid-19 is so new that there is currently no specific vaccine or treatment. Clinical trials are currently underway. In vitro tests are also being conducted to assess the efficacy of chloroquine and hydroxychloroquine for the treatment of this epidemic, which is considered a pandemic by the WHO. We note that the content of this review is dated. The information it contains is subject to change and modification as the epidemic progresses.	32473904	Diabetes & metabolic syndrome	1878-0334	10.1016/j.dsx.2020.05.030	Comorbidades no COVID-19: Resultados em coorte de hipertensos e controvérsias com bloqueadores do sistema renina angiotensina 	A doença Covid-19 é causada pelo SARS-CoV-2, um vírus pertencente à família dos coronavírus. O Covid-19 é tão novo que atualmente não existe vacina ou tratamento específico. Os ensaios clínicos estão em andamento. Testes in vitro também estão sendo realizados para avaliar a eficácia da cloroquina e da hidroxicloroquina para o tratamento dessa epidemia, que é considerada uma pandemia pela OMS. Observamos que o conteúdo desta revisão é datado. A informação que contém está sujeita a alterações e modificações à medida que a epidemia progride.